ID;CODE;DRUG-GENERIC1;CONNECTOR1;CATEGORY;CONNECTOR2;CONNECTOR3;OPTIONAL CONNECTOR1;with…..;OPTIONAL CONNECTOR2;CONNECTOR4;FORMULA;CONNECTOR5;DRUG-GENERIC2;CONNECTOR6;COUNTRY;CONNECTOR7;NAMES-TRADE;NAMES-OLD;CONNECTOR8;TEXT for HOW IT MIGHT WORK;REFERENCE1;REFERENCE;COMBINATION_new;DEPOT1_new;DEPOT2_new;COMBINATION;DEPOT1;DEPOT2;Drug-generic (with additions);;;
1;A.III.1 ;Acepromazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;aliphatic side chain; and a ;full chemical formula of ;10-[3-(dimethylamino)propyl]phenothiazin-2-yl methyl ketone (maleate);. ;Acepromazine; has been marketed or used in ;United States of America, France, Denmark; under the trade or premarketing names of ;AY 57.062, 1522 CB, Plégicil, Plegicil, Noctran, Mepronizine;NM: AY 57.062 Ayerst, USA NM: 1522 CB Clin Byla, F NM: Plégicil Clin Midy, F: gouttes (10 drops 1mg) (deleted) NM: Plegicil Medimerc, DK: s-c tabs. 10mg - mikstur (syrup) 5mg/ml NM: Noctran Menarini, F: tabs.0.75mg+7.5mg acetopromazine+10mg clorazepate di K+ NM: Mepronizine Sanofi Winthrop, F: tabs. 10mg acetopromazine+400mg meprobamate;. ;"Atypical neuroleptic agent. Sedative, antiemetic and spasmolytic properties/ minor or no extrapyramidal effects. In NL formerly promoted as ""neuroleptic calmative"". Used in the treatment of anxiety and tension at a dosage of 10 to 60 mg/day. Also as antiemetic in the management of nausea. Deleted in USA, but reintroduced for veterinary use in the treatment of porcine stress syndrome.";Brock N~Acepromazine revisited~The Canadian veterinary journal La revue veterinaire canadienne~1994~35(7)~458-9#Muir WW, 3rd, Mason DE~Effects of diazepam, acepromazine, detomidine, and xylazine on thiamylal anesthesia in horses~Journal of the American Veterinary Medical Association~1993~203(7)~1031-8;Brock N: Acepromazine revisited. Can Vet J 35/7: 458-459, 1994 - Muir WW, Masonde: Effects of diazepam, acepromazine, detomidine and xylazine on thiamylal anesthesia in horses. J Am Vet Med Assoc 23/7: 1031-1038, 1993.;;;;;;;acepromazine (acetylpromazine);;;
2;A.III.1 ;Promazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;aliphatic side chain; and a ;full chemical formula of ;10-[3-(dimethylamino)propyl]phenothiazine hydrochloride;. ;Promazine; has been marketed or used in ;Netherlands, Belgium, Switzerland, Italy, Greece, Finland, United Kingdom, Republic of South Africa; under the trade or premarketing names of ;Promazine, Prazine, Protactyl, Sparine, Prozyl, Promazin, Sinophenin, Talofen;NM: Promazine Pharmachemie, NL: s-c tabs. 25mg, 50mg, 100mg (deleted) NM: Prazine Wyeth Libamedi, B - Wyeth, CH: s-c tabs. 25mg, 50mg, 100mg - vials 100mg/2ml, 500mg/10ml - drops 30mg/ml (not in CH) - in CH also susp. 50mg/5ml NM: Prazine Parke Davis, ITA: tabs. 10mg, 20mg - drops 30mg/ml (range deleted) NM: Protactyl Wyeth, BRD: s-c tabs. 25mg, 50mg, 100mg - amps. 50mg/ml, 100mg/2ml - suspension 50mg/5ml NM: Sparine Wyeth, DK: s-c tabs. 25mg, 50mg NM: Sparine Wyeth, GR: s-c tabs. 25mg, 50mg - syrup 2mg/ml - vials 500mg/10ml NM: Sparine Wyeth, FIN: s-c tabs. 50mg, 100mg NM: Sparine Wyeth, UK: amps. 50mg/ml, 100mg/2ml (deleted) - oral suspension 50mg/5ml NM: Sparine Akromed, RSA: s-c tabs.25mg, 50mg - syrup 10mg/5ml - amps. 50mg/ml NM: Prozyl Vita, GR: s-c tabs. 25mg, 50mg - amps. 50mg/ml (deleted) NM: Promazin Orion, FIN: s-c tabs. 100mg - mikstuura 5mg/ml NM: Sinophenin Rodleben, BRD: f-c tabs. 25mg - drops 20mg/ml - amps. 20mg/2ml NM: Talofen Fournier-Pierrel, ITA: tabs. 25mg - sol. 4% - amps 50mg/2ml;. ;Low potency neuroleptic. DA antagonist. Extrapyramidal effects in usual dosage weak or absent. Like acepromazine also for veterinary use. Dosage 75 to 300 mg daily, occasionally up to 1g daily. Used in the management of agitation or confusional states in the elderly. High concentration of the injectable form (5%). Potentiation of analgesia. Some major metabolites are the sulfoxides, N-oxide, the 3-hydroxy derivative and N-demethylated compounds.;"Ford JM, Prozialeck WC, Hait WN~Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance~Molecular pharmacology~1989~35(1)~105-15#Curry SH, Hu OY~A third, ""deep,"" compartment for phenothiazine drug disposition: a new look at an old problem~Psychopharmacol Bull~1990~26(1)~95-8#
Hu OY, Tang HS, Sheeng TY, Chen TC, Curry SH~Pharmacokinetics of promazine in patients with hepatic cirrhosis--correlation with a novel galactose single point method~Journal of pharmaceutical sciences~1995~84(1)~111-4
";"Ford JM, Prozialeck WC, Hait WN: Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35: 105-115, 1989 - Curry SH, Hu OYP: A third, ""deep"", compartment for phenothiazine drug disposition: a new look at an old problem. Psychopharmacol Bull 26(1): 95-98, 1990 -Tang HS, Sheeng TY & al: Pharmacokinetics of promazine in patients with hepatic cirrhosis-correltaion with a novel galactose single-point method. J Pharm Sci 84/1: 111-114, 1995.";;;;;;;promazine (WY 1094);;;
3;A.III.1 ;Chlorpromazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;aliphatic side chain; and a ;full chemical formula of ;2-chloro-10-(3-dimethylaminopropyl)phenothiazine;. ;Chlorpromazine; has been marketed or used in ;Netherlands, Belgium, Switzerland, Greece, Denmark, Norway, Iceland, Italy, Spain, Republic of South Africa, Finland, Portugal, Austria, Sweden, Germany, United States of America; under the trade or premarketing names of ;Largactil, Largatrex, Ancholactil, Biscasil, Chlorazin, Chlorpromazin, Hibanil, Hibernal, Klorproman, Megaphen, Nevropromazine, Propaphenin, Prozil, Prozin, Repazine, Solidon, Thorazine, Zuledin;NM: Largactil Rhône-Poulenc Rorer, NL: tabs. 25mg, 100mg (deleted) - amps. 25mg/5ml - B: tabs. 25mg, 100mg - drops 4% - CH, GR: tabs. 25mg, 100mg - amps. 25mg/5ml drops 4% (1 drop 1mg) - Spécia(RPR), F:tabs.100mg(deleted)-amps. 25mg/5ml-goutt.buvables 4% (1drop 1mg) NM: Largactil Rhône-Poulenc Rorer, UK: f-c tabs. 10mg, 25mg, 50mg, 100mg - amps. 50mg/2ml - syrup 5mg/ml - suppos. 100mg (deleted) - suspension forte 100mg/5ml (embonate) - DK, NOR, ICL: tabs. 10mg, 25mg, 50mg, 100mg - amps. 50mg/2ml (not in DK, ICL) - syrup 10mg/ml (not in DK) - ITA, ESP: tabs. 25mg, 100mg - drops 4% - amps. 50mg/2ml (also 25mg/5ml in ESP) - RSA: tabs. 10mg, 25mg, 100mg - syrup 5mg/ml - amps. 25mg/1ml, 50mg/2ml NM: Largactil Rhône-Poulenc Rorer, FIN, ESP, ITA, PORT: tabs. 25mg, 100mg (in FIN and ESP also mixt. 20mg/ml) NM: Largactil Gerot, A: f-c tabs. 25mg, 100mg- amps. 25mg/5ml-drops 4% NM: Largatrex Vitoria, PORT: tabs. 25mg, 100mg (combination product) NM: Ancholactil Antiviotiki, GR: tabs. 25mg, 100mg NM: Biscasil Leontik, GR: tabs. 100mg NM: Chlorazin Streuli, CH: tabs. 25mg, 100mg - drops 25mg/ml - suppos. 25mg, 100mg - amps. 25mg/5ml (i.m.) and 50mg/2ml (i.v.) NM: Chlorpromazin Dumex, NOR: tabs. 10mg, 25mg, 50mg and 100mg - mikstur (syrup) 20mg/ml NM: Hibanil Kabi Pharmacia, NOR: tabs. 10mg, 25mg, 50mg, 100mg - mikstur (syrup) 10mg/ml - amps. 50mg/2ml (range deleted) NM: Hibernal Rhône-Poulenc Rorer, SWE: tabs. 10mg, 25mg, 50mg, 100mg - amps. 50mg/2ml - embonat mixtur 10mg/ml - depot caps. (sust.-release caps.) 75mg, 150mg NM: Klorproman Orion Farmos, FIN: s-c tabs. 25mg, 50mg, 100mg, 200mg - mikstuura 20mg per ml (embonate) - amps. 50mg/2ml (deleted) NM: Megaphen Bayer, BRD: s-c tabs. 25mg - drops 4% - amps. 50mg/2ml (deleted) NM: Nevropromazine Proel, GR: tabs. 25mg, 100mg - amps. 25mg/5ml NM: Propaphenin Rodleben, BRD: f-c tabs. 25mg - drops 20mg/ml - amps. 50mg/2ml NM: Prozil Dumex, DK: tabs. 10mg, 25mg, 50mg, 100mg - saft (syrup) 7mg/ml - amps. 25mg/ml and 50mg/2ml - suppositories 100mg (range deleted) - Dumex, ICL: syrup 7mg/ml NM: Prozin Lusofarmaco, ITA: tabs. 25mg, 100mg - drops 4 % NM: Repazine Lennon, RSA: amps. 25mg/1ml, 50mg/2ml NM: Solidon Adelco, GR: tabs. 25mg, 100mg - drops 4% - amps. 25mg/5ml NM: Thorazine SmithKline Beecham, USA: tabs. 10mg, 25mg, 50mg - amps. 25mg/ml - vials 250mg/10ml - suppos. 25mg, 100mg - syrup 2mg/ml NM: Zuledin Demo, GR: tabs. 25mg, 50mg, 100mg - amps. 25mg/5ml;. ;The first neuroleptic described. D /D receptors antagonist. High affinity for 5-HT and 5-HT 2 1 6 7 receptors. For the symptomatic treatment of psychoses and manic states. Management of behavioral disturbances with excessive motor activity. Adjunct in the treatment of anxiety. Control of nausea and vomiting. Used for the relief of intractable hiccups. Premedication in surgery. Active metabolites. Terminal plasma T½ after single oral dose about 17 hrs, in steady state approx.30 hrs.;"Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Jr., Shen Y, et al.~Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors~The Journal of pharmacology and experimental therapeutics~1994~268(3)~1403-10#Rasheed A, Javed MA, Nazir S, Khawaja O~Interaction of chlorpromazine with tricyclic anti-depressants in schizophrenic patients~JPMA The Journal of the Pakistan Medical Association~1994~44(10)~233-4#
Lenzi A, Marazziti D, Raffaelli S, Cassano GB~Effectiveness of the combination verapamil and chlorpromazine in the treatment of severe manic or mixed patients~Progress in neuro-psychopharmacology & biological psychiatry~1995~19(3)~519-28
";Roth BL, Craigo SC, Choudhary MS & al: Binding of typical and atypical antipsychotic agents to 5- hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268/3: 1403-1410, 1994 - Rasheed A, Javed MA, Nazir S, Khawaja O: Interaction of chlorpromazine with tricyclic antidepressants in schizophrenic patients. J Pak Med Assoc 44/10: 233-234, 1994 - Lenzi A, Marazziti D, Raffaelli S, Cassano GB: Effectiveness of the combination verapamil and chlorpromazine in the treatment of severe manic or mixed patients. Prog Neuro-Psychopharmacol & Biol Psychiat 19: 519-528, 1995.;;;;;;;chlorpromazine (4560 RP);;;
4;A.III.1 ;Etymemazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;aliphatic side chain; and a ;full chemical formula of ;2-ethyl-10-[3-(dimethylamino)-2-methylpropyl] phenothiazine hydrochloride;. ;Etymemazine; has been marketed or used in ;France; under the trade or premarketing names of ;Sergétyl, Nuital;NM: Sergétyl (deleted) Vaillant-Defresne, F: tabs. 10mg NM: Nuital (deleted) Vaillant-Defresne, F: tabs. 5mg;. ;Atypical neuroleptic with analgesic properties. Minor extrapyramidal effects. Has been used in the treatment of severe pain, anxiety and agitation. Dosage about 40 mg daily. Insomnia at low doses reported.;; ;;;;;;;etymemazine (étymémazine, 6484 RP, ethylisobutrazine);;;
5;A.III.1 ;Methotrimeprazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;aliphatic side chain; and a ;full chemical formula of ;L-10-[3-(dimethylamino)-2-methylpropyl]-2-methoxyphenothiazine;. ;Methotrimeprazine; has been marketed or used in ;Denmark, Iceland, Finland, Netherlands, Austria, FranceNorway, United Kingdom, Sweden, Italy, Portugal, Germany, United States of America, Spain; under the trade or premarketing names of ;Nozinan, Nozinan Nozinan, Nozinan faible, Neurocil, Levoprome, Levozin, Sinogan, Tisercin, Veractil, Veractil;NM: Nozinan Rhône-Poulenc Rorer, DK, ICL: tabs. 5mg, 25mg, 100mg - amps. 25mg/ml (deleted) - vials 250mg/10ml (deleted) - mikstur 1% (not in ICL) NM: Nozinan FIN: tabs. 5mg, 25mg, 50mg, 100mg - mikstuura embonate 10mg/ml - amps. 25mg/ml NM: Nozinan Rhône-Poulenc Rorer, NL, B, CH - Gerot, A: f-c tabs. 25mg and 100mg - drops 4% -amps. 25mg/ml - NL, CH: Minozinan tabs. 2mg NM: Nozinan Spécia (RPR), F: tabs. 25mg and 100mg - tabs. 2mg (Nozinan faible) - amps. 25mg/ml - gouttes buvables 4% (1 drop 1 mg) NM: Nozinan Specia, GR: tabs. 25mg - amps. 25mg/ml NM: Nozinan Pharmacia, NOR: tabs. 5mg, 25mg, 100mg - mixtur 5mg/ml - amps.25mg/ml NM: Nozinan Rhône-Poulenc Rorer, UK: tabs. 25mg - amps. 25mg/ml NM: Nozinan SWE: (Rhône-Poulenc) tabs. 2½mg, 5mg, 25mg and 100mg - mixtur (embonate) 5mg/ml - amps. 25mg/ml NM: Nozinan Rhône-Poulenc Rorer, ITA: tabs. 25mg, 100mg NM: Nozinan Vitoria, PORT: tabs. 25mg, 100mg - drops 4% NM: Neurocil Bayer, BRD: tabs. 25mg, 100mg - drops 4% - amps. 25mg/ml NM: Levoprome Lederle, USA: amps. and vials 20mg/ml NM: Levozin Orion, FIN: tabs. 5mg, 25mg, 50mg and 100mg - amps. 25mg/ml - mikstuura 5mg/ml (as embonate) NM: Sinogan RPR, ESP: tabs. 25mg, 100mg - sol. 4% - amps.25mg/ml NM: Tisercin Thiemann, BRD: f-c tabs. 25mg - amps. 25mg/ml NM: Veractil RPR, UK: tabs. 25mg (for amps. see Nozinan, RPR, UK) (deleted) NM: Veractil Rhône-Poulenc Rorer, NOR: tabs. 5mg, 25mg, 50mg, 100mg – mikstur (syrup) 10mg/ml;. ;Levo-isomer. Pronounced sedative properties. Used in the management of psychomotor agitation, aggressive behavior, confusional states. Combined with antidepressants in agitated depressions. Also as premedication in surgery and for the relief of pain/ in USA almost exclusively for analgesia. Main neuroleptic active metabolites are N-demethyl-methotrimeprazine and its sulfoxides. Terminal plasma half-life after multiple oral administration 16 to 78 hours.;"Bagli M, Hoflich G, Rao ML, Langer M, Baumann P, Kolbinger M, et al.~Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects~International journal of clinical pharmacology and therapeutics~1995~33(12)~646-52#Hals PA, Dahl SG~Metabolism of levomepromazine in man~European journal of drug metabolism and pharmacokinetics~1995~20(1)~61-71#
Bagli M, Hoflich G, Rao ML, Langer M, Baumann P, Kolbinger M, et al.~Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects~International journal of clinical pharmacology and therapeutics~1995~33(12)~646-52
";Bagli M, Rao ML, Höflich G: Quantification of chlorprothixene, levopromazine and promethazine in human serum using high-performance liquid chromatography with coulometric electrochemical detection. J Chromatogr B Biomed Appl 657/1: 141-148, 1994 - Hals PA, Dahl SG: Metabolism of levopromazine in man. Eur J Drug Metab Pharmacokinet 20/1: 61-71, 1995 - Bagli M, Rao ML, Höflich G: Bioequivalence and absolute bioavailibility of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. Int J Clin Pharmacol Ther 33/12: 646-652, 1995.;;;;;;;methotrimeprazine (levomepromazine, 7044 RP);;;
6;A.III.1;Cyamemazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;aliphatic side chain; and a ;full chemical formula of ;10-[3-(dimethylamino)-2-methylpropyl] phenothiazine-2- carbonitrile;. ;Cyamemazine; has been marketed or used in ;France, Portugal; under the trade or premarketing names of ;Tercian;NM: Tercian Spécia (RPR), F: f-c tabs. 25mg, 100mg - gouttes 4% (1 drop 1mg) - amps. 50mg/5ml NM: Tercian Vitoria, PORT: tabs. 100mg - drops 4%;. ;Major sedative neuroleptic. Dosage 50 up to 600 mg daily. At low dosage in the treatment of insomnia and anxiety states. Plasma half-life about 10 hours.;WHO Drug Information~Cyamemazine~~1988~2(3)~158;Cyamemazine. WHO Drug Information vol 2(3): 158, 1988 - Remy AJ, Larrey D, Pageaux GP & al: Cross hepatotoxicity between tricyclic antidepressants and phenothiazines. Eur J Gastroenterol Hepatol 7/4: 373- 376, 1995.;;;;;;;cyamemazine (cyamepromazine, 7204 RP);;;
7;A.III.1 ;Methopromazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;aliphatic side chain; and a ;full chemical formula of ;10-[3-(dimethylamino)propyl]-2-methoxy phenothiazine;. ;Methopromazine; has been marketed or used in ;United States of America, France; under the trade or premarketing names of ;Tentone, CL 22.373, 4362 RP;NM: Tentone Lederle, USA (deleted) NM: CL 22.373 Lederle NM: 4362 RP Rhône-Poulenc Rorer, F;. ;Atypical neuroleptic agent. In comparison to chlorpromazine lower neuroleptic potency. Anticholinergic effects. Formerly used in the management of psychomotor disturbances. Dosage 25-100mg/day, incidentally much higher.;;;;;;;;;methopromazine (methoxypromazine);;;
8;A.III.1 ;Triflupromazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;aliphatic side chain; and a ;full chemical formula of ;10-(3-dimethylaminopropyl)-2-(trifluoromethyl) phenothiazine;. ;Triflupromazine; has been marketed or used in ;Netherlands, Belgium, Austria, Germany; under the trade or premarketing names of ;Siquil, Psyquil, Psyqui, Psyquil Compositum, Vesprin;NM: Siquil Bristol Myers Squibb, NL: tabs. 10mg, 25mg - vials 100mg/10ml (deleted) - B: vials 100mg/10ml (deleted) NM: Psyquil Bristol Myers Squibb, A - Sanofi Winthrop, BRD: s-c tabs. 10mg (not in BRD), 25mg, 50mg (not in A) - amps. 10mg/ml, 20mg/ml - suppos. 70mg (not in A) NM: Psyquil Squibb, CH: amps. 10mg/ml (deleted) NM: Psyquil Compositum B.M.S., BRD: amps. of 2ml containing 20mg triflupromazine + 50mg pethidine (deleted) NM: Vesprin Squibb, USA: tabs. 10mg, 25mg, 50mg - amps. 10mg/ml and 20mg/ml - also vials 100mg/10ml - high potency suspension 50mg/5ml;. ;Used in the symptomatic treatment of psychotic disorders. Studied for the control of severe nausea and vomiting. In BRD also as premedication in surgery. Dosage in clinical treatment 75 - 150 mg daily. Doses over 800 mg/day reported.;Gowda A~Determination of triflupromazine (TFH) and trifluperazine hydrochloride (TPH) in pharmaceutical preparations~Indian J Pharm Sci~1984~46(220-2)~;Gowda A: Determination of triflupromazine (TFH) and trifluperazine hydrochloride (TPH) in pharmaceutical preparations. Indian J Pharm Sci 46: 220-222, 1984 - Zivin J, Kochhar A, Saitoh T: Phenothiazines reduce ischemic damage to the central nervous system. Brain Research 482: 189-193, 1989.;;;;;;;triflupromazine;;;
9;A.III.1 ;Aminopromazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;aliphatic side chain; and a ;full chemical formula of ;10-[2,3-bis(dimethylamino) propyl]phenothiazine fumarate (Ebutenedioate);. ;Aminopromazine; has been marketed or used in ;France; under the trade or premarketing names of ;Lispamol;NM: Lispamol Specia, F: (deleted);. ;Neuroleptic activity weak or absent/ marked anticholinergic properties. Has been used as spasmolytic agent in the treatment of colitis, obstipation and dysmenorrhea.;;;;;;;;;aminopromazine (3828 RP);;;
10;A.III.2 ;Propiomazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;antihistaminic properties; and a ;full chemical formula of ;1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]-1-propanone maleate;. ;Propiomazine; has been marketed or used in ;United States of America, Belgium, France, Sweden; under the trade or premarketing names of ;Largon, Dorevane, Propavan, WY 1359;NM: Largon Wyeth, USA (deleted) NM: Dorevane Clin Byla, (formerly in B and F) NM: Propavan Sanofi Winthrop, SWE: tabs. 25mg NM: WY 1359 Wyeth, USA;. ;Antihistamine with sedative, hypnotic and analgesic properties.Studied as a sleep-inducing agent in the elderly. Not identical with the more specific sedating isomer propiopromazine (Combelen). -Plasma half-life about 8 hours.;Almqvist M, Liljenberg B, Hetta J, Rimon R, Hambert G, Roos BE~Effects of propiomazine on the EEG sleep of normal subjects~Pharmacology & toxicology~1987~61(5)~278-81#Roslund K, Olsen I~A clinical trial of propiomazine and placebo in the treatment of insomnia in the elderly~Current therapeutic research~1987~41(1)~6-12;Almqvist M, Liljenberg B, Hetta J, et al: Effects of propiomazine on the EEG sleep of normal subjects. Pharmacol Toxicol 61: 278-284, 1987 - Roslund K, Olsen I: A clinical trial of propiomazine and placebo in the treatment of insomnia in the elderly. Curr Ther Res 41: 6-12, 1987.;;;;;;;propiomazine (CB 1678);;;
11;A.III.2 ;Alimemazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;antihistaminic properties; and a ;full chemical formula of ;10-[3-(dimethylamino)2-methylpropyl]phenothiazine;. ;Alimemazine; has been marketed or used in ;Netherlands, Germany, Belgium, France, Denmark, Finland, Norway, United Kingdom; under the trade or premarketing names of ;Nedeltran, Theralene, Théralène, Theralen, Repeltin, Vallergan;NM: Nedeltran Rhône-Poulenc Rorer, NL: tabs. 5mg (deleted), 10mg (deleted), 25mg - drops 4% (1 drop 1mg) - syrup ½mg/ml NM: Theralene Rhône-Poulenc, BRD: drops 4% - syrup 0.5mg/ml NM: Théralène Rhône-Poulenc Rorer, B: tabs. 5mg, 10mg - drops 4% - syrup 2½mg/5ml NM: Théralène Théraplix, F: f-c tabs. 5mg - syrup 2½mg/5ml - sol. buvable 40mg/ml - amps. 25mg/5ml NM: Theralen Rhône-Poulenc Rorer, SWE: tabs. 5mg - drops 40mg/ml - mixtur ½mg/ml NM: Repeltin Pierre Fabre Dermo Kosmetic, BRD: tabs. 5mg - Repeltin forte tabs. 25mg NM: Vallergan Rhône-Poulenc Rorer, DK, FIN (deleted), NOR: tabs. 10mg - mixtur 5mg/ml (not in DK) NM: Vallergan Rhône-Poulenc Rorer, UK: f-c tabs. 10mg - syrup 7½mg/5ml and 30mg/5ml;. ;Histamine H antagonist. No neuroleptic properties. Sedative effects. Used as hypnotic and for 1 premedication. Studied in the management of agitation and confusion in the elderly. Plasma halflife 4.4 to 18.3 hours/ median 6.8 hours.;Phillips GH, Mian T, Becker U, Stone PA, Jones HM~Oral premedication in children. A comparison of trimeprazine with a trimeprazine, droperidol and methadone mixture~Anaesthesia~1990~45(10)~870-2#Sponheim S, Aune H, Gulliksen M, Morland J~Pharmacokinetics of trimeprazine in children~Pharmacology & toxicology~1990~67(3)~243-5;Phillips GH, Mian T, Becker U, et al: Oral premedication in children. A comparison of trimeprazine with a trimeprazine, droperidol and methadone mixture. Anaesthesia 45: 870-872, 1990 - Sponheim S, Aune H, Gulliksen M, et al: Pharmacokinetics of trimeprazine in children. Pharmacol Toxicol 67: 243-245, 1990.;;;;;;;alimemazine (trimeprazine, 6549 RP);;;
12;A.III.2 ;Oxomemazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;antihistaminic properties; and a ;full chemical formula of ;10-[3-(dimethylamino)-2-methylpropyl]phenothiazine- 5,5-dioxide;. ;Oxomemazine; has been marketed or used in ;Belgium, Netherlands, France, Switzerland; under the trade or premarketing names of ;Doxergan, Imakol, Toplexil, Aplexil;NM: Doxergan Rhône-Poulenc Rorer, B, NL: tabs. 10mg (not in NL) - syrup 1mg/ml NM: Doxergan Spécia, F: tabs. 10mg - syrup 1mg/ml (deleted) NM: Imakol Rhône-Poulenc, BRD: tabs./syrup (deleted) NM: Toplexil Rhône-Poulenc Rorer,B, GR, NL, CH: syrup 1.66mg/5ml+add. NM: Toplexil Spécia, F: syrup 1.66mg/5ml - caps. 1.65 mg NM: Aplexil brand name of Spécia NM: Aplexil Gerot, A: caps. 1.65mg+add. - syrup 1.65mg/5ml+add.;. ;Derivative of the histamine H antagonist alimemazine. No neuroleptic effects. Due to sedative 1 properties also used in the management of insomnia and aggressive behavior. Very low proteine binding reported. No recent references.;Friedrich R~Aplexil zur Behandlung der unspezifischen chronischen Erkrankungen der Atmungsorgane und des Hustens~Therapiewoche~1966~16(1704-1706)~#Thoma K, Arning M~[Colloidal, partition and binding properties of phenothiazine derivatives, V: Relationships between albumin binding and physical properties (author's transl)]~Archiv der Pharmazie~1976~309(12)~945-59;Friedrich R: Aplexil zur Behandlung der unspezifischen chronischen Erkrankungen der Atmungsorgane und des Hustens. Therapiewoche 16: 1704-1706, 1966 - Thoma K, Arning M: Kolloidchemische Eigenschaften, Verteilungs- und Bindungsverhalten von Phenothiazinderivaten. Beziehungen zwischen Eiweissbindung und physikalischchemischen Eigenschaften. Archiv Pharmazie 309: 945-959, 1976.;;;;;;;oxomemazine (6847 RP);;;
13;A.III.2 ;Promethazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;antihistaminic properties; and a ;full chemical formula of ;10-[2-(dimethylamino)propyl]phenothiazine;. ;Promethazine; has been marketed or used in ;Belgium, Greece, Netherlands, Finland, Denmark, France, United Kingdom, Austria, Germany, Sweden, Switzerland, Spain; under the trade or premarketing names of ;Phenergan, Atosil, Avomine, Eusedon mono, Lergigan, Nardyl, Prothazin liq., Prothazin, Psicho-Soma, Sominex, Soporil;NM: Phenergan Théraplix (RPR), B, GR, NL: s-c tabs. 25mg - amps. 50mg/2ml - also syrup 1mg/ml (not in NL) - DK, NOR, FIN: s-c tabs. 10mg (not in DK), 25mg - amps. 50mg/2ml (DK also mikstur 1mg/ml) NM: Phenergan Théraplix (RPR), F - RPR, CH: s-c tabs. 25mg - amps. 50mg per 2ml - syrup 5mg/5ml ( 0.1 %) - crème NM: Phenergan Rhône-Poulenc, UK: f-c tabs. 10mg, 25mg - amps. 25mg/ml - elixir 5mg/5ml NM: Phenergan Gerot, A: s-c tabs. 25mg - amps. 50mg/ml - syrup 1mg/1ml NM: Atosil Bayer, BRD - Kolassa, A: f-c tabs. 25mg - drops 20mg/ml - syrup 1mg/ml - suppositories 50mg - amps. 50mg/2ml (deleted in A) NM: Avomine Rhône Poulenc Rorer, UK: tabs. 25mg (theoclate) NM: Eusedon mono Krewel, BRD: drops 5mg/ml NM: Lergigan Recip, SWE: f-c tabs. 5mg, 25mg, 50mg - mixtur (syrup) 1mg/ml -Lergigan comp. tabs. 10mg+add. NM: Nardyl Vifor Fribourg, CH: s-c tabs. 10mg in combination with hyosciamine, atropine, scopolamine NM: Prothazin liq. Pharma Wernigerode, BRD: sol. 20mg/ml NM: Prothazin Rodleben, BRD: s-c tabs. 25mg - amps. 50mg/ml - sol.20mg/ml NM: Psicho-Soma Ferrer, ESP: sol.7½mg/5g+magnesium glutamate NM: Sominex Beecham, UK: tabs. 20mg (as sleeping aid for insomnia) (deleted) NM: Soporil Duphar, BRD: s-c tabs. 25mg;. ;Histamine H -antagonist. Antiemetic and sedative properties/ no neuroleptic activity. Used in 1 combination with neuroleptics in lytic cocktails for premedication. As hypnotic and adjuvans in analgesia. Parenteral administration in the management of neuroleptic-induced dyskinesia. Mean terminal plasma half-life in healthy subjects after i.v. administration approx. 12.2 hours.;Blanc M, Girard M, Granier F, Escande M, Cotonat J~[Pharmacokinetics of pipothiazine palmitate, after intramuscular administration in schizophrenic patients]~Therapie~1986~41(1)~27-30#Ponder GW, Stewart JT~A liquid chromatographic method for the determination of promethazine enantiomers in human urine and serum using solid-phase extraction and fluorescence detection~Journal of pharmaceutical and biomedical analysis~1995~13(9)~1161-6;Blanc VF, Ruest P, Milot J, et al: Antiemetic prophylaxis with promethazine or droperidol in paediatric outpatient strabismus surgery. Can J Anaesthesia 38: 54-60, 1991 - Bagli M, Rao ML, Höflich G: Quantification of chlorprothixene, levopromazine and promethazine in human serum using highperformance liquid chromatography with coulometric electrochemical detection. J Chromatogr B Biomed Appl 657/1: 141-148, 1994 - Ponger GW, Stewart JT: A liquid chromatographic method for the determination of promethazine enantiomers in human urine and serum using solid-phase extraction and fluorescence detection. J Pharm Biomed Appl 13: 1161-1166, 1995.;;;;;;;promethazine (3277 RP);;;
14;A.III.3 ;Butaperazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;methylpiperazine side chain; and a ;full chemical formula of ;1-[10-[3-(4-methyl-1-piperazinyl)propyl] phenothiazin-2-yl]-1- butanone (dimaleate);. ;Butaperazine; has been marketed or used in ;Germany, United States of America; under the trade or premarketing names of ;Randolectil, Neuronal, Repoise;NM: Randolectil Bayer, BRD - Bay 1362 (deleted) NM: Neuronal formerly Asche, BRD NM: Repoise Robins, USA;. ;Has been used in the treatment of severe psychoses and therapy-resistant schizophrenia. Incisive neuroleptic activity. Dosage up to 30 mg/day. Formerly also in NL. Terminal plasma half-life about 6 up to 26 hours.;Simpson GM, Yadalam K~Blood levels of neuroleptics: state of the art~The Journal of clinical psychiatry~1985~46(5 Pt 2)~22-8;Simpson GM, Yadalam K: Blood levels of neuroleptics: state of the art. J Clin Psychiatry 46: 22-28, 1985 - Wolf ME, Javaid JI, Mosnaim AD: Butaperazine pharmacokinetics in tardive dyskinesia. Biopharm Drug Dispos 6: 223-227, 1985.;;;;;;;butaperazine (butyrylperazine, AHR 712);;;
15;A.III.3 ;Thioproperazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;methylpiperazine side chain; and a ;full chemical formula of ;N,N-dimethyl-10-[3-(4-methyl-1-piperazinyl) propyl]phenothiazine-2-sulfonamide (mesylate);. ;Thioproperazine; has been marketed or used in ;Belgium, France, Finland, Greece; under the trade or premarketing names of ;Majeptil;NM: Majeptil Rhône-Poulenc Rorer, B: tabs. 10mg - drops 4% Spécia, F: f-c tabs. 10mg - goutt. buvables 4% (1drop 1mg) NM: Majeptil FIN: tabs. 25mg - GR, ESP (deleted): tabs. 10mg;. ;Potent neuroleptic for the treatment of severe psychotic disorders. Continuous or discontinuous therapy (chimioshock/ Jean Delay). Motor phenomena. Antiemetic effects.;Boireau A, Blanchard JC, Garret C, Julou L~The use of thioproperazine, a phenothiazine derivative, as a ligand for neuroleptic receptors--II. In vivo studies~Biochemical pharmacology~1980~29(21)~2939-42;Boireau A, Blanchard JC, Garret C: The use of thioproperazine, a phenothiazine derivative, as ligand for neuroleptic receptors. Biochem Pharmacol 29: 2939-2942, 1980 - Boschi G, Launay N, Rips R: Neuroleptic-induced hypothermia in mice: lack of evidence for a central mechanism. Br J Pharmacol 90: 745-751, 1987.;;;;;;;thioproperazine (7843 RP);;;
16;A.III.3 ;Perazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;methylpiperazine side chain; and a ;full chemical formula of ;10-[3-(4-methyl-1-piperazinyl)propyl] phenothiazine (hydrogen malonate);. ;Perazine; has been marketed or used in ;Netherlands, Belgium, Germany; under the trade or premarketing names of ;Taxilan;NM: NM: Taxilan Byk, NL: s-c tabs. 25mg, 100mg (other forms deleted) NM: Taxilan Byk Belga, B (deleted) - Promonta Lundbeck, BRD: s-c tabs. 25mg, 100mg - drops 44mg/ml - amps. 50mg/2ml;. ;Particularly used in delusional states. At low dosage for behavioral disturbances in the elderly. Sedative and anticholinergic effects. Plasma half-life about 35 hours.;Rao ML~Monitoring of serum bioactivity levels of perazine and its metabolites by radioreceptor assay~Pharmacopsychiatry~1989~22(3)~104-7;Rao ML: Monitoring of serum bioactivity of perazine and its metabolites by radioreceptor assay. Pharmacopsychiatry 22: 104-107, 1989 - Brand U, Menge HG, Neumann BW, et al: Pharmacological studies on perazine and its primary metabolites. Pharmacopsychiatry 22: 255-257, 1989.;;;;;;;perazine;;;
17;A.III.3 ;Thiethylperazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;methylpiperazine side chain; and a ;full chemical formula of ;2-ethylthio-10-[3-(4-methyl-1-piperazinyl) propyl]phenothiazine (hydrogen maleate);. ;Thiethylperazine; has been marketed or used in ;Netherlands, Austria, Belgium, Denmark, Finland, Greece, SwedenItaly, United Kingdom, Spain, Germany, Norway, France, United States of America; under the trade or premarketing names of ;Torecan, Torécan;NM: Torecan Wander, NL - Sandoz, A: s-c tabs. 6½mg - amps. 6½mg/ml (deleted in NL) - suppositories 6½mg NM: Torecan Wander, B: s-c tabs. 6½mg (suspended) - amps. 6½mg/ml (deleted) NM: Torecan Sandoz, BRD, CH, DK, FIN, GR, NOR, SWE, ITA, UK (deleted) - ESP: s-c tabs.6½mg (not in SWE) - amps. 6½mg/ml (not in ESP, DK, BRD, ITA) - suppos. 6½mg (not in BRD, NOR) NM: Torécan Sandoz, F: s-c tabs. 10mg (dimaleate) (deleted) NM: Torecan Boehringer Ingelheim, USA: tabs. 10mg - amps. 10mg/2ml - suppos. 10mg (all forms maleate);. ;Neuroleptic-type antiemetic for the treatment of nausea and vomiting. May be effective in vertigo. Potential antipsychotic efficacy/ extrapyramidal symptoms may occur, also dystonic effects and prolactin stimulation. Elimination half-life after oral administration about 12 hours.;;Rotrosen J: Thiethylperazine. Clinical antipsychotic efficacy and correlation with potency in predictive systems. Arch Gen Psychiatry 35: 1112-1118, 1978 -Vlachos P: Dystonic reactions following thiethylperazine in children. Toxicol Letters 13: 183-184, 1982 - Sulkava R: Thiethylperazine and tardive dyskinesia. Acta Neurol Scand 70: 369-372, 1984.;;;;;;;thiethylperazine;;;
18;A.III.3 ;Chlorperazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;methylpiperazine side chain; and a ;full chemical formula of ;2-chloro-10-[3-(4-methyl-1-piperazinyl) propyl]pheno-thiazine (dimaleate);. ;Chlorperazine; has been marketed or used in ;Netherlands, Switzerland, Finland, Norway, IcelandSweden, Republic of South Africa, United Kingdom, France, United States of America; under the trade or premarketing names of ;Stemetil, Tementil, Buccastem, Compazine, Klometil, Trinigrin, Vertigon;NM: Stemetil Rhône-Poulenc Rorer, NL, CH: tabs. 10mg (not in NL)- suppositories 5mg, 25mg - CH: also drops 1% (range deleted in CH) NM: Stemetil Rhône-Poulenc Rorer, DK, FIN, NOR, ICL: tabs. 5mg, 25mg - amps. 25mg/2ml (not in FIN, NOR, ICL) - suppos. 25mg (FIN also 5mg) NM: Stemetil Rhône-Poulenc Rorer, SWE: tabs. 5mg, 10mg - mixtur 1mg/ml (deleted) - suppositories 25mg - amps. 10mg/2ml NM: Stemetil Rhône-Poulenc Rorer, RSA: tabs. 5mg - syrup 5mg/5ml - amps. 12½mg/ml, 25mg/2ml - suppos.5mg NM: Stemetil Rhône-Poulenc Rorer, UK: tabs. 5mg, 25mg - syrup 5mg/5ml - amps. 12½mg/ml - amps. 25mg/2ml - suppositories 5mg and 25mg - effervescent powder 5mg/sachet NM: Tementil Spécia, F: gouttes buvables 4% (1 drop 1mg) (deleted) NM: Buccastem Reckitt Colman, UK: lozenges 3mg NM: Compazine SmithKline Beecham, USA: spansules 10mg, 15mg, 30mg, 75mg - tabs. 5mg, 10mg, 25mg- various other presentations NM: Klometil Orion Farmos, FIN: tabs. 5mg, 10mg, 25mg - suppositories 5mg and 25mg NM: Trinigrin Lääkefarmos, FIN: tabs. 5mg+2mg diazepam+1mg ergotamin tartrate (antimigraine) NM: Vertigon S.K.F., UK: spansules 10mg and 15mg;. ;At low dosage for the treatment of nausea, vomiting and minor mental disturbances/ in NL classified as an antiemetic. Has been used in the management of schizophrenic psychoses at doses of 50 to 100 mg daily/ dosage up to 200 mg daily reported. Plasma half-life after i.v. administration 6.8 ± 0.7 hours.;Taylor WB, Bateman DN~Preliminary studies of the pharmacokinetic and pharmacodynamics of prochlorperazine in healthy volunteers~British journal of clinical pharmacology~1987~23(2)~137-42#Dannenberg A, Zakim D~Effects of prochlorperazine on the function of integral membrane proteins~Biochemical pharmacology~1988~37(7)~1259-62;Taylor WB, Bateman DN: Preliminary studies of the pharmacokinetics and pharmacodynamics of chlorperazine in healthy subjects. Br J Clin Pharmacology 23: 137-142, 1987 - Dannenberg A, Zakim D: Effects of prochlorperazine on the function of integral membrane proteins. Biochem Pharmacology 37: 1259-1262, 1988.;;;;;;;chlorperazine (prochlorperazine, 6140 RP);;;
19;A.III.3 ;Trifluoperazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;methylpiperazine side chain; and a ;full chemical formula of ;10-[3-(4-methyl-1-piperazinyl)propyl]-2-trifluoromethylpheno thiazine (hydrochloride);. ;Trifluoperazine; has been marketed or used in ;Netherlands, Switzerland, France, Denmark, Sweden, Greece, SpainGermany, Austria, Italy, United Kingdom, United States of America, Republic of South Africa, Saudi-Arabia; under the trade or premarketing names of ;Terfluzine, Terfluzin, Discimer, Eskazine, Foille, Iremo Pierol, Jatroneural, Modalina, Oxyperazine, Sedofren, Sporalon, Stelazine, Stelium, Terflurazine, Terfluoperazine, SFK 5019, 7623 RP;NM: Terfluzine Rhône-Poulenc Rorer, NL: tabs.1mg, 10mg and 100mg - Rhône-Poulenc, CH: tabs. 10mg (deleted) - Spécia (RPR), F: f-c tabs. 10mg, 100mg - gouttes 40mg/ml (1drop 1mg) NM: Terfluzin Rhône-Poulenc Rorer, DK, FIN: s-c tabs. 1mg, 5mg (range deleted) - NOR: s-c tabs. 1mg, 5mg and f-c tabs. 10mg (range deleted) - SWE: tabs. 1mg, 5mg (range deleted) NM: Discimer Bros, GR: tabs. 1mg, 5mg NM: Eskazine Smith Kline French, ESP: s-c tabs. 1mg, 2mg, 5mg NM: Foille Livafarm, GR: s-c tabs. 1mg, 2mg, 5mg (deleted) NM: Iremo Pierol Pefanic, GR: tabs. 1mg, 2mg, 5mg NM: Jatroneural Procter & Gamble Pharmaceuticals, BRD - Roehm Pharma, A: retard caps.2mg NM: Modalina Midy, ITA: s-c tabs. 1mg, 2mg NM: Oxyperazine Coup, GR: tabs. 2mg, 5mg NM: Sedofren Proel, GR: tabs. 1mg, 2mg, 5mg NM: Sporalon Velka, GR: tabs. 2mg, 5mg NM: Stelazine S.K.B., GR/ spansules 2mg, 15mg - tabs. 1mg, 2mg and 5mg - S.K.B., UK: s-c tabs. 1mg, 5mg - syrup 1mg/5ml -spansules 2mg, 10mg, 15mg - amps. 1mg/ml - concentrate 10mg/ml - S.K.B., USA: tabs. 1mg, 2mg, 5mg, 10mg - vials - 20mg per 10ml - concentrate 10mg/ml - S.K.B., RSA: tabs. 1½mg NM: Stelium Ni-The, GR: tabs. 1mg, 3mg, 5mg NM: Terflurazine Lennon, SAR: tabs. 1mg, 2mg, 5mg NM: Terfluoperazine Smith Kline French, ESP: tabs. 1mg, 2mg NM: SFK 5019 Smith Kline Beecham, USA NM: 7623 RP Rhône-Poulenc Rorer, F;. ;D /weak D receptors antagonist. Dosage in the treatment of schizophrenic psychosis and 2 severe psychomotor disorders up to about 40 mg/day. Much higher doses have been given occasionally. At low dosage also used to control excessive anxiety states. Main active metabolites are the sulfoxides and the N-demethylated derivative. Terminal plasma half-life in healthy volunteers after oral administration 13.3 + 0.9 hours/ plasma half-life of the active 7- hydroxy metabolite 10.6 + 5.7 hours.;" Ngen CC, Singh P~Long-term phenothiazine administration and the eye in 100 Malaysians~The British journal of psychiatry : the journal of mental science~1988~152(278-80)~#Midha KK, Hawes EM, Hubbard JW, Korchinski ED, McKay G~A pharmacokinetic study of trifluoperazine in two ethnic populations~Psychopharmacology~1988~95(3)~333-8
#Cortijo J, Foster RW, Small RC, Morcillo EJ~Calcium antagonist properties of cinnarizine, trifluoperazine and verapamil in guinea-pig normal and skinned trachealis muscle~The Journal of pharmacy and pharmacology~1990~42(6)~405-11
";Ngen CC, Singh P: Long-term phenothiazine administration and the eye in 100 Malaysians. Br J Psychiatry 152: 278-280, 1988 - Midha KK, Hawes EM, Hubbard JW, et al: A pharmacokinetic study of trifluoperazine in two ethnic populations. Psychopharmacology 95 (3) : 333-338, 1988 - Cortijo J, Foster RW, Small RC, et al: Calcium antagonist properties of cinnarizine, trifluoperazine and verapamil in guinea pig normal and skinned trachealis muscle. J Pharm Pharmacology 42: 405-411, 1990.;Parstelin (1mg trifluoperazine/10mg tranylcypromine), Jatrosom N (1mg trifluoperazine/10mg tranylcypromine), Stelabid (deleted), Stelabid forte (deleted), Stelabid mite (1mg trifluoperazine/5mg isopropamide), Stelabid forte (2mg trifluoperazine/5mg isopropamide), Stelbid (1mg trifluoperzanine/5mg isopropamide), Stelbid forte (2mg trifluoperzanine/7 mg 1/2 isopropamide);;;COMB: FIXED COMBINATIONS OF TRIFLUOPERAZINE WITH OTHER AGENTS: NM: Parstelin S.K.B., UK/ s-c tabs. 1mg trifluoperazine/10mg tranylcypromine NM: Jatrosom N Röhm Pharma, BRD, A,: s-c tabs. 1mg trifluoperazine/10mg tranylcypromine NM: Stelabid S.K.B., UK: (deleted) NM: Stelabid forte S.K.B., UK: (deleted) NM: Stelabid mite Röhm, BRD, A: s-c tabs. 1mg trifluoperazine/5mg isopropamide (deleted in BRD) NM: Stelabid forte Röhm, BRD, A: s-c tabs. 2mg trifluoperazine/5mg isopropamide (deleted in BRD) NM: Stelbid S.K.B., GR: s-c tabs. 1mg trifluoperzanine/5mg isopropamide NM: Stelbid forte S.K.B., GR: s-c tabs. 2mg trifluoperzanine/7 mg 1/2 isopropamide;;;trifluoperazine;;;
20;A.III.4 ;Perphenazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperazineethanol side chain; and a ;full chemical formula of ;4-[3-(2-chlorophenothiazin-10-yl)propyl]-1-piperazine-ethanol (dihydrochloride);. ;Perphenazine; has been marketed or used in ;Netherlands, Belgium, Switzerland, France, Norway, Sweden, Republic of South Africa, GermanyAustria, Spain, United Kingdom, Finland; under the trade or premarketing names of ;Trilafon, Trilifan, Decentan, Fentazin, Peratsin;NM: Trilafon Schering Plough, NL: s-c tabs. 2mg, 4mg, 8mg - amps. 5mg/ml (deleted) - Schering Plough, B: s-c tabs. 2mg, 4mg, 8mg - repetabs. 8mg (deleted) - Essex Chemie, CH: s-c tabs. 2mg, 4mg and 8mg - amps. 5mg/ml (deleted) NM: Trilifan Schering Plough, F: s-c tabs. 16mg (deleted) NM: Trilafon Schering Plough, DK: s-c tabs. 2mg, 4mg, 8mg and 16mg - amps. 5mg/ml - drops 3.2mg/ml - Schering Plough, ITA: s-c tabs.2mg,4mg, 8mg-amps. 5mg/ml - Schering Plough, NOR: f-c tabs. 2mg, 4mg, 8mg, 16mg - prolongatum (4 + 4)mg - drops 3.2mg/ml - amps. 5mg/ml - Schering Plough, SWE: s-c tabs. 2mg, 4mg, 8mg - drops. 3.2mg/ml - amps. 5mg/ml (deleted) - prolongatum depot tabs. (4 + 4)mg NM: Trilafon Schering Plough, RSA: tabs. 4mg - SR tabs. 8mg NM: Trilafon Essex, ICL: tabs. 2mg, 4mg, 8mg, 16mg - mixture 3.2mg/ml - amps. 5mg/ml NM: Decentan Merck, BRD, A: tabs. 4mg - tabs. 8mg - amps. 5mg/ml (deleted) - drops 4mg/ml (5 drops 1mg) NM: Decentan Merck, ESP: tabs. 8mg (deleted) NM: Fentazin Fowley Ltd, UK - Evans Medical, UK: s-c tabs. 2mg, 4mg - amps. 5mg/ml (deleted) NM: Peratsin Orion Farmos, FIN: s-c tabs. 2mg, 4mg, 8mg - mikstuura 3.2mg/ml - amps. 5mg/ml - depot tabs. 8mg (4 + 4);. ;DA antagonist. Potent neuroleptic for the management of psychotic disorders, especially also chronic forms. Control of severe nausea and vomiting. Oral dosage 6 to 24 mg daily/ much higher doses are given clinically. The esterified forms, perphenazine enanthate and decanoate are used as long-acting depot injections, with intervals between injections of 1 to 3 weeks and 2 to 4 weeks respectively. Mean terminal plasma half-life of orally administered perphenazine about 9 hours.;"Dencker SJ, Gios I, Martensson E, Norden T, Nyberg G, Persson R, et al.~A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients~Psychopharmacology~1994~114(1)~24-30#
Spigset O, Carleborg L, Mjorndal T, Norstrom A, Sundgren M~Carbamazepine interference in a high-performance liquid chromatography analysis for perphenazine~Therapeutic drug monitoring~1994~16(3)~332-3#
Linnet K~Comparison of the kinetic interactions of the neuroleptics perphenazine and zuclopenthixol with tricyclic antidepressives~Therapeutic drug monitoring~1995~17(3)~308-11

";Dencker SJ, Gios I, Martensson E & al: A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. Psychopharmacology 114/1: 24-30, 1994 - Spigset O, Carleborg L, Mjorndal T & al: Carbamazepine interference in a highperformance liquid chromatography analysis for perphenazine. Ther Drug Monit 16/3: 332-333, 1994 - Linnet K: Comparison of the kinetic interactions of the neuroleptics perphenazine and zuclopenthixol with tricyclic antidepressives. Ther Drug Monit 17/3: 308-311, 1995.;;PERPHENAZINE ENANTHATE IN SESAME OIL (100 mg perphenazine enanthate 78.3 mg perphenazine): Trilafon enanthaat (amps. 100mg/ml), Trilafon enantat (amps. 100mg/ml), Trilifan retard (amps. 100mg/ml), Trilafon enantato (amps. 100mg/ml), Trilafon Depot (amps. 100mg/ml), Decentan-Depot (amps. 100mg/ml - vials 1g/1Oml), Peratsin Enantaati (amps. 100mg/ml);PERPHENAZINE DECANOATE IN SESAME OIL (108.2 mg perphenazine decanoate 78.3 mg perphenazine): Trilafon decanoaat (deleted), Trilafon decanoat (amps. 108.2 mg/ml), Trilafon dekanoat (amps. 108mg/ml), Peratsin Dekanoaatti (amps. 108 mg/ml);;DEP: DEPOT INJECTIONS PERPHENAZINE ENANTHATE IN SESAME OIL: (100 mg perphenazine enanthate 78.3 mg perphenazine) NM: Trilafon enanthaat Schering Plough, NL: amps. 100mg/ml NM: Trilafon enantat Schering Plough, DK, SWE - Essex, ICL: amps. 100mg/ml NM: Trilifan retard Schering Plough, F: amps. 100mg/ml NM: Trilafon enantato Schering Plough, ITA: amps. 100mg/ml NM: Trilafon Depot Schering Plough, RSA: amps. 100mg/ml NM: Decentan-Depot Merck, BRD: amps. 100mg/ml - vials 1g/1Oml NM: Peratsin Enantaati Orion, FIN: amps. 100mg/ml;DEP: DEPOT INJECTIONS PERPHENAZINE DECANOATE IN SESAME OIL: (108.2 mg perphenazine decanoate 78.3 mg perphenazine) NM: Trilafon decanoaat Shering Plough, NL: amps. 108.2 mg/ml (deleted) NM: Trilafon decanoat Schering Plough, DK: amps. 108.2 mg/ml NM: Trilafon dekanoat Schering Plough, NOR, SWE - Essex, ICL: amps. 108mg/ml NM: Peratsin Dekanoaatti Orion, FIN: amps. 108 mg/ml;perphenazine (SCH 3940, chlorperphenazine);;;
21;A.III.4 ;Thiopropazate;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperazineethanol side chain; and a ;full chemical formula of ;4-[3-(2-chlorophenothiazin-10-yl)propyl]-1-piperazine-ethanol acetate;. ;Thiopropazate; has been marketed or used in ;Netherlands, Belgium, Finland, United Kingdom; under the trade or premarketing names of ;Dartal, Dartalan;NM: Dartal Searle, NL: (deleted) NM: Dartalan Searle, B: formerly tabs. of 5mg NM: Dartalan Searle, FIN: formerly tabs. 5mg and 10mg NM: Dartalan Searle, UK: formerly tabs. of 5mg Acetyl ester of perphenazine/ release of free perphenazine after hydrolysis. In USA preferably used in combination with propantheline. Has been used in the treatment of tardive dyskinesia, Huntington's chorea and other motor disturbances.;. ;;Smith JS, Kiloh LG~Six month evaluation of thiopropazate hydrochloride in tardive dyskinesia~Journal of neurology, neurosurgery, and psychiatry~1979~42(6)~576-9#Gayte-Sorbier A, Airaudo CB~[Ultraviolet spectrophotometry of phenothiazine derivatives. III. Derivatives halogenated at the 2-position]~Annales pharmaceutiques francaises~1983~41(2)~167-76;Smith JS, Kiloh LG: Six month evaluation of thiopropazate hydrochloride in tardive dyskinesia. J Neurol Neurosurg Psychiatry 42: 576-579, 1979 - Gayté-Sorbier A, Airaudo CB: Etude spectrophotométrique dans l'ultraviolet des dérivés de la phénothiazine. Ann Pharm Franç 41: 167-176, 1983.;(DELETED): Tonoquil Boehringer (6mg thiopropazate + 6mg chlorphencyclan), Vesitan (10mg thiopropazate + 15mg chlorphencyclan);;;COMB: COMBINATIONS (DELETED): NM: Tonoquil Boehringer, BRD: s-c tabs. 6mg thiopropazate + 6mg chlorphencyclan NM: Vesitan Boehringer, BRD: s-c tabs. 10mg thiopropazate + 15mg chlorphencyclan;;;thiopropazate (SC 7105);;;
22;A.III.4 ;Fluphenazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperazineethanol side chain; and a ;full chemical formula of ;4-[3-[2-(trifluoromethyl)phenothiazin-10-yl] propyl]-1- piperazineethanol;. ;Fluphenazine; has been marketed or used in ;Netherlands, Belgium, France, Iceland, Italy, Greece, Portugal, AustriaSwitzerland, Germany, Republic of South Africa, Spain, Denmark, Finland, Sweden, Norway, United States of America; under the trade or premarketing names of ;Moditen, Anatensol, Cardilac, Cenilene, Dapotum, Dapotum Acutum, Eutimox, Flufenazin, Lyogen, Lyorodin, Omca, Pacinol, Pacinol Prolongatum, Permitil, Prolixin, Sevinol, Siqualone;NM: Moditen Sanofi Winthrop/Bristol Meyers Squibb, NL: s-c tabs. ½mg, 1mg, 2½mg (range deleted) NM: Moditen Sanofi Winthrop, B: s-c tabs. ½mg, 1mg (range deleted) NM: Moditen Sanofi Winthrop, F: s-c tabs. 25mg - tabs. 100mg - gouttes 4% (1 drop 1 mg) NM: Moditen Bristol Myers Squibb, ICL: tabs. 1mg, 5mg NM: Moditen Sanofi Winthrop, UK: s-c tabs. lmg, 2½mg, 5mg NM: Anatensol Bristol Myers Squibb, NL: s-c tabs. 2½mg (deleted), 5mg NM: Anatensol Bristol Myers Squibb, ITA: s-c tabs. 1mg NM: Cardilac Helos, GR: sust.-release tabs. 3mg NM: Cenilene Schering Essex, PORT: s-c tabs. 1mg NM: Dapotum Squibb Heyden/Sanofi Winthrop, BRD, Bristol Myers Squibb A: tabs. 5mg - drops 4mg/ml NM: Dapotum Squibb, CH: tabs. 5mg, 100mg - s-c tabs. 25mg -drops 4mg/ml NM: Dapotum Acutum Squibb Heyden/Sanofi Winthrop, BRD - BMS, A - Squibb, CH - BMS ETH, RSA: as dihydrochloride salt in aqueous solution for injection: amps. 10mg/ml (in BRD, CH), 2½mg/ml, 25mg/ml (in RSA) NM: Eutimox Squibb, ESP: amps. 25mg/ml NM: Flufenazin Bristol Myers Squibb, DK, ICL - Schering Plough, FIN, SWE - Essex, FIN: tabs.¼mg (not in DK, ICL) - SR tabs. prolangatum (0.75mg + 0.25mg) - in DK, FIN: tabs.1mg NM: Lyogen Promonta Lundbeck, BRD - Byk Gulden, A: tabs. 1mg, 4mg - retard drag. 3mg,6mg - drops 2½mg per ml - amps. 5mg/ml (range deleted in A) NM: Lyogen Byk, CH: tabs. 1mg -SR tabs. 3mg, 6mg (deleted) NM: Lyorodin Rodleben, BRD: s-c tabs. 1mg, 4mg NM: Omca Squibb Heyden, BRD: s-c tabs. 1mg NM: Pacinol Schering Plough, DK, SWE, FIN - Essex, ICL: s-c tabs. ¼mg - s-c tabs. 1mg (prolongatum) NM: Pacinol NM: Prolongatum Schering Plough, NOR: SR tabs. 1mg NM: Permitil White, B: chronotabs. ½mg, 1mg NM: Prolixin Bristol Myers Squibb, USA: tabs. 1mg, 2½mg, 5mg and 10mg - elixir 5mg/10ml - vials 25mg/10ml NM: Sevinol Schering Plough, B, GR: repetabs. 1mg NM: Siqualone Bristol Myers Squibb, FIN, NOR, SWE: s-c tabs. 1mg, 5mg NM: Siqualone Faes, ESP: s-c tabs. ½mg, 1mg;. ;For combinations Motival and Motipress Squibb, GR, UK, Motival Sanofi Winthrop F - Dominans, ITA: see nortriptyline D /D antagonist. High affinity for 5-HT /5-HT receptors. Oral dosage in minor disturbances 1 2 6 7 2 to 5 mg/day/ in the treatment of psychotic disorders up to 20 mg - 40 mg daily. Much higher doses have been used/ according to older data incidentally up to I200mg daily. Mean plasma half-life after administration of the oral form about 13 hours. A half-life of 3.4 - 43.6 hours after single 400 mg dosage has been reported. Release half-life of the decanoate ester 7 to 10 days/ of the enanthate ester about 3.7 days (old references reflecting only a few subjects). Active metabolites found in plasma: sulfoxides, N-oxide, and 7- and 8-hydroxyderivatives.;"Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Jr., Shen Y, et al.~Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors~The Journal of pharmacology and experimental therapeutics~1994~268(3)~1403-10#Miller RS, Peterson GM, McLean S, Westhead TT, Gillies P~Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate~Journal of clinical pharmacy and therapeutics~1995~20(2)~55-62#
Hadad S, Edom R, Mckay G, Hawes E, Midha K~Simultaneous measurement of fluphenazine and [2H4] fluphenazine in plasma using solids probe tandem mass spectrometry~Journal of Mass Spectrometry~1995~30(6)~849-56
";Roth BL, Craigo SC, Choudhary MS & al: Binding of typical and atypical antipsychotic agents to 5- hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268/3: 1403-1410, 1994 - Miller RS, Peterson GM, McLean S & al: Monitoring plasma levels of fluphenazine using chronic therapy with fluphenazine decanoate. J Clin Pharm Ther 20/2: 55-62, 1995 - Hadad S, Edom R, McKay G & al: Simultaneous measurement of fluphenazine and (2H4)fluphenazine in plasma during using solids probe tandem mass spectrometry. J Mass Spectom 30/6: 849-856, 1995.;;FLUPHENAZINE ENANTHATE IN SESAME OIL: Moditen Action Prolongée (amps. 25mg/ml, 100mg/4ml), Moditen Enanthate (amps. 25mg/ml), Siqualone Enantat (amps. 25mg/ml), Flufenazin Enantat (amps. 25mg/ml);FLUPHENAZINE DECANOATE IN SESAME OIL: Anatensoi Decanoaat (amps. 12½mg/½ml - amps./syringes 25mg/ml - vials 250mg/10ml), Anatensol Concentraat (amps. 50mg/½ml, 100mg/ml), Anatensol Decanoate (deleted), Anatensol Decanoate (amps. 25mg/ml, 50mg/ml), Dapotum D (amps. 12½mg/½ml - amps. 25mg/ml, 50mg/½ml, 100mg/ml - vials 250mg/10ml), Dapotum D (amps.2½mg/ml (D2.5) 12½mg/½ml (D12.5), 25mg/ml (D25),50mg/½ml (D50), 100mg/ml (D100) - vials 250mg/10ml (D250)), Dapotum Depot (amps. 12½mg/½ml, 25mg/ml, 50mg/½ml, 100mg/ml - Spritzamp 25mg/ml), Decazate (amps.25mg, 100mg), Flufenazin dekanoat (amps. 12½mg/½ml (deleted), 25mg/ml - vials 250mg/10ml (deleted), (amps. 100mg/ml), Flufenazin dekanoat (amps. 25mg/ml), Lyogen Depot (amps. and syringes 12½mg/½ml, 25mg/ml, 50mg/½ml, 100mg/ml - vials 250mg per 10ml), Lyoridin Depot (amps. 25mg/2ml), Modécate (amps. 25mg/ml multidoses 12.5mg/ 5ml), Modecate (amps. 25mg/ml and 100 mg/ml), Modecate (amps. 12½mg/½ml - amps./disposable syringes 25mg/ml and 50mg/2ml - vials 250mg/10ml), Modecate Concentrate (amps. 50mg/½ml and 100mg/ml), Modecate (amps. 25mg/ml), Modecate (amps. 25mg/ml), Modecate (amps. 25mg/ml - vials 250mg/10ml), Moditen Depot (amps. 25mg/ml), Prolixin Decanoate (amps./syringes 25mg/ml - vials 125mg/5ml), Siqualone decanoat (amps./syringes 25mg/ml);;DEP: DEPOT INJECTIONS FLUPHENAZINE ENANTHATE IN SESAME OIL: NM: Moditen Action Prolongée Sanofi Winthrop, F: amps. 25mg/ml and 100mg/4ml NM: Moditen Enanthate Bristol Myers Squibb, UK: amps. 25mg/ml NM: Siqualone Enantat Bristol Myers Squibb, FIN, NOR, SWE: amps. 25mg/ml NM: Flufenazin Enantat Bristol Myers Squibb, DK: amps. 25mg/ml;DEP: DEPOT INJECTIONS FLUPHENAZINE DECANOATE IN SESAME OIL: NM: Anatensoi Decanoaat Bristol Myers Squibb, NL: amps. 12½mg/½ml - amps./syringes 25mg/ml - vials 250mg/10ml NM: Anatensol NM: Concentraat Bristol Myers Squibb, NL: Anatensol decanoate amps. 50mg/½ml, 100mg/ml NM: Anatensol Decanoate Bristol Myers Squibb, B: amps. 25mg/ml (deleted) NM: Anatensol Decanoate Bristol Myers Squibb, ITA: amps. 25mg/ml, 50mg/ml NM: Dapotum D Squibb, CH: amps. 12½mg/½ml - amps. 25mg/ml, 50mg/½ml, 100mg/ml - vials 250mg/10ml NM: Dapotum D Squibb Heyden/Sanofi Winthrop, BRD: amps.2½mg/ml (D2.5) 12½mg/½ml (D12.5), 25mg/ml (D25),50mg/½ml (D50), 100mg/ml (D100) - vials 250mg/10ml (D250) NM: Dapotum Depot Bristol Myers Squibb, A: amps. 12½mg/½ml, 25mg/ml, 50mg/½ml, 100mg/ml - Spritzamp 25mg/ml NM: Decazate Berk Pharmaceuticals, UK: amps.25mg, 100mg NM: Flufenazin dekanoat Bristol Myers Squibb, DK: amps. 12½mg/½ml (deleted) and 25mg/ml - vials 250mg/10ml (deleted) - amps. 100mg/ml NM: Flufenazin dekanoat Bristol Myers Squibb, ICL: amps. 25mg/ml NM: Lyogen Depot Promonta Lundbeck, BRD: amps. and syringes 12½mg/½ml, 25mg/ml, 50mg/½ml, 100mg/ml - vials 250mg per 10ml NM: Lyoridin Depot Rodleben, BRD: amps. 25mg/2ml NM: Modécate Sanofi Winthrop, F: amps. 25mg/ml multidoses 12.5mg/ 5ml NM: Modecate Squibb, GR: amps. 25mg/ml and 100 mg/ml NM: Modecate Sanofi Winthrop, UK: amps. 12½mg/½ml - amps./disposable syringes 25mg/ml and 50mg/2ml - vials 250mg/10ml NM: Modecate Concentrate Squibb, UK: amps. 50mg/½ml and 100mg/ml NM: Modecate Squibb, ESP: amps. 25mg/ml NM: Modecate Bristol Myers Squibb, ICL: amps. 25mg/ml NM: Modecate Bristol Myers Squibb, RSA: amps. 25mg/ml - vials 250mg/10ml NM: Moditen Depot Bristol Myers Squibb, ITA: amps. 25mg/ml NM: Prolixin Decanoate Bristol Myers Squibb, USA: amps./syringes 25mg/ml - vials 125mg/5ml NM: Siqualone decanoat Bristol Myers Squibb, FIN, NOR, SWE: amps./syringes 25mg/ml;fluphenazine;;;
23;A.III.4 ;Acetophenazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperazineethanol side chain; and a ;full chemical formula of ;10-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propyl] phenothiazin-2-yl methyl keton (maleate);. ;Acetophenazine; has been marketed or used in ;Denmark, Sweden, United States of America, Finland; under the trade or premarketing names of ;Tindal;NM: Tindal Schering Plough, DK: s-c tabs. 20mg (deleted) - Schering Plough, SWE, USA, FIN: s-c tabs. 20mg (deleted);. ;Neuroleptic with sedative effects and minor or no extrapyramidal symptoms. In the treatment of psychoses 40 - 80 mg/day/ dosage up to 600mg daily reported. Formerly in NL for the treatment of agitational states in the elderly.;Hollister LE, Overall JE, Pokorny AD, Shelton J~Acetophenazine and diazepam in anxious depressions~Archives of general psychiatry~1971~24(3)~273-8#Helms PM~Efficacy of antipsychotics in the treatment of the behavioral complications of dementia: a review of the literature~Journal of the American Geriatrics Society~1985~33(3)~206-9;Hollister LE, Overall JE, Pokorny AD, et al: Acetophenazine and diazepam in anxious depression. Arch Gen Psychiatry 24: 273-278, 1971 - Helms PM: Efficacy of antipsychotics in the treatment of the behavioral complications of dementia: a review of the literature. J Am Geriatr Soc 33: 206-209, 1985.;;;;;;;acetophenazine (SCH 6673);;;
24;A.III.4 ;Carphenazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperazineethanol side chain; and a ;full chemical formula of ;1-[10-[3-(4-(2-hydroxyethyl)-1-piperazinyl) propyl]phenothiazin-2- yl]-1-propanone (hydrogen maleate);. ;Carphenazine; has been marketed or used in ;United States of America; under the trade or premarketing names of ;Prokethazine;NM: Prokethazine Wyeth, USA: formerly tabs. 25mg and 50mg;. ;According to old references used in the management of chronic schizophrenic psychoses. Dosage 50 - 150 mg/day.;Bronsky I~CARPHENAZINE THERAPY OF ACUTELY PSYCHOTIC PATIENTS IN THE PSYCHIATRIC WARD OF A GENERAL HOSPITAL~The American journal of psychiatry~1965~121(1203-4)~;Bronsky I: Carphenazine therapy of acutely psychotic patients in the psychiatric ward of a general hospital. Am J Psychiatry 121: 1203-1204, 1965.;;;;;;;carphenazine (WY 2445, WY 2443, WY 71553);;;
25;A.III.4 ;Dixyrazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperazineethanol side chain; and a ;full chemical formula of ;2-[2-[4-(3-(10-phenothiazinyl)-2-methyl propyl)-1- piperazinyl]ethoxy] ethanol;. ;Dixyrazine; has been marketed or used in ;Sweden, Belgium, Denmark, Finland, Italy, Norway, Germany; under the trade or premarketing names of ;Esucos, Roscal;NM: Esucos UCB, SWE: tabs. 10mg, 25mg - mixtur (syrup) 1mg/ml - amps. 20mg/2ml NM: Esucos UCB, B, DK, FIN, A: tabs. 10mg, 25mg (not in DK) - amps. 20mg/2ml NM: Esucos UCB, ITA, NOR: tabs. 10mg, 25mg Rodleben, BRD: tabs. 25mg, drops 22mg/ml NM: Roscal Rosco, DK: tabs. 10mg, 25mg (deleted);. ;Sedative in the management of anxiety, behavioral disorders and as premedication for surgery. Only minor extrapyramidal effects. Plasma half-life approx. 6 hours.;Larsson S, Jonmarker C~Postoperative emesis after pediatric strabismus surgery: the effect of dixyrazine compared to droperidol~Acta anaesthesiologica Scandinavica~1990~34(3)~227-30#Oikkonen M, Karkela J, Seppala T: CSF concentrations and clinical effects following intravenous dixyrazine premedication. Eur J Clin Pharmacol 47/5: 445-447, 1995.;Larsson S, Jonmarker C: Postoperative emesis after pediatric strabismus surgery: the effect of dixyrazine compared to droperidol. Acta Anaesthesiol Scand 34: 227-230, 1990 - Oikkonen M, Karkela J, Seppala T: CSF concentrations and clinical effects following intravenous dixyrazine premedication. Eur J Clin Pharmacol 47/5: 445-447, 1995.;;;;;;;dixyrazine (UCB 3412);;;
26;A.III.5 ;Methophenazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperazineethyl side chain; and a ;full chemical formula of ;4-[3-(2-chlorophenothiazin-10-yl)propyl]-1-piperazinyl-ethyl 3,4,5-trimethoxybenzoate;. ;Methophenazine; has been marketed or used in ;Germany, Hungary; under the trade or premarketing names of ;Frenolon, Methofenazin;NM: Frenolon Thiemann, BRD: s-c tabs. 2mg, 5mg NM: Frenolon Medimpex, Egyt, HUN NM: Methofenazin Lentia, BRD: (deleted);. ;Esterified derivative of perphenazine. As major tranquilizer used in the treatment of schizophrenic and schizoaffective psychoses. Studied for the management of Tourette's disorder. Oral dosage 20 to 100 mg/day.;Vencovský E, Fišarová M~Die Anwendung von Frenolon bei der Behandlung des Tics~Arzneim Forsch~1969~19(518-9)~#Gayte-Sorbier A, Airaudo CB~[Ultraviolet spectrophotometry of phenothiazine derivatives. III. Derivatives halogenated at the 2-position]~Annales pharmaceutiques francaises~1983~41(2)~167-76;Vencovský E, Fišarová M: Die Anwendung von Frenolon bei der Behandlung des Tics. Arzneim Forsch 19: 518-519, 1969 - Gayté-Sorbier A, Airaudo CB: Etude spectrophotométrique dans l'ultraviolet des dérivés de la phénothiazine. Ann Pharm Franç 41: 167-176, 1983. N S CH2 CH2 N CH3 S CH3;;;;;;;methophenazine (methophenazate);;;
27;A.III.5 ;Imiclopazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperazineethyl side chain; and a ;full chemical formula of ;1-[2-[4-(3-(2-chlorophenothiazin-10-yl) propyl)-1- piperazinyl]ethyl]-3-methylimidazolidin-2-one;. ;Imiclopazine; has been marketed or used in ;Germany; under the trade or premarketing names of ;Ponsital;NM: Ponsital Asta-Werke, BRD: (deleted);. ;Classified as moderately potent antipsychotic. Neuroleptic threshold 13½ mg. Oral dosage up to 30 mg/day.;Haase HJ, Linden KJ, Boragk J~[Experience in the therapy of schizophrenic psychoses with the phenothiazine derivative imiclopazine under the criterion for the neuroleptic threshold]~Die Medizinische Welt~1969~28(1565-70)~;Haase HJ, Linden KJ, Boragk J: Erfahrungen in der Therapie schizophrener Psychosen mit dem Phenothiazinderivat Imiclopazine unter dem Kriterium der neuroleptischen Schwelle. Med Welt 28: 1565-1570, 1969.;;;;;;;imiclopazine (chlorimpiphenine);;;
28;A.III.5 ;Oxaflumazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperazineethyl side chain; and a ;full chemical formula of ;10-[3-[4-(2-(1,3-dioxanyl)ethyl)-1-piperazinyl]propyl]-2- (trifluoromethyl) phenothiazine;. ;Oxaflumazine; has been marketed or used in ;France; under the trade or premarketing names of ;Oxaflumine;NM: Oxaflumine Diamant, F: (deleted: formerly as tabs. 100mg and drops 4%);. ;Clinical dosage according to references 50 to 300 mg daily (maximum about 600 mg/day). Has been used in the management of psychoses with marked delusional features. Rapid onset of action reported. In small doses desinhibition, at high dosage sedative effects.;Deniker P, Ginestet D, Peron-Magnan P, Colonna L, Loo H~[Clinical study of oxaflumazine/ its place among the neuroleptics]~Therapie~1971~26(1)~227-33#Sizaret P, Degiovanni A, Penaud J~[Discriminative study of the effect of a psychotropic drug by use of B.P.R.S. cards]~L'Encephale~1972~61(4)~316-24;Deniker P, Ginestet D, Peron Magnan P, et al: Etude clinique de l'oxaflumazine. Sa place parmi les neuroleptiques. Thérapie 26: 227-233, 1971 - Sizaret P, Degiovanni A, Penaud J: Etude discriminative de l'action d'un psychotrope par emploi des fiches B.P.R.S. L'Encéphale 61: 316-324, 1972.;;;;;;;oxaflumazine;;;
29;A.III.6  ;Thioridazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperidine side chain; and a ;full chemical formula of ;(±)-10-[2-(1-methyl-2-piperidyl)ethyl]-2- methylthiophenothiazine (hydrochloride);. ;Thioridazine; has been marketed or used in ;Netherlands, Austria, Germany, Belgium, Republic of South Africa, Switzerland, Denmark, France, Finland, Greece, Norway, United Kingdom, Italy, Portugal, Spain, Iceland, Sweden, United States of America; under the trade or premarketing names of ;Melleril, Melleretten, Meleril, Mallorol, Elperil, Flaracantyl, Mefurine, Orsanil, Ridazine, Stalleril, Tirodil, Mellaril, Visergil;NM: Melleril Sandoz Wander, NL: tabs. 25mg, 50mg, 100mg - s-c tabs. 25mg, 100mg - retard tabs. 200mg - susp. 10mg/ml NM: Melleretten Sandoz Wander,NL:s-c tabs.10mg solution 3% - Sandoz, A, BRD: f-c tabs.5mg (in BRD also drops 30mg/ml (1dr 1mg) saft 10mg/5ml)-(in A also sol. 1 %) NM: Melleril Sandoz, BRD, A: s-c/f-c tabs. 25mg,50mg (in A) 100mg -retard tabs.200mg - drops 30mg/ml NM: Melleril Wander Sandoz, B: s-c tabs. 25mg and 100mg NM: Melleril Sandoz, CH - Wander, RSA: s-c tabs. 10mg, 25mg, 50mg, 100mg (not in CH) - retard tabs. 30mg and 200mg - suspension 5mg/ml (deleted in CH) - Melleretten drops 30mg/ml (not in RSA) NM: Melleril Sandoz, DK: s-c tabs. 10mg, 25mg, 50mg, 100mg - drops 30mg/ml (deleted) - mikstur (syrup) 5mg/ml (deleted) NM: Melleril Sandoz, F: s-c tabs. 10mg, 50mg, 100mg - supension buvable 4% - suspension à 2 pour mille: 10mg/5ml NM: Melleril Sandoz, FIN: f-c tabs. 10mg, 25mg, 50mg, 100mg - retard tabs. 200mg NM: Melleril Sandoz, GR: s-c tabs. 100mg - retard tabs. 30mg and 200mg NM: Melleril Sandoz Pharma, NOR: s-c tabs. 10mg, 25mg, 50mg, 100mg - mikstur 5mg/ml NM: Melleril Sandoz, UK: f-c tabs. 10mg, 25mg, 50mg, 100mg - syrup 25mg/5ml - suspension 25mg/5ml and 100mg/5ml NM: Melleril Sandoz, ITA: s-c tabs. 25mg, 50mg - SR tabs. 200mg - Mellerette: s-c tabs. 10mg - sol. 30mg/ml NM: Melleril Sandoz, PORT: s-c tabs. 10mg, 25mg, 100mg - SR tabs. 200mg - sol. 30mg/ml NM: Meleril Sandoz Pharma, ESP: s-c tabs. 10mg, 50mg, 100mg - SR tabs. 200mg - sol. 30mg/ml - susp. 0.2% NM: Melleril Sandoz, A: f-c tabs. 25mg, 50mg, 100mg - SR tabs. 200mg - susp. 1% NM: Melleril Sandoz, ICL: tabs. 10mg, 25mg, 100mg - mixture 5mg/ml NM: Mallorol Sandoz, SWE: tabs. 10mg, 25mg, 50mg, 100mg - drops 30mg/ml - mixtur 10mg/ml - Mallorol retard SR tabs.200mg NM: Elperil Elpen, GR: s-c tabs. 100mg - retard tabs. 30mg, 200mg NM: Flaracantyl Leontik, GR: tabs. 100mg NM: Mefurine Uni-Pharma, GR: tabs. 25mg, 50mg and 100mg NM: Orsanil Orion, FIN: s-c tabs. 10mg, 25mg, 50mg, 100mg - mikstuura 10mg per ml - Orsanil retard tabs. 50mg and 200mg NM: Ridazine Rolab, RSA: tabs. 25mg, 50mg, 100mg NM: Stalleril Pharmacal, FIN: f-c tabs. 25mg, 50mg, 100mg - retard tabs. 50mg and 200mg - mikstuura 10mg/ml (range deleted) NM: Tirodil Medipolar, FIN: tabs. 10mg, 25mg, 50mg, 100mg - depot tabs. 50mg and 200mg - mikstuura 10mg/ml (range deleted) NM: Mellaril Sandoz, USA: tabs. 10mg, 15mg, 50mg, 100mg, 150mg, 200mg - suspension 25mg/5ml and 100mg/5ml - concentrate 30mg/ml and concentrate 100mg/ml NM: Visergil Sandoz, ITA: s-c tabs. 10mg+0.58mg dihydroergotoxin mesylate - drops 10mg+0.58mg;. ;For the treatment of psychotic disorders, anxiety states, behavioral disturbances and as short-term treatment of depressive symptoms. Minor extrapyramidal effects/ anticholinergic properties. Dosage 75 to 150 mg daily, clinically up to 600 - 800 mg/day. Various active metabolites, e.g. mesoridazine and sulforidazine. The (+) and (-) isomers act as partially selective D and D antagonists respectively. 2 1 Terminal plasma half-life of thioridazine and mesoridazine about 16 hours/ also other data reported.;"Eap CB, Koeb L, Powell K, Baumann P~Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma~Journal of chromatography B, Biomedical applications~1995~669(2)~271-9#Buckley NA, Whyte IM, Dawson AH~Cardiotoxicity more common in thioridazine overdose than with other neuroleptics~Journal of toxicology Clinical toxicology~1995~33(3)~199-204#
Lambert T, Keks N, McGrath J, Catts S, Hustig H, Vaddadi K, et al.~Remoxipride versus thioridazine in the treatment of first episodes of schizophrenia in drug?naive patients: A case for specific, low potency D2 antagonists~Human Psychopharmacology: Clinical and Experimental~1995~10(6)~455-60
";Eap CB, Koeb L, Powell K, Baumann P: Determination of the enantiomers of thioridazine, thioridazine 2- sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma. J Chromatogr B 669: 271-279, 1995 - Buckley NA, Whyte IM, Dawson AH: Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. Clin Toxicol 33/3: 199-204, 1995 - Lambert T, Keks N, McGrath J & al: Remoxipride versus thioridazine in the treatment of first episode of schizophrenia in drug-naive patients: A case for specific, low potency D antagonists. Hum Psychopharmacol 10/6: 455-460, 2 1995.;;;;;;;thioridazine;;;
30;A.III.6  ;Mesoridazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperidine side chain; and a ;full chemical formula of ;10-[2-(1-methyl-2-piperidyl)ethyl]-2-methyl sulfinylphenothiazine (as besylate);. ;Mesoridazine; has been marketed or used in ;United States of America, Netherlands, Italy, Switzerland; under the trade or premarketing names of ;Serentil, Lidanil, TPS 23;NM: Serentil Boehringer Ingelheim, USA: tabs. 10mg, 25mg, 50mg and 100mg - amps. 25mg/ml -concentrate for oral use 25mg/ml NM: Lidanil Sandoz, NL, ITA: (deleted) NM: TPS 23 Sandoz, CH;. ;Active metabolite of thioridazine. Used in the management of psychotic disorders. Dosage between 100 and 400 mg/day/ at lower dosage in the treatment of behavioral disturbances, as adjunct in mental retardation and alcoholism. Terminal plasma half-life about 16 hours/ for other data list half-lives.;"Niedzwiecki DM, Cubeddu LX, Mailman RB~Comparative anticholinergic properties of thioridazine, mesoridazine and sulforidazine~The Journal of pharmacology and experimental therapeutics~1989~250(1)~126-33#
Mohammad T, Midha K, Hawes E~Synthesis of deuterium labelled analogues of S?oxidative metabolites of thioridazine~Journal of Labelled Compounds and Radiopharmaceuticals~1989~27(2)~181-8
";Niedzwiecki DM, Cubeddu LX, Mailman RB: Comparative anticholinergic properties of thioridazine, mesoridazine and sulforidazine. J Pharmacol Exp Ther 250: 126-133, 1989 - Mohammad T, Midha KK, Hawes EM: Synthesis of deuterium labelled analogues of S-oxidative metabolites of thioridazine. J Label Compd Radiopharm 27: 181-188, 1989.;;;;;;;mesoridazine (NC 123, thioridazine sulfoxide);;;
31;A.III.6  ;Sulforidazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperidine side chain; and a ;full chemical formula of ;10-[2-(1-methyl-2-piperidyl)ethyl]-2-methyl sulfonylphenothiazine;. ;Sulforidazine; has been marketed or used in ;Germany; under the trade or premarketing names of ;Inofal;NM: Inofal Sandoz, BRD: s-c tabs. 50mg (deleted);. ;Active metabolite of thioridazine. Used in the treatment of schizophrenia and manic states. Dosage 100 to 400 mg daily. Mean plasma half-life about 13 hours. A less active metabolite is the N-demethylated derivative (TPD 6).;Mohammad T, Midha K, Hawes E~Synthesis of deuterium labelled analogues of S?oxidative metabolites of thioridazine~Journal of Labelled Compounds and Radiopharmaceuticals~1989~27(2)~181-8#Cohen BM, Lipinski JF, Waternaux C~A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites~Psychopharmacology~1989~97(4)~481-8;Mohammad T, Midha KK, Hawes EM: Synthesis of deuterium labelled analogues of S-oxidative metabolites of thioridazine. J Label Compd Radiopharm 27: 181-188, 1989 - Cohen BM, Lipinski JF, Waternaux C: A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites. Psychopharmacology 97(4) : 481-488, 1989.;;;;;;;sulforidazine (TPN 12);;;
32;A.III.6  ;Periciazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperidine side chain; and a ;full chemical formula of ;10-[3-(4-hydroxypiperidino)propyl] phenothiazine-2-carbonitrile;. ;Periciazine; has been marketed or used in ;Netherlands, Switzerland, Belgium, France, Austria, Germany, Finland, Republic of South Africa, Denmark, Norway, Sweden, Greece, United Kingdom, Spain; under the trade or premarketing names of ;Neuleptil, Aolept, Neuperil, Neulactil, Nemactil;NM: Neuleptil Rhône-Poulenc Rorer, NL, CH: caps. 5mg,10mg -tabs.25mg - drops 1% and 4% B: caps. 5mg, 10mg - drops 1% and 4% NM: Neuleptil Spécia, F: caps. 10mg - f-c tabs. 25mg -drops 1% (4 drops 1 mg) and drops 4% NM: Neuleptil Rhône-Poulenc Rorer, ITA: tabs.10mg - drops 2% NM: Neuleptil Vitoria, PORT: tabs. 10mg - drops 4% NM: Neuleptil Gerot, A: tabs. 10mg - drops 1%, 4% NM: Aolept Bayer, BRD: Tropfen 4% (1 drop 1mg) (deleted) NM: Neuperil Orion, FIN: tabs. 2½mg, 10mg and 25mg (range deleted) NM: Neulactil Rhône-Poulenc Rorer, DK, RSA: tabs. 2½mg, 10mg - Neulactil Embonate: mixture 2mg/ml (mikstur in DK deleted) - Rhône-Poulenc Rorer, FIN: tabs. 2½mg, 10mg, 25mg - Rhône-Poulenc Rorer, NOR: tabs.10mg and 25mg NM: Neulactil Rhône-Poulenc Rorer, SWE: tabs. 10mg NM: Neuleptil Specia, GR: caps. 10mg - drops 4% (1 drop 1 mg) NM: Neulactil Rhône-Poulenc Rorer, UK: tabs. 2½mg, 10mg, 25mg - forte syrup 10mg/5ml NM: Nemactil Rhône-Poulenc Rorer, ESP: tabs. 10mg, 50mg - drops 5% (range deleted);. ;Used in the treatment of behavioral disorders, major psychoses, severe anxiety and tension, confusional states, agitation in the elderly. Dosage about 10 to 75 mg daily. According to French references incidentally up to 500 mg/day.;"Becker R~PROPERICIAZINE-EFFECTIVENESS AGAINST HOSTILITY AND AGGRESSION AS COMPARED TO CHLORPROMAZINE~CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL~1981~29(6)~925-8#Jonckheere JA, de Broe ME, de Leenheer AP~Assay for propericiazine in human plasma by GLC/MS~Clin Chem~1983~29(1280)~#
Nishikawa T, Tsuda A, Tanaka M, Hoaki Y, Koga I, Uchida Y~Prophylactic effect of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of haloperidol and propericiazine~Psychopharmacology~1984~82(3)~153-6
";Becker RE: Propericiazine: effectiveness against hostility and aggression as compared to chlorpromazine. Curr Ther Res 29: 925-928, 1981 - Jonckheere JA, de Broe ME, de Leenheer AP: Assay for propericiazine in human plasma by GLC/MS. Clin Chem 29: 1280, 1983 - Nishikawa T, Tsuda A, Tanaka M: Propylactic effect of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of haloperidol and propericiazine. Psychopharmacology 82: 153-156, 1984.;;;;;;;periciazine (pericyazine, propericiazine, 8909 RP);;;
33;A.III.6  ;Piperacetazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperidine side chain; and a ;full chemical formula of ;10-[3-[4-(2-hydroxyethyl)piperidino]propyl] phenothiazin-2-yl methyl ketone;. ;Piperacetazine; has been marketed or used in ;Belgium, United States of America; under the trade or premarketing names of ;Actazine, Quide, Psymod, SC 10.490PC 1421;NM: Actazine Lakeside/Wellcome, B: tabs. 10mg, 25mg -amps. 1ml (deleted) NM: Quide Dow Pharmaceuticals, USA: tabs.10mg, 25mg NM: Psymod Pitman Moore, USA: veterinary tranquilizer NM: SC 10.490 Searle, USA - PC 1421 (Pitman Moore);. ;Neuroleptic with minor extrapyramidal symptoms. Anticholinergic effects/ postural hypotension, bradycardia. Used in the treatment of psychoses. Dosage 40 to 160 mg/day. Also used as a tranquilizer for small animals.;Lapierre YD, Lee M~Piperacetazine in the treatment of mixed neurotics~Current therapeutic research, clinical and experimental~1976~19(1)~105-9#Rhoades HM, Overall JE~Side effect potentials of different antipsychotic and antidepressant drugs~Psychopharmacol Bull~1984~20(1)~83-8;Lapierre YD, Lee M: Piperacetazine in the treatment of mixed neurotics. Curr Ther Res 19: 105-109, 1976 - Dominguez RA: Tardive dyskinesia following low doses of piperacetazine. Am J Psychiatry 137: 1617- 1618,l98O - Rhoades HM, Overall JE: Side effect potentials of different antipsychotic and antidepressant drugs. Psychopharmacol Bull 20(1) : 83-88, 1984.;;;;;;;piperacetazine;;;
34;A.III.6  ;Pipotiazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperidine side chain; and a ;full chemical formula of ;10-[3-[4-(2-hydroxyethyl)piperidino]propyl]-N,N-dimethylphenothiazine- 2-sulfonamide;. ;Pipotiazine; has been marketed or used in ;Netherlands, Switzerland, Belgium, France, FinlandNorway, Iceland, United Kingdom, Republic of South Africa, Spain; under the trade or premarketing names of ;Piportil, Piportil Longum-4, Piportyl palmitat, Piportil Depot, Lonseren, Piportil 19.336 RP Piportil L 419.552 RP, Piportil M 2 19.551 RP;NM: Piportil Rhône-Poulenc Rorer, NL, CH: tabs. 10mg B: tabs. 10mg - drops 4% (1 gt 1mg) NM: Piportil Spécia, F: tabs. 10mg - amps. 10mg per 2ml - gouttes buvables 4% NM: Piportil Longum-4 Rhône-Poulenc Rorer, B, CH, NL - Spécia, F: amps. 25mg/ml (not in NL) and amps. 100mg/4ml (palmitate ester) NM: Piportyl palmitat Rhône-Poulenc Rorer, DK, FIN, NOR, ICL: amps.50mg/ml and 100mg/2ml NM: Piportil Depot Rhône-Poulenc Rorer, UK: amps. 50mg/ml - 100mg/2ml (palmitate) NM: Piportil Depot Rhône-Poulenc Rorer,RSA: amps. 50mg/ml (palmitate) NM: Lonseren Rhône-Poulenc Rorer, ESP: tabs. 10mg - amps. 100mg/4ml (palmitate) NM: Piportil Pipotiazine base = 19.336 RP NM: Piportil L 4 palmitate ester= 19.552 RP NM: Piportil M 2 undecylenate ester = 19.551 RP (deleted);. ;DA antagonist. 'Neuroleptique majeur' for the management of psychotic disorders. Dosage of the oral form (base) about 5 to 15 mg once daily. At doses over 60 mg more marked neuroleptic effects. Terminal plasma half-life of pipotiazine base after oral administration to patients about 11 hours. Intervals between succesive administrations of Piportil Longum-4 about 4 weeks, with peak levels after approx. 2 weeks. Formerly also used as undecylenate.;"Bechelli LP, Navas-Filho F~Short-term double-blind trial of pipothiazine palmitate and haloperidol in the acute phase of schizophrenia~L'Encephale~1986~12(3)~121-5#Blanc M, Girard M, Granier F, Escande M, Cotonat J~[Pharmacokinetics of pipothiazine palmitate, after intramuscular administration in schizophrenic patients]~Therapie~1986~41(1)~27-30#
Pérez-Arnau FA, Olmedillas Alvaro R, Turón Gil JV, Miró Aguede A~Terapéutica de mantenimiento con palmitato de pipotiazina~Psiquis~1992~13(9)~386-92
";Bechelli LPC, Navas-Filho F: Short-term double-blind trial of pipothiazine palmitate and haloperidol in the acute phase of schizophrenia. L'Encéphale XII: 121-125,l986 - Blanc M, Girard M, Granier F: Pharmacocinétique de l'ester palmitique de pipotiazine, après administration intramusculaire chez des malades schizophrènes. Therapie 41: 27-30, 1986 - Pérez-Arnau FA, Olmedillas Alvaro R, Turón Gil JV, Miró Aguede A: Terapéutica de mantenimiento con palmitato de pipotiazina. Psiquis 13/9: 386-392, 1992.;;;;;;;pipotiazine;;;
35;A.III.6  ;A 124;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperidine side chain; and a ;full chemical formula of ;10-[3-(4-methoxypiperidino)propyl]phenothiazin-2-yl methyl ketone;. ;A 124; has been marketed or used in ;Germany; under the trade or premarketing names of ;;;. ;(Siegfried, BRD) Neuroleptique à gauche/ minor antidepressant properties. Studied in the treatment of psychoses. Dosage 300 mg/day.;Berzewski H, Hippius H, Petri H, Schiffter R~[Clinical studies with a new piperidyl-phenothiazine derivative (A 124)]~Arzneimittel-Forschung~1970~20(7)~949-52;Berzewski H, Hippius H, Petri H, et al: Klinische Untersuchungen mit einem neuen Piperidylphenothiazin-Derivat (A 124). Arzneim Forsch 20: 949-952,l970.;;;;;;;A 124;;;
36;A.III.6  ;Pecazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperidine side chain; and a ;full chemical formula of ;10-[(1-methyl-3-piperidyl)methyl]phenothiazine;. ;Pecazine; has been marketed or used in ;Germany; under the trade or premarketing names of ;Pacatal;NM: Pacatal Promonta-Lundbeck, BRD: deleted: formerly as tabs. 12½mg, 25mg and amps. 50mg/2ml);. ;Atypical neuroleptic. Pronounced anticholinergic effects. Has been used for artificial hibernation. No recent data.;Davis JM~Recent developments in the drug treatment of schizophrenia~The American journal of psychiatry~1976~133(2)~208-14;Davis JM: Recent developments in the drug treatment of schizophrenia. Am J Psychiatry 133: 208-214, 1976.;;;;;;;pecazine (mepazine);;;
37;A.III.6  ;Pipamazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperidine side chain; and a ;full chemical formula of ;1-[3-(2-chlorophenothiazin-10-yl)propyl] piperidine-4- carboxamide (hydrochloride);. ;Pipamazine; has been marketed or used in ;United States of America, France; under the trade or premarketing names of ;Mornidine, Nausidol;NM: Mornidine Searle, USA: (deleted: formerly in tabs. 5mg and amps. of 5mg/ml) NM: Nausidol Gremy-Longuet, F: (not marketed);. ;Insignificant neuroleptic activity/ at high doses postural hypotension and slight extrapyramidal symptoms. Claimed to exert a selective inhibitive effect on the vomiting center. In USA introduced as antiemetic in 1958.;; ;;;;;;;pipamazine (SC 8016);;;
38;A.III.6  ;Homophenazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperidine side chain; and a ;full chemical formula of ;perhydro-4-[3-(2-trifluoromethylphenothiazin-10-yl)propyl]-1,4- diazepin-1-ethanol;. ;Homophenazine; has been marketed or used in ;Belgium, Germany, Italy; under the trade or premarketing names of ;Pasaden;NM: Pasaden Asta Medica, B: tabs. 3mg (deleted) Pasaden Homburg, BRD: (deleted) Pasaden Farmades, ITA: tabs. ½mg, 1mg - drops 0.5%;. ;Low-dose neuroleptic with minor extrapyramidal symptoms. Has been used in the treatment of behavioral disorders, especially in the elderly. No recent information.;Pernhaupt G, Quatember R~[Psychopharmacologic contribution to the clinical use of a psychosedative]~Wiener medizinische Wochenschrift (1946)~1970~120(42)~737-40;Pernhaupt G, Quatember R: Pharmacopsychologischer Beitrag zur klinischen Anwendung eines Psychosedativums. Wien Med Wochenschr 120: 737-740, 1970.;;;;;;;homophenazine (D 775);;;
39;A.III.6  ;Perimetazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperidine side chain; and a ;full chemical formula of ;1-[3-(2-methoxyphenothiazin-10-yl)-2-methylpropyl]-4- piperidinol;. ;Perimetazine; has been marketed or used in ;France; under the trade or premarketing names of ;Leptryl;NM: Leptryl Roger Bellon, F (deleted: formerly tabs. of 25mg, 100mg, amps. 10mg/ml, drops. 4%);. ;Minor neuroleptic activity. Sedative and analgesic properties. Dosage 100 to 300 mg daily. No recent data.;Picard JM, Pagnon F, Helmer J, Henry A~[Perimetazin in cardiac surgery with extracorporeal circulation]~Anesthesie, analgesie, reanimation~1972~29(3)~395-9;Picard JM, Pagnon F, Helmer J, et al: La périmétazine en chirurgie cardiaque sous circulation extracorporelle. Anaesth Analg Reanim 29: 395-399, 1972.;;;;;;;perimetazine (9159 RP, 1317 AN);;;
40;A.III.6  ;Metopimazine;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperidine side chain; and a ;full chemical formula of ;1-[3-[2-(methylsulfonyl)phenothiazin-10-yl] propyl]piperidine-4- carboxamide;. ;Metopimazine; has been marketed or used in ;Belgium, France, Greece, Denmark; under the trade or premarketing names of ;Vogalène, Vogalene;NM: Vogalène Rhône Poulenc Rorer, B: tabs. 2½mg - drops 4mg per ml - amps. 10mg/ml - suppos. 5mg NM: Vogalène Schwartz Pharma, F: s-c tabs. 2½mg - Lyoc tabs. 7½mg - gouttes 4mg/ml - soluté buvable 5mg/5ml - gélules 15mg - suppositories 5mg - amps. 10mg/ml NM: Vogalene Theraplix, GR: drops 5mg/5ml - caps. 15mg NM: Vogalene Rhône-Poulenc Rorer, DK: f-c tabs. 5mg;. ;Sedative, analgesic and antiemetic agent. Anticholinergic properties. Used in the treatment of nausea and vomiting. Elimination half-life about 4½ hours.;Moertel CG, Reitemeier RJ~Controlled studies of metopimazine for the treatment of nausea and vomiting~Journal of clinical pharmacology~1973~13(7)~283-7#Seigneuric C, Plantavid M, Sorbette F, Montastruc JL, Galley M, Heguy J~[Extrapyramidal syndrome. Possible role of metopimazine]~Presse medicale (Paris, France : 1983)~1983~12(15)~962-3;Moertel CG, Reitemeier RJ: Controlled studies of metopimazine for the treatment of nausea and vomiting. J Clin Pharmacology 13: 283-287, 1973 - Seigneuric C, Plantavid M, Sorbette F, et al: Syndrome extrapyramidal. Rôle possible de la métopimazine. Presse Médicale 12: 962-963, 1983.;;;;;;;metopimazine (9965 RP, EXP 999);;;
41;A.III.6  ;Duoperone;is in the ;phenothiazine; category of antipsychotic.;It has a;n addional ;piperidine side chain; and a;full chemical formula of ;p-fluorophenyl-1-[3-(2-trifluoromethylphenothiazin- 10-yl]propyl-4-piperidyl ketone (fumarate);. ;Duoperone; has been marketed or used in ;United States of America; under the trade or premarketing names of ;AHR 6646;NM: AHR 6646 A.H. Robins, USA;. ;Phenothiazine-type neuroleptic with perone side chain, related to milenperone and setoperone. Preliminary pharmacological studies. Biochemical profile differs from that of reference antipsychotics. Long-acting agent/ may be administered once weekly. So far no clinical data.;Scrip~~~1986~No 1104(May 21st)~23#Suppl to WHO Chronicle~~~1986~40(6)~4;Scrip May 21st no 1104: 23, 1986 - Suppl to WHO Chronicle vol 40(6): 4, 1986.;;;;;;;duoperone;;;
42;A.III.7   ;Perthipendyl;is in the ;azaphenothiazine; category of antipsychotic.;It has a;;;;full chemical formula of ;4-(3-(1-azaphenothiazin-10-yl)propyl)-1-piperazineethanol;. ;Perthipendyl; has been marketed or used in ;Germany, United States of America; under the trade or premarketing names of ;Pervetral;NM: Pervetral Homburg, BRD (deleted: formerly tabs. of 25mg - suppos. 30mg, amps. 25mg/ml) NM: Pervetral Wallace, USA (not marketed);. ;Studied in the treatment of chronic psychoses. Sedative properties, minimal behavioral changes. At doses up to 1 g daily no significant antipsychotic properties.;Simpson GM, Angus JW~A preliminary study of oxypendyl in chronic schizophrenia~Current therapeutic research, clinical and experimental~1967~9(4)~225-8;Simpson GM, Angus JWS: A preliminary study of oxypendyl in chronic schizophrenia. Curr Ther Res 9: 225- 228, 1967.;;;;;;;perthipendyl (oxypendyl);;;
43;A.III.7   ;Prothipendyl;is in the ;azaphenothiazine; category of antipsychotic.;It has a;;;;full chemical formula of ;10-(3-dimethylaminopropyl)-1-azaphenothiazine (hydrochloride);. ;Prothipendyl; has been marketed or used in ;Netherlands, Belgium, Germany, United States of America; under the trade or premarketing names of ;Dominal, Dominal forte, Tolnate, Timovan;NM: Dominal Homburg, NL (deleted) - Asta Medica B: sc tabs. 40mg, forte 80mg - amps. 40mg/2ml, forte 80mg/4ml NM: Dominal Asta Medica, BRD: oral solution 50mg/ml NM: Dominal forte Asta Medica, BRD: s-c tabs. 40mg - f-c tabs. 80mg - amps. 40mg/2ml NM: Dominal Asta Medica, A: f-c tabs. 80mg - amps. 40mg/2ml NM: Tolnate S.K.F., UK (deleted) NM: Timovan Ayerst, USA (deleted);. ;Minor neuroleptic activity. Used in the treatment of agitation and confusion in the elderly, sleep disturbances and as adjunct for premedication.;Graben N, Daul A~Erfolgreiche Behandlung einer schweren Prothipendyl-Vergiftung mittels kombinierter Hämoperfusion über unbeschichtete Aktivkohle und Hämodialyse~Die Medizinische Welt~1984~35(1661-4)~#Cools AR, Prinssen EP, Ellenbroek BA~The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine~Psychopharmacology~1995~119(4)~428-39;Graben N, Daul A: Erfolgreiche Behandlung einer schweren Prothipendyl-Vergiftung mittels kombinierter Hämoperfusion über unbeschichtete Aktivkohle und Hämodialyse. Med Welt 35: 1661-1664, 1984 - Cools AR, Prinssen PM, Ellenbroek BA: The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine. Psychopharmacology 119: 428-439, 1995.;;;;;;;prothipendyl (thipendyl);;;
44;A.III.8.a ;Clopipazan;is in the ;xanthene derivative; category of antipsychotic.;It has a;;;;full chemical formula of ;4-(2-chloroxanthen-9-ylidene)-N-methylpiperidine (mesylate);. ;Clopipazan; has been marketed or used in ;United States of America; under the trade or premarketing names of ;Clopipazan;NM: Clopipazan Ciba-Geigy/SmithKline Beecham, USA;. ;Potential neuroleptic agent. Presumably almost free of extrapyramidal effects. Slow onset of action. Used dosage in preliminary clinical trials 5 to 40 mg/day, with a maximum of 80 mg daily. Preliminary studies.;"#Itil T, Fredrickson J, Schneider S, Francis I, Khan M~CLOPIPAZAN (SKF-69634), A NEW NEUROLEPTIC ESSENTIALLY FREE OF EXTRAPYRAMIDAL LIABILITY-QUANTITATIVE PHARMACO-EEG AND OPEN LABEL CLINICAL-TRIAL~CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL~1980~27(5)~719-30#
Neale R, Gerhardt S, Liebman JM~Effects of the novel antipsychotics, RMI 81582 and clopipazan, on predictors of extrapyramidal liability in squirrel monkeys~Drug development research~1983~3(2)~171-6
";Itil TM, Fredrickson JW, Schneider SJ, et al: Clopipazan (SKF 69.634), a new neuroleptic essentially free of extrapyramidal liability: quantitative pharmaco-EEG and open label clinical trial. Curr Ther Res 27: 719-730, 1980 - Neale R, Gerhardt S, Liebman JM, et al: Effects of the novel antipsychotics, RMI 81582 and clopipazan, on predictors of extrapyramidal liability in squirrel monkeys. Drug Develop Res 3: 171-176, 1983.;;;;;;;clopipazan (SKF 69.634);;;
45;A.III.8.b ;Chlorprothixene;is in the ;thioxanthene; category of antipsychotic.;It has a;;;;full chemical formula of ;(Z)-2-chloro-N,N-dimethyl-thioxanthene- 9, -propylamine;. ;Chlorprothixene; has been marketed or used in ;Netherlands, Austria, Hungary, Germany, Belgium, Denmark, NorwaySweden, Greece, Iceland, Republic of South Africa, United Kingdom, United States of America, Finland; under the trade or premarketing names of ;Truxal, Truxaletten, Taractan, Cloxan;NM: Truxal Lundbeck, NL: s-c tabs. 5mg, 15mg, 50mg - amps. 50mg/ml - mixture (syrup) 10mg/ml (citrate) NM: Truxal CH: s-c tabs. 5mg (Truxaletten), 15mg, 50mg - Saft 2½mg per ml ( NM: Truxaletten) - mixture 10mg/ml - amps. 50mg/ml NM: Truxal Lundbeck, A, HUN - Promonta-Lundbeck, BRD: s-c tabs. 15mg, 50mg - susp 20mg/ml (not in A, HUN) - syrup 20mg/ml - amps. 50mg/ml NM: Truxaletten Lundbeck, A: s-c tabs. 5mg - Saft 2½mg/ml NM: Truxal Lundbeck, B: s-c tabs. 15mg, 50mg - Truxalettes s-c tabs. 5mg (range deleted) NM: Truxal Lundbeck, DK, FIN, NOR, SWE: s-c tabs. 5mg, 15mg, 25mg, 50mg and 100mg - amps. 50mg/ml - mikstur (syrup) 10mg/ml NM: Truxal Tropon, GR: s-c tabs. 15mg, 50mg - syrup 2½mg/ml NM: Truxal Lundbeck, ICL, RSA: tabs. 15mg, 50mg - amps. 50mg/ml (not in RSA) NM: Taractan Roche, DK: s-c tabs. 5mg, 15mg, 50mg (range deleted) NM: Taractan Roche, BRD: s-c tabs. 15mg, 50mg - drops 40mg/ml (1 drop 2mg) (range deleted) NM: Taractan Roche, UK: s-c tabs. 15mg, 50mg (range deleted) NM: Taractan Roche, USA: tabs. 10mg, 25mg, 50mg, 100mg - amps. 25mg/2mlconcentrate for oral use 100mg/5ml NM: Cloxan Orion, FIN: s-c tabs. 25mg, 50mg and 100mg - amps. 50mg/ml (deleted) - mikstuura 10mg/ml;. ;D /D antagonist. Possibly 5-HT antagonist. High affinity for 5-HT /5-HT receptors. Used in the 1 2 2 6 7 management of psychomotor agitation, anxiety states and schizoaffective psychoses. Anticholinergic properties/ minor extrapyramidal reactions. Sedative properties/ quick-acting injections. Doses over 150 mg daily preferably under clinical supervision. Cis-trans isomerism. Terminal plasma half-life 8 to 12 hours (quoted data).;"Bagli M, Rao ML, Hoflich G~Quantification of chlorprothixene, levomepromazine and promethazine in human serum using high-performance liquid chromatography with coulometric electrochemical detection~Journal of chromatography B, Biomedical applications~1994~657(1)~141-48#Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Jr., Shen Y, et al.~Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors~The Journal of pharmacology and experimental therapeutics~1994~268(3)~1403-10#
Verweij A, Hordijk M, Lipman P~Quantitative Liquid Chromatography, Thermospray/Tandem Mass Spectrometric (LC/TSP/MS/MS) Analysis of Some Tranquilizers of the Thioxanthene Group in Whole-Blood~Journal of Liquid Chromatography & Related Technologies~1994~17(19)~4099-110
";Bagli M, Rao ML, Höflich G: Quantification of chlorprothixene, levopromazine and promethazine in human serum using high-performance liquid chromatography with coulometric electrochemical detection. J Chromatogr B Biomed appl 657/1: 141-148, 1994 - Roth BL, Craigo SC, Choudhary MS & al: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268/3: 1403-1410, 1994 - Verweij AMA, Hordijk ML, Lipman PJL: Quantitative liquid chromatography, thermospray/tandem mass spectrometric (LC/TSP/MS/MS) analysis of some tranquilizers of the thioxanthene group in whole blood. J Liq Chromatogr 17/19: 4099-4110, 1994.;;;;;;;chlorprothixene;;;
46;A.III.8.b ;Clopenthixol;is in the ;thioxanthene; category of antipsychotic.;It has a;;;;full chemical formula of ;(Z)-4-[3-(2-chlorothioxanthen-9-ylidene)propyl]-1- piperazineethanol Clopenthixol = 1/3 (Z)-clopenthixol+2/3 (E)-clopenthixol (Z)-clopenthixol = zuclopenthixol;. ;Clopenthixol; has been marketed or used in ;Netherlands, Spain, Austria, Iceland, Hungary, SlovakiaLTV, Czech Republic, Denmark, Belgium, Switzerland, United Kingdom, Republic of South Africa, France, Germany, Greece, Italy; under the trade or premarketing names of ;Cisordinol, Clopixol, Ciatyl Z, Ciatyl, Sordinol;NM: Cisordinol Lundbeck, NL, ESP: f-c tabs. 2mg (not in ESP), 10mg, 25mg and 40mg - drops 20mg/ml - amps. 10mg/ml (1 %)(not in ESP) NM: Cisordinol Lundbeck FIN, NOR, A, ICL, HUN, CZ, SK, LTV: f-c tabs. 2mg (not in HUN, CZ, SK), 10mg, 25mg, 40mg (not in CZ, SK) - drops 20mg/ml (not in CZ, SK) - amps. 10mg per ml - mikstur 2mg/ml (not in HUN, CZ, SK) NM: Cisordinol DK,SWE: f-c tabs. 2mg, 10mg, 25mg - amps. 10mg per ml - mixtur 2mg/ml - droppar 20mg/ml NM: Clopixol Lundbeck, B: f-c tabs. 2mg, 10mg, 25mg - amps. 10mg/ml - drops 20mg/ml NM: Clopixol Lundbeck, CH: f-c tabs. 2mg, 10mg, 25mg, 40mg - amps. 10mg/ml - drops 20mg per ml - mixture (syrup) 2mg/ml NM: Clopixol Lundbeck, UK, RSA, SLV: f-c tabs. 2mg (not in SLV), 10mg, 25mg NM: Clopixol Lundbeck, F: f-c tabs. 10mg, 25mg - drops 20mg/ml NM: Ciatyl Z Bayer, BRD: f-c tabs. 2mg, 10mg, 25mg - Tropfen 20mg/ml NM: Ciatyl Bayer, BRD - Tropon, GR: (1/3 Z-isomer + 2/3 E-isomer) f-c tabs. 25mg (in BRD also amps.25mg/ml) NM: Sordinol Lundbeck, ITA: s-c tabs. 5mg, 10mg, 25mg (1/3 Z-isomer + 2/3 E-isomer) NM: Clopixol Lundbeck, ITA: f-c tabs. 10mg, 25mg, 40mg - drops 20mg/ml - amps.10mg/ml NM: Clopixol Lundbeck, RSA: f-c tabs.2mg, 10mg, 25mg - drops 20mg/ml;. ;D /D antagonist. Potent neuroleptic in the treatment of schizophrenic disorders, especially 1 2 psychoses with agitation and aggressive behavior. The (Z)-isomer is assumed to be the neuroleptic active component. Usual oral dosage 20 mg - 75 mg, up to 150mg or higher daily. Plasma elimination half-life of zuclopenthixol in healthy subjects after oral administration about 20.4 hours/ mean plasma half-life of (E)-clopenthixol in healthy volunteers approx. 31 hours. Release half-life of zuclopenthixol decanoate (oily solution) recorded in patients about 19 days. No early plasma peak is observed after the injection.;"Poulsen JH, Olesen OV, Larsen NE~Fluctuation of serum zuclopenthixol concentrations in patients treated with zuclopenthixol decanoate in viscoleo~Therapeutic drug monitoring~1994~16(2)~155-9#Chauvot B, Bertholon F, Pascalis JG, Rifai A~Prise en charge des psychoses et zuclopenthixol. A propos de 14 cas cliniques~Presse Médicale~1994~26(9)~972-9#
Malt UF, Nystad R, Bache T, Noren O, Sjaastad M, Solberg KO, et al.~Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients~The British journal of psychiatry : the journal of mental science~1995~166(3)~374-7
";Poulsen JH, Olesen OV, Larsen NE: Fluctuation of serum zuclopenthixol concentrations in patients treated with zuclopenthixol decanoate in viscoleo. Ther Drug Monit 16/2: 155-159, 1994 - Chauvot B, Bertholon F, Pascalis JG, Rifai A: Prise en charge des psychoses et zuclopenthixol. A propos de 14 cas cliniques. Presse Médicale 26/9: 972-979, 1994 - Malt UF, Nystad R, Bache T & al: Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients. Br J Psychiatry 166: 374-377, 1995.;;"20% ZUCLOPENTHIXOL DECANOATE IN VISCOLEO: Cisordinol Depot (amps. 200mg/ml - vials 2g/10ml - amps. 200mg/ml - amps. 500mg/ml amps. 100mg/½ml), Cisordinol Depot (amps. 100mg/½ml, 200mg/ml,500mg/ml), Clopixol injection (amps.200mg/ml - vials 2g/10ml), Clopixol Conc. (amps.500mg/ml (50 %)), Clopixol Depot (amps. 200mg/ml - vials 2g/10ml, amps. 50mg/ml), Clopixol, Action Prolongée (amps. 200mg/ml), Ciatyl Z Depot (amps. 200mg/ml)/ 5 % ZUCLOPENTHIXOL ACETATE IN VISCOLEO: Cisordinol-Acufase (amps. 50mg/ml), Cisordinol-Acutard (amps. 50mg/ml, 100mg/2ml), Clopixol-Acutard (amps. 50mg/ml, 100mg/2ml), Clopixol-Acuphase (amps. 50mg/ml, 100mg/2ml), Clopixol), Action Semi Prolongée (amps. 50mg/ml, 100mg/2ml), Ciatyl Z Acuphase (amps. 50mg/ml, 100mg/2ml), Lu 0-108 (zuclopenthixol), Lu 18-069 (zuclopenthixol acetate), Lu 8-008 (zuclopenthixol decanoate)
";;;DEP: DEPOT INJECTIONS 20% ZUCLOPENTHIXOL DECANOATE IN VISCOLEO: NM: Cisordinol Depot Lundbeck, DK, FIN, NOR: amps. 200mg/ml - vials 2g/10ml - SWE, A, ESP, NL, HUN, CZ, SK, LTV: amps. 200mg/ml - DK, NL, FIN, A, LTV: also amps. 500mg/ml (in DK also amps. 100mg/½ml) NM: Cisordinol Depot Lundbeck, ICL: amps. 100mg/½ml, 200mg/ml,500mg/ml NM: Clopixol injection Lundbeck, UK: amps.200mg/ml - vials 2g/10ml NM: Clopixol Conc. Lundbeck, UK: amps.500mg/ml (50 %) NM: Clopixol Depot Lundbeck, B, CH, RSA, ITA, SLV: amps. 200mg/ml - in CH also vials 2g/10ml, in RSA also amps. 50mg/ml NM: Clopixol NM: Action Prolongée Lundbeck, F: amps. 200mg/ml NM: Ciatyl Z Depot Bayer, BRD: amps. 200mg/ml INJECTIONS 5 % ZUCLOPENTHIXOL ACETATE IN VISCOLEO: NM: Cisordinol-Acufase Lundbeck, ESP: amps. 50mg/ml NM: Cisordinol-Acutard Lundbeck, DK, FIN, NL, SWE, A, ICL, NOR, HUN, CZ, SK: amps. 50mg/ml and 100mg/2ml NM: Clopixol-Acutard Lundbeck, CH, B: amps. 50mg/ml and 100mg/2ml NM: Clopixol-Acuphase Lundbeck, IRL, UK, RSA, ITA, SLV: amps. 50mg/ml, 100mg/2ml (not in SLV) NM: Clopixol NM: Action Semi Prolongée Lundbeck, F: amps. 50mg/ml, 100mg/2ml NM: Ciatyl Z Acuphase Bayer, BRD: amps. 50mg/ml, 100mg/2ml NM: Lu 0-108 zuclopenthixol NM: Lu 18-069 zuclopenthixol acetate NM: Lu 8-008 zuclopenthixol decanoate;;clopenthixol;;;
47;A.III.8.b ;Flupentixol;is in the ;thioxanthene; category of antipsychotic.;It has a;;;;full chemical formula of ;4-[3-(2-(trifluoromethyl)thioxanthen-9-ylidene) propyl]-1- piperazineethanol (dihydrochloride);. ;Flupentixol; has been marketed or used in ;Netherlands, Austria, Hungary, Czech Republic, SlovakiaBelgium, Switzerland, United Kingdom, France, Germany, Denmark, Norway, Iceland, Republic of South Africa, Finland, Sweden, Portugal; under the trade or premarketing names of ;Fluanxol, Depixol;NM: Fluanxol Lundbeck, NL, A, HUN, CZ, SK: s-c tabs. ½mg (not in HUN, CZ, SK), 1mg (not in HUN), 5mg (not in CZ, SK) -drops. 100mg/ml (10%) (not in HUN, CZ, SK) (in A also drops 0.4%) NM: Fluanxol Lundbeck, B: s-c tabs. ½mg, 1mg, 3mg -drops. 0.4% and drops 10% NM: Fluanxol Lundbeck, CH: s-c tabs. ½mg, 1mg, 5mg - drops 4mg/ml - forte drops 100mg/ml (10%) NM: Fluanxol Lundbeck, UK: s-c tabs. ½mg and 1mg NM: Depixol Lundbeck, UK: s-c tabs. 3mg NM: Fluanxol Lundbeck, F: solution buvable 40mg/ml (1 drop 1 mg) NM: Fluanxol Lundbeck, SLV: tabs.3mg NM: Fluanxol Bayer, BRD: s-c tabs. ½mg and 5mg - drops 50mg/ml NM: Fluanxol Lundbeck, DK, NOR: mite s-c tabs. ¼mg, ½mg, 1mg - tabs. 5mg - drops 100mg/ml - mikstur 0.2mg/ml (not in NOR) NM: Fluanxol Lundbeck, ICL, RSA: tabs. ¼mg, ½mg, 1mg NM: Fluanxol Lundbeck, FIN: s-c tabs. ½mg, 1mg, 5mg - drops 100mg/ml (10%) SWE: s-c tabs, ¼mg, ½mg, 1mg, 5mg NM: Fluanxol Bial, PORT: s-c tabs. 3mg (2%):;. ;D /D /5-HT antagonist. Strong inhibitor of the adenylcyclase activity by dopamine stimulation. 1 2 2 Oral dosage in the management of schizophrenic disorders l5 to 60 mg daily. According to French data up to 200 or 400 mg daily. At low dosage, 1 to 3 mg/day, mood elevating and anxiolytic properties reported. Intervals between depot injections 2 to 4 weeks. Mean plasma half-life in patients after oral administration of the (Z)-isomer about 35 hours. Release half-life of flupentixol decanoate 3 to 8 days/ release t½ of (Z)-flupentixol palmitate about 17 days.;"Gawin F, Khalsa M, Brown J, Jatlow P~Flupenthixol treatment of crack users: Initial double-blind results~NIDA RESEARCH MONOGRAPH~1993~132(319-)~#Kutcher S, Papatheodorou G, Reiter S, Gardner D~The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol~Journal of psychiatry & neuroscience : JPN~1995~20(2)~113-8#
Böning J, Matern C, Fleischmann H, Täschner K-L, Jungkunz G, Jansen H, et al.~Drug-supported prevention of relapse in alcoholism with flupentixol-decanoate. Critical reflections about methodology and standard~European Neuropsychopharmacology~1995~5(3)~396-7
";Gawin FH, Khalsa ME, Brown J, Jatlow P: Flupenthixol in the treatment of crack users: Initial double-blind results. NIDA Res Monogr Ser -/132: 319, 1993 - Kutcher S, Papatheodorou G, Reither S, Gardner D: The succesful pharmacological treatment of adolescents and young adults with borderline personality disorder: A preliminary open trial of flupenthixol. J Psychiatry Neurosci 20/2: 113-118, 1995 - Böning J, Matern Ch, Fleischmann H & al: Drug-supported prevention of relapse in alcoholism with flupentixol decanoate. Critical reflections about methodology and standard. Eur Neuropsychopharmacology 5/3: 396- 397 (abstr P-10-13), 1995.;;(Z)-FLUPENTIXOL DECANOATE IN VISCOLEO: Fluanxol Depot 2% (amps. 20mg/ml, 40mg/2ml - vials 200mg/10ml – amps. 20mg/ml, 40mg/2ml - amps./syringes 20mg/ml, 40mg/2ml - vials 200mg/10ml, amps.20mg/ml), Fluanxol Depot (amps.syringes 20mg/ml, 40mg/2ml, vials 200mg/10ml), Fluanxol Depot 2% (amps. 10mg/½ml, 20mg/ml - vials 60mg/3ml, vials 200mg/10ml), Fluanxol LP 20mg/ml (amps. 20mg/ml), Depixol injection (amps./syringes 20mg/ml, 40mg/2ml -vials 200mg/10ml), Fluanxol Depot 2% (amps. 20mg/ml, 40mg/2ml), Fluanxol Retard (amps. 20mg/ml (10%));(Z)-FLUPENTIXOL DECANOATE IN VISCOLEO: Fluanxol Depot 10% (amps. 100mg/ml, amps. 100mg/ml - vials 500mg/5ml, amps. 50mg/½ml), Fluanxol Depot 10% (amps. 100mg/ml), Fluanxol LP 100mg/ml (100mg/ml), Depixol-Conc. (amps. 100mg/ml, 50mg/½ml, 200mg/ml (low volume)- vials 500mg/5ml, 200mg/10ml), Fluanxol Retard (amps.100mg/ml), Lu 7105 ((Z)-flupentixol decanoate 10% solution in Viscoleo), Lu 5-110 ((Z)-flupentixol decanoate), Lu 10-040 ((Z)-flupentixol palmitate (development discontinued));;DEP: DEPOT INJECTIONS (Z)-FLUPENTIXOL DECANOATE IN VISCOLEO: NM: Fluanxol Depot 2% Lundbeck, NL: amps. 20mg/ml, 40mg/2ml - vials 200mg/10ml – B, FIN: amps. 20mg/ml and 40mg/2ml - DK, A, HUN, CZ, SK: amps./syringes 20mg/ml (not in CZ, SK), 40mg/2ml - vials 200mg/10ml (not in A, HUN, CZ, SK) - SLV: amps.20mg/ml NM: Fluanxol Depot Lundbeck, CH, NOR, SWE, RSA: amps.syringes 20mg/ml, 40mg/2ml (vials 200mg/10ml in RSA) NM: Fluanxol Depot 2% Bayer, BRD: amps. 10mg/½ml and 20mg/ml - vials 60mg/3ml and vials 200mg/10ml NM: Fluanxol LP 20mg/ml Lundbeck, F: amps. 20mg/ml NM: Depixol injection Lundbeck, UK: amps./syringes 20mg/ml and 40mg/2ml -vials 200mg/10ml NM: Fluanxol Depot 2% Lundbeck, ICL: amps. 20mg/ml, 40mg/2ml NM: Fluanxol Retard Bial, PORT: amps. 20mg/ml (10%):;DEP: DEPOT INJECTIONS (Z)-FLUPENTIXOL DECANOATE IN VISCOLEO: NM: Fluanxol Depot 10% Lundbeck, B, NL, RSA, A, HUN: amps. 100mg/ml/ CH, DK, FIN, NOR, SWE, ICL: amps. 100mg/ml - vials 500mg/5ml (in CH, FIN, DK also amps. 50mg/½ml) NM: Fluanxol Depot 10% Bayer, BRD: amps. 100mg/ml NM: Fluanxol LP 100mg/ml Lundbeck, F: 100mg/ml NM: Depixol-Conc. Lundbeck, UK: amps. 100mg/ml, 50mg/½ml, 200mg/ml (low volume)- vials 500mg/5ml, 200mg/10ml NM: Fluanxol Retard Bial, PORT: amps.100mg/ml NM: Lu 7105 (Z)-flupentixol decanoate 10% solution in Viscoleo NM: Lu 5-110 (Z)-flupentixol decanoate NM: Lu 10-040 (Z)-flupentixol palmitate (development discontinued);flupentixol (N 7009);;;
48;A.III.8.b ;Piflutixol;is in the ;thioxanthene; category of antipsychotic.;It has a;;;;full chemical formula of ;1-[3-(6-fluoro-2-trifluoromethyl-thioxanthen-9- ylidene)propyl]-4-piperidineethanol;. ;Piflutixol; has been marketed or used in ;Denmark; under the trade or premarketing names of ;Lu 13-013, Lu 13-078;NM: Lu 13-013 Lundbeck, DK NM: Lu 13-078 (E)-isomer;. ;Potential neuroleptic agent. At low dosage cataleptic effects in animal model. Inhibits methylphenidate-induced stereotypy. Antagonizes conditioned avoidance reactions. Stereoselectivity. Studied in the treatment of psychoses.;Kilpatrick GJ, Jenner P, Marsden CD~Specific [3H]piflutixol binding to CHAPS-solubilised rat striatal preparations involves dopamine D-2 but not D-1 binding sites~Journal of neurochemistry~1986~46(2)~413-21;Kilpatrick GJ, Jenner P, Marsden CD: Specific [ H]piflutixol binding to CHAPS-solubilized rat striatal 3 preparations involves D-2 but not D-1 binding sites. J Neurochemistry 46: 413-421, 1986.;;;;;;;piflutixol;;;
49;A.III.8.b ;Teflutixol;is in the ;thioxanthene; category of antipsychotic.;It has a;;;;full chemical formula of ;4-[3-(6-fluoro-2-trifluoromethyl-thioxanthen -9-yl)propyl]-1- piperazineethanol;. ;Teflutixol; has been marketed or used in ;Denmark; under the trade or premarketing names of ;Lu 10-022, Lu 10-163;NM: Lu 10-022 Lundbeck, DK NM: Lu 10-163 (decanoate ester);. ;Long-acting dopamine receptor blocking effect. Clinical trials in the management of psychotic disorders. Dosage 3 - 20 mg once daily. In later studies ½ up to 3 mg/day.;Botte L~Teflutixol (Lu 10-022): a new thioxanthene derivative with antipsychotic properties. A pilot study~Acta psychiatrica Belgica~1983~83(4)~397-406;Botte L: Teflutixol (Lu 10-022): a new thioxanthene derivative with antipsychotic properties. Acta Psychiatr Belg 83: 397-406, 1983.;;;;;;;teflutixol;;;
50;A.III.8.b ;Thiothixene;is in the ;thioxanthene; category of antipsychotic.;It has a;;;;full chemical formula of ;(Z)-N,N-dimethyl-9-[3-(4-methyl-1-piperazinyl) propylidene]thioxanthene-2-sulfonamide;. ;Thiothixene; has been marketed or used in ;Netherlands, Denmark, Sweden, Finland; under the trade or premarketing names of ;Navane, Orbinamon, P 4657 A;NM: Navane Pfizer, NL, DK - Roerig, SWE: tabs. 10mg NM: Navane Pfizer, FIN: tabs. 10mg (deleted) NM: Navane Roerig, USA: caps.1mg, 2mg, 5mg, 10mg, 20mg - amps.2mg/ml and 5mg/ml - concentrate for oral use 5mg/ml NM: Orbinamon Pfizer, BRD: tabs. 10mg (deleted) NM: P 4657 A (E)-isomer;. ;Potent neuroleptic agent. Clinical dosage 20 to 60 mg daily. Stereoselectivity/ the (Z)-isomer appears to be the neuroleptic active compound. Only minor sedative properties. Terminal plasma half-life in patients about 34 hours.;Finkel SI, Lyons JS, Anderson RL, Sherrell K, Davis J, Cohen?Mansfield J, et al.~A randomized, placebo?controlled trial of thiothixene in agitated, demented nursing home patients'~International Journal of Geriatric Psychiatry~1995~10(2)~129-36#Markowitz JS, Gaulin BD, Good MI~Significance of plasma thiothixene concentrations~The Annals of pharmacotherapy~1995~29(7-8)~789-90;Finkel SI, Lyons JS, Anderson RL & al: A randomized, placebo-controlled trial of thiothixene in agitated, demented nurisng home patients. Int J Geriatr Psychiatry 10/2: 129-136, 1995 - Markowitz LS, Gaulin BD, Good MI: Significance of plasma thiothixene concentrations. Ann Pharmacotherapy 29: 789-790, 1995.;;;;;;;thiothixene (P 4657 B, (Z)-isomer);;;
51;A.III.8.b ;Clothixamide;is in the ;thioxanthene; category of antipsychotic.;It has a;;;;full chemical formula of ;(Z)-4-[3-(2-chlorothioxanthen-9-ylidene) propyl]piperazin-1-yl- N-methyl-propionamide;. ;Clothixamide; has been marketed or used in ;United States of America; under the trade or premarketing names of ;P 4385 B, P 4385 A;NM: P 4385 B Pfizer, USA (Z)-isomer/ shown in formula NM: P 4385 A (E)-isomer;. ;As hydrochloride or as dimaleate. Stereoselectivity/ the (Z)- isomer of clothixamide is reported to be a psychotropic with neuroleptic activity/ the (E)-form appeared to be significantly less active. No recent references.;;;;;;;;;clothixamide (P 4385);;;
52;A.III.8.b ;Fluprothixene;is in the ;thioxanthene; category of antipsychotic.;It has a;;;;full chemical formula of ;(E)-N,N-dimethyl-3-[2-(trifluoromethyl) thioxanthen-9- ylidene]propylamine;. ;Fluprothixene; has been marketed or used in ;United States of America; under the trade or premarketing names of ;SKF 10.812;NM: SKF 10.812 SmithKline Beecham, USA;. ;Preliminary clinical studies in the treatment of chronic schizophrenia. Used dosage 30 to 150 mg daily/ doses up to 300 mg/day have been given. Tachycardia reported/ only minor extrapyramidal reactions. Cis/trans-isomerism/ the publications refer to the trans-form.;Sugerman A~Studies with the thioxanthenes~Modern Problems of Pharmacopsychiatry: The Thioxanthenes Basel, S Karger~1969~2(80-4)~#Abernathy CO, Zimmerman HJ~The toxicity of thioxanthene neuroleptics to isolated rat liver cells~Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine (New York, NY)~1975~150(2)~385-9;Sugerman AA: Studies with the thioxanthenes. In: Modern Problems Pharmacopsychiatry. Karger Basel/New York. Vol. 2, pp. 80-84, 1969 - Abernathy CO, Zimmerman HJ: The toxicity of thioxanthene neuroleptics to isolated rat liver cells. Proc Soc Biol Med 150: 385-389, 1975.;;;;;;;fluprothixene;;;
53;A.III.8.c ;Pimethixene;is in the ;thioxanthene ; category of antipsychotic.;It has a;;;;full chemical formula of ;N-methyl-4-(thioxanthen-9-ylidene)piperidine;. ;Pimethixene; has been marketed or used in ;Greece, France; under the trade or premarketing names of ;Audicalm, Bovix simple, Calmixène, Haustin, Neo Kalmetta, Salcemetic, Sedosil ;NM: Audicalm Medichrom, GR: syrup 1mg/ml NM: Bovix simple Erfar, GR: syrup 1mg/ml NM: Calmixène Sandoz, F: syrup 2mg/10ml NM: Haustin Chrispa, GR: syrup 1mg/ml NM: Neo Kalmetta Coup,GR: syrup 1mg/ml NM: Salcemetic Remedina, GR: syrup 1mg/ml NM: Sedosil Vifor Fribourg, CH: syrup ½mg/5ml;. ;Thioxanthene derivative without neuroleptic activity. Antagonistic effects on histamine, serotonin and catecholamines reported. Sedative, anxiolytic and hypnotic properties. Also investigated as premedication for surgery. Mainly used as antihistaminic and 'calmative'.;Du Pan RM, Vuille G~[Difference in sensitivity to sedative drugs between infant and child of school age. Study of a new sedative, BP 400 (author's transl)]~Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis~1975~64(33)~1050-7#Neuhaus T~[BP 400. A new sedative drug for pediatric patients (author's transl)]~Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis~1976~65(51)~1603-10;de Pan R, Vuille G: A propos de Ia différence de sensibilité aux sédatifs entre le nourisson et l'enfant d'âge scolaire. Etude d'un nouveau sédatif, le BP 400. Praxis 64: 1050-1057, 1975 - Neuhaus T: BP 400 - ein neues Sedativum fur die pädiatrische Praxis. Praxis 65: 1603-1610, 1976.;;;;;;;pimethixene (BP 400);;;
54;A.III.9 ;Rilapine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;(Z)-2-chloro-10-(4-methyl-1-piperazinyl)-5Hdibenzo[ a,d]cycloheptene- 5, -acetonitrile;. ;Rilapine; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;High affinity for 5-HT receptor. Potential antipsychotic agent. 7 Preliminary pharmacological investigations. So far no clinical data available. Development discontinued.;Suppl to WHO Chronicle~Formula and steric configuration~~1984~38(4)~19#Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Jr., Shen Y, et al.~Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors~The Journal of pharmacology and experimental therapeutics~1994~268(3)~1403-10;Formula and steric configuration according to supplement INN WHO Chronicle 38(4): 19, 1984 - Roth BL, Craigo SC, Choudhary MS & al: Binding of typical and atypical antipsychotic agents to 5- hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268/3: 1403-1410, 1994.;;;;;;;rilapine;;;
55;A.III.9 ;Tenilapine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;(E)-5-(4-methyl-1-piperazinyl)-9H-dithieno [3,4-b:3',4'-e]azepine- 9, -acetonitrile;. ;Tenilapine; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;According to animal model potential antipsychotic agent. Preliminary pharmacological investigations and preclinical studies.;Suppl to WHO Chronicle~~~1984~38(Oct)~21;Suppl to WHO Chronicle 38(Oct.): 21, 1984.;;;;;;;tenilapine;;;
56;A.III.9 ;Flutroline;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;(±)-8-fluoro- ,5-bis(p-fluorophenyl)-1,3,4,5-tetrahydro-2Hpyrido[ 4,3-b] indole-2-butanol;. ;Flutroline; has been marketed or used in ;United States of America; under the trade or premarketing names of ;CP 36.584;NM: CP 36.584 Pfizer, USA;. ;Derivative of gamma-carboline. Neuroleptic agent. Effective dose 20 to 100 mg/day. With increasing dosage higher incidence of extrapyramidal symptoms reported. Double-blind clinical investigations in the treatment of schizophrenic psychoses.;"Delenk-Heydenreich K, Henkler G, Keller U, Klotzbach M, Koch H, Muller W, et al.~[Progress in the field of drug development. 17]~Die Pharmazie~1984~39(11)~725-37#Sarges R, Howard HR, Donahue KM, Welch WM, Dominy BW, Weissman A, et al.~Neuroleptic activity of chiral trans-hexahydro-gamma-carbolines~Journal of medicinal chemistry~1986~29(1)~8-19#
Lehmann J, Knoch F, Jiang N~[Indoles. 10. Synthesis, structure and D2-affinity of beta-carboline analogs of flutroline]~Archiv der Pharmazie~1993~326(12)~947-51

";Délenk-Heydenreich K, Henkler G, Keller U, et al: Fortschritte auf dem Gebiet der Arzneimittelentwicklung.Pharmazie 39:725-737, 1984 - Dominy BW, Weissman A: Neuroleptic activity of chiral trans hexahydro gamma-carbolines. J Med Chem 29: 8-19, 1986 - Indoles. 10. Mitt Synthese, Struktur und D -Affinität des beta-Carbolin-Analogen 2 von Flutrolin. Arch Pharm (Weinheim) 326: 12: 947-951, 1993.;;;;;;;flutroline;;;
57;A.III.9 ;Gevotroline;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;8-fluoro-2,3,4,5-tetrahydro-2-[3-(3-pyridinyl) propyl]-1Hpyrido[ 4,3-b]indole hydrochloride;. ;Gevotroline; has been marketed or used in ;United States of America; under the trade or premarketing names of ;WY 47.384;NM: WY 47.384 Wyeth-Ayerst, USA;. ;Gamma-carboline-type neuroleptic/ antipsychotic compound. Preliminary pharmacological studies. Weak affinity for D 2 dopamine receptor and affinity to sigma sites. Low potential for EPSE. Clinical investigations in the treatment of schizophrenic psychoses.;Council UN~Gevotroline hydrochloride. WY-47.384~Clinical pharmacology and therapeutics~1990~48(110)~#Matheson GK, Guthrie D, Bauer C, Knowles A, White G, Ruston C~Sigma receptor ligands alter concentrations of corticosterone in plasma in the rat~Neuropharmacology~1991~30(1)~79-87#WHO Drug Information~~~1989~3(2)~95;WHO Drug Information vol 3(2): 95, 1989 - USA N Council. Gevotroline hydrochloride. WY-47.384. Clin Pharmacol Ther 48: 110, 1990 - Matheson GK, Guthrie D, Bauer C, et al: Sigma receptor ligands alter concentrations of corticosterone in plasma in the rat. Neuropharmacol 30: 79-87, 1991.;;;;;;;gevotroline;;;
58;A.III.9 ;Piquindone;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;(±)-trans-3-ethyl-1,4a,5,6,7,8,8a,9-octahydro-2,6-di-methyl- 4H-pyrrolo[2,3-g]isoquinolin-4-one;. ;Piquindone; has been marketed or used in ;Switzerland; under the trade or premarketing names of ;Ro 22-1319;NM: Ro 22-1319 Roche, CH;. ;Potent D antagonist. Reported to be an atypical neuroleptic/ 2 minor extrapyramidal symptomatology anticipated. Efficacy in the treatment of Tourette's disorder.;"Brooks MA, Lee TL~Determination of piquindone in canine plasma and urine by high-performance liquid chromatography~Journal of chromatography~1986~375(2)~349-57#Cohen J, VANPUTTEN T, Marder S, Stahl S~TREATMENT OF THE SYMPTOMS OF SCHIZOPHRENIA WITH PIQUINDONE-A NEW ATYPICAL NEUROLEPTIC~Psychopharmacology Bulletin~1987~23(3)~514-8#
Kaneda H, Shintani T, Kakigi T, Terada T, Tanimoto K~Comparison of prolactin responses to D-1 and D-2 antagonists in rats: Ro 22-1319 is a potent D-2 antagonist~Biological psychiatry~1989~25(4)~517-22
";Brooks MA, Lee TL: Determination of piquindone in canine plasma and urine by high-performance liquid chromatography. J Chromatogr Biomed Appl 375: 349-357, 1986 - Cohen JD, Van Putten T, Marder S: Treatment of the symptoms of schizophrenia with piquindone: a new atypical neuroleptic. Psychopharmacol Bull 23: (3): 514-518, 1987 - Kaneda H, Shintani T, Kakigi T, et al: Comparison of prolactin responses to D-1 and D-2 antagonists in rats: Ro 22-1319 is a potent D-2 antagonist. Biol Psychiatry 25: 517-522, 1989.;;;;;;;piquindone;;;
59;A.III.9 ;Rimcazole;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;(cis)-9-[3-(3,5-dimethyl-1-piperazinyl) propyl]carbazole(dihydrochloride);. ;Rimcazole; has been marketed or used in ;United States of America; under the trade or premarketing names of ;BW-234 U;NM: BW-234 U Glaxo Wellcome, USA;. ;Affinity for sigma receptors reported. Potential antipsychotic agent. Studied in the treatment of schizophrenia. Tentative dosage 300 to 400 mg/day. Acts as a typical neuroleptic. Mode of action unclear: no blocking effect on dopamine receptors: no influence on conditioned avoidance reactions. Negligible cataleptogenic and anticholinergic effects. Potential anxiolytic or antidepressant.;"Maj J, Rogoz Z, Skuza G~Influence of 1,3-di-o-tolylguanidine and rimcazole, selective sigma ligands, on apomorphine and neuroleptic effects~Polish journal of pharmacology~1993~45(3)~327-30#Maj J, Rogó? Z, Skuza G~Pharmacological effects of rimcazole and 1, 3-di-< i> o</i>-tolylguanidine, sigma receptor ligands, as potential antipsychotic agents~European Neuropsychopharmacology~1994~4(3)~386-7#
Wyrick SD, Booth RG~Progress in sigma receptor research~Drugs of the Future~1995~20(10)~1033
";Maj J, Rogòz Z, Skuza G: Influence of 1,3-di-o-tolylguanidine and rimcazole, selective sigma ligands, on apomorphine and neuroleptic effects. Pol J Pharmacol 45/3: 327-330, 1993 - Maj J, Rogòz Z, Skuza G: Pharmacological effects of rimcazole and 1,3-di-o-tolylguanidine, sigma receptor ligands, as potential antipsychotic agents. Eur Neuropsychopharmacol 4/3: 387 (abst P3-39), 1994 - Wyrick SD, Booth RG: Progress in sigma receptor research. Drugs Fut 20/10: 1033-1044, 1995.;;;;;;;rimcazole;;;
60;A.III.9 ;Pinoxepin;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;(Z)-4-[3-(2-chlorodibenz[b,e]oxepin-11(6H)-ylidene)propyl]- piperazineethanol (dihydrochloride);. ;Pinoxepin; has been marketed or used in ;United States of America; under the trade or premarketing names of ;P 5227;NM: P 5227 Pfizer, USA;. ;Neuroleptic/ active (Z)-isomer. Studied in the treatment of schizophrenia. Dosage 50 - 400 mg up to 900 mg daily.;Claghorn JL, Schoolar JC, Kinross-Wright J~Pinoxepin vs. chlorpromazine: a double-blind comparison~Current therapeutic research, clinical and experimental~1967~9(8)~434-6#Holden JM, Itil TM, Keskiner A~Comparison of perphenazine and P-5227 in chronic schizophrenics: clinical and EEG effects~The Journal of clinical pharmacology and the journal of new drugs~1969~9(3)~163-75;Claghorn JL, Schoolar JC, Kinross Wright J: Pinoxepin vs chlorpromazine: a double-blind comparison. Curr Ther Res 9: 434-436, 1967 - Holden JMC, Itil TM, Keskiner A, et al: A comparison of perphenazine and P-5227 in chronic schizophrenics. J Clin Pharmacology 9: 163-175, 1969.;;;;;;;pinoxepin;;;
61;A.III.9 ;Perlapine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;6-(4-methyl-1-piperazinyl)-11H-dibenz[b,e]azepine;. ;Perlapine; has been marketed or used in ;United States of America; under the trade or premarketing names of ;AW 14'2333;NM: AW 14'2333 Dorsey, division of Sandoz-Warner, USA;. ;D /D antagonist. Atypical neuroleptic, pharmacological profile 1 2 ranking between antipsychotic agents and benzodiazepine-type anxiolytics. No neuroleptic-like EEG. In human investigations mainly sedative and hypnotic effects. Minor anticholinergic properties.;"Allen SR, Oswald I~The effects of perlapine on sleep~Psychopharmacologia~1973~32(1)~1-9#Schmutz J~Neuroleptic piperazinyl-dibenzo-azepines. Chemistry and structure-activity relationships~Arzneimittel-Forschung~1975~25(5)~712-20#
Wilk S, Stanley M~Perlapine and dopamine metabolism: prediction of antipsychotic efficacy~European journal of pharmacology~1977~41(1)~65-72
";Allen SR, Oswald I: The effects of perlapine on sleep. Psychopharmacologia 32:1-9,1973 - Schmutz J: Neuroleptic piperazinyl-dibenzo-azepines. Chemistry and structure-activity relationships. Arzneim Forsch 25:712-720,1975 - Wilk S, Stanley M: Perlapine and dopamine metabolism: prediction of antipsychotic efficacy. Eur J Pharmacology 41:65-72,1977.;;;;;;;perlapine;;;
62;A.III.9 ;Fluperlapine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;3-fluoro-6-(4-methyl-1-piperazinyl)morphanthridine;. ;Fluperlapine; has been marketed or used in ;Switzerland; under the trade or premarketing names of ;NB 106-689;NM: NB 106-689 Sandoz, CH;. ;Atypical neuroleptic. D /D /5-HT antagonist with high affinity for 1 2 2 5-HT receptor. Significant antipsychotic properties/ also 7 improvement of depressive symptoms reported. Anticholinergic and sedative effects. Clinical investigations in the treatment of schizophrenic psychoses. Dosage 300 up to 800 mg daily.;Fischer V, Wiebel FJ~Metabolism of fluperlapine by cytochrome P450-dependent and flavin-dependent monooxygenases in continuous cultures of rat and human cells~Biochemical pharmacology~1990~39(8)~1327-33#Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Jr., Shen Y, et al.~Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors~The Journal of pharmacology and experimental therapeutics~1994~268(3)~1403-10;Fischer V, Wiebel FJ: Metabolism of fluperlapine by cytochrome P 450-dependent and flavine-dependent monooxygenases in continuous cultures of rat and human cells. Biochem Pharmacol 39: 1327-1333, 1990 - Roth BL, Craigo SC, Choudhary MS & al: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268/3: 1403-1410, 1994.;;;;;;;fluperlapine;;;
63;A.III.9 ;Flumezapine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;7-fluoro-2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3- b][1,5] benzodiazepine;. ;Flumezapine; has been marketed or used in ;United States of America; under the trade or premarketing names of ;LY 120.362;NM: LY 120.362 Lilly, USA;. ;Structurally related to tranquilizers with diazepam moiety like bentazepam. Central dopamine and serotonin receptor antagonist. Potent neuroleptic agent with relatively few extrapyramidal effects. Temperature lowering properties reported.;"Fuller RW, Snoddy HD~Flumezapine and zotepine: 5-hydroxytryptamine antagonism not involved in the lack of synergism of these antipsychotic drugs with amfonelic acid in rats~The Journal of pharmacy and pharmacology~1985~37(10)~755-6#Sullivan HR, Franklin RB~In vitro thiomethylation. Studies with flumezapine~Drug metabolism and disposition: the biological fate of chemicals~1985~13(3)~276-8#
Fuller RW, Mason NR~Flumezapine, an antagonist of central dopamine and serotonin receptors~Research communications in chemical pathology and pharmacology~1986~54(1)~23-34
";Fuller RW, Snoddy HD: Flumezapine and zotepine: 5- hydroxytryptamine antagonists not involved in the lack of synergism of these antipsychotic drugs with amfonelic acid in rats. J Pharm Pharmacol 37: 755-756, 1985 - Sullivan HR, Franklin RB: In vitro thiomethylation. Studies with flumezapine. Drug Metab Dispos 13: 276-278, 1985 - Fuller RW, Mason NR: Flumezapine, an antagonist of central dopamine and serotonin receptors. Res Commun Chem Path Pharmacol 54: 23-34, 1986. S N N N H2C C H2 O C H2 CH2 OH;;;;;;;flumezapine;;;
64;A.III.9 ;Metiapine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2-methyl-11-(4-methyl-1-piperazinyl)dibenzo [b,f][1,4]thiazepine;. ;Metiapine; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;sed in the treatment of schizophrenic disorders. Daily dosage 75 to 300mg. Minor extrapyramidal symptoms. Somnolence and weight gain reported. Efficacy in achieving clininal improvement comparable with chlorpromazine.;Steinbook RM, Goldstein BJ, Brauzer B, Jacobson AF, Moreno SS~Metiapine: a double-blind comparison with chlorpromazine in acute schizophrenic patients~Journal of clinical pharmacology~1975~15(10)~700-4#Kramer M, Roth T, Goldstein S, Ryan MS, Blackwell B~A double-blind evaluation of metiapine in hospitalized acute schizophrenics~Current therapeutic research, clinical and experimental~1975~18(6)~839-48;Steinbook RM, Goldstein BJ, Brauzer B, et al: Metiapine, a double-blind comparison with chlorpromazine in acute schizophrenic patients. J Clin Pharmacol 15: 700-704, 1975 - Kramer M, Roth T, Goldstein S: A double-blind evaluation of metiapine in hospitalized acute schizophrenics. Curr Ther Res 18: 839-848, 1975.;;;;;;;metiapine (methiapine);;;
65;A.III.9 ;Clotiapine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2-chloro-11-(4-methyl-1-piperazinyl)dibenzo [b,f][1,4]thiazepine;. ;Clotiapine; has been marketed or used in ;Belgium, Switzerland, Italy, Spain, United States of America; under the trade or premarketing names of ;Etumine, Entumine, Entumin, Etumina, Etomine, HF 2159, LW 2159;NM: Etumine Wander Sandoz, B: tabs. 40mg - amps. 40mg/4ml NM: Entumine Wander, CH: tabs. 40mg - amps. 40mg/4ml NM: Entumin Sandoz, ITA: tabs. 40mg - amps.40mg/ml - drops 100mg/ml NM: Etumina Sandoz Pharma, ESP: tabs. 40mg (deleted) NM: Etomine Wander Sandoz, RSA: tabs. 40mg - amps. 40mg/4ml NM: HF 2159 Wander, CH NM: LW 2159 Dorsey-Wander, USA;. ;For the treatment of psychotic disorders, anxiety, drug dependence and alcoholism. Dosage 80 to 200 mg/day. Anticholinergic properties/ low incidence of EPSE. High affinity for 5-HT and 5- 6 HT receptors. 7;Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Jr., Shen Y, et al.~Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors~The Journal of pharmacology and experimental therapeutics~1994~268(3)~1403-10#Toren P, Samuel E, Weizman R, Golomb A, Eldar S, Laor N~Case study: emergence of transient compulsive symptoms during treatment with clothiapine~Journal of the American Academy of Child and Adolescent Psychiatry~1995~34(11)~1469-72;Roth BL, Craigo SC, Choudhary MS & al: Binding of typical and atypical antipsychotic agents to 5- hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268/3: 1403-1410, 1994 - Toren P, Samuel E, Weizman R & al: Case study: Emergence of transient compulsive symptoms during treatment with clothiapine. J Am Acad Child Adolesc Psychiatry 34/11: 1469-1472, 1995.;;;;;;;clotiapine (clothiapine);;;
66;A.III.9 ;Quetiapine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]- ethanol-(E)-2-butanedioate (2:1) salt;. ;Quetiapine; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;(Seroquel , Zeneca) R Moderate 5-HT /weak D and antagonist. Antipsychotic studied 2 2 2 in the treatment of acute exacerbation of schizophrenia and in prevention of psychotic relapses. No acute dystonic reactions nor effect on prolactine. Compared to clozapine. No report on agranulocytosis. Phase III clinical trials running (1995). Few EPSE.;"Fabre LF, Jr., Arvanitis L, Pultz J, Jones VM, Malick JB, Slotnick VB~ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia~Clinical therapeutics~1995~17(3)~366-78#Fulton B, Goa KL~ICI 204,636. An initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia~CNS Drugs~1995~4(1)~66-78#
Wong J, Ewing B, Fabre L, Thyrum P, Yeh C~Multiple-dose pharmacokinetics of “Seroquel”(ICI 204,636) in schizophrenic men and women~European Psychiatry~1996~11(429s-30s)~#
Borison RL, Arvanitis LA, Miller BG~ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group~Journal of clinical psychopharmacology~1996~16(2)~158-69
";Fabre LF, Arvanitis L, Pultz J & al: ICI 204,636, novel, atypical antipsychotic: Early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 17/3: 366-378, 1995 - Fulton B, Goa KL: ICI 204,636. An initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia. CNS Drugs 4/1: 66-78, 1995 - Wong JYW, Ewing BJ, Fabre LF & al: Multipledose pharmacokinetics of 'Seroquel' (ICI 204,636) in schozphrenic men and women. Eur Psychiatry 11 (suppl 4): 429s-430s, 1996 - Borison RL, Arvanitis LA, Miller BG: ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16/2: 158-169, 1996.;;;;;;;quetiapine (fumarate, ICI 204.636);;;
67;A.III.9 ;Traboxopine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;(±)-2-chloro-12-[3-(dimethylamino)-2-methylpropyl]-12Hdibenzo[ d,g][1,3,6] dioxazocine;. ;Traboxopine; has been marketed or used in ;Hungary; under the trade or premarketing names of ;EGYT 2509;NM: EGYT 2509 HUN;. ;Potent D receptor blocker. Neuroleptic properties/ potential 2 antipsychotic agent. No cataleptogenic activity/ minor prolactin stimulating effects. Investigated for inhibiting affinity to striatal H-spiperone receptors. Preliminary clinical trials. 3;Birkas Faigl E, Engler J, Zolyomi G, al e~Synthesis of C-labelled 14 dibenzo [d,g][l,3,6]dioxazocine derivatives (Egyt-2447 and Egyt-2509)~J Label Compd Radiopharm~1985~22(1061-6)~#Doda M~Interactions of apomorphine and a novel neuroleptic dibenzodioxazocine derivative, as evidenced by changes of somato-autonomic reflexes and spontaneous sympathetic activity in cats~The Journal of pharmacy and pharmacology~1989~41(8)~549-54#WHO Drug Information~~~1987~1(3)~191;Birkas Faigl E, Engler J, Zolyomi G, et al: Synthesis of C-labelled 14 dibenzo [d,g][l,3,6]dioxazocine derivatives (Egyt-2447 and Egyt-2509). J Label Compd Radiopharm 22: 1061-1066, 1985 - WHO Drug Information vol 1(3): 191, 1987 - Dóda M: Interactions of apomorphine and a novel neuroleptic dibenzodioxazocine derivative, as evidenced by changes of somato-autonomic reflexes and spontaneous sympathetic activity in cats. J Pharm Pharmacol 41: 549-554, 1989.;;;;;;;traboxopine;;;
68;A.III.9 ;Clorotepine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;4-(8-chloro-10,11-dihydro-dibenzo[b,f]thiepin-10-yl)-1- methylpiperazine (maleate or methanesulfonate);. ;Clorotepine; has been marketed or used in ;Czech Republic; under the trade or premarketing names of ;Clotepin;NM: Clotepin Spofa, CZ;. ;D /D antagonist with high affinity for 5-HT receptor. 1 2 7 Psychosedative agent with neuroleptic properties. Mainly pharmacological studies. Closely related to oxyprothepin. Various structurally related analogues synthesized in which sulfur is replaced by oxygen or selenium.;Bogeso KP, Liljefors T, Arnt J, Hyttel J, Pedersen H~Octoclothepin enantiomers. A reinvestigation of their biochemical and pharmacological activity in relation to a new receptor-interaction model for dopamine D-2 receptor antagonists~Journal of medicinal chemistry~1991~34(7)~2023-30#Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Jr., Shen Y, et al.~Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors~The Journal of pharmacology and experimental therapeutics~1994~268(3)~1403-10;Bøgesø KP, Liljefors T, Arnt J, & al: Octoclothepin enantiomers. A reinvestigation of their biochemical and pharmacological activity in relation to a new receptor-interaction model for dopamine D receptor 2 antagonists. J Med Chem 34: 2023-2030, 1991 - Roth BL, Craigo SC, Choudhary MS & al: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268/3: 1403-1410, 1994. S N N H2C C H2 CH2 OH H S CH3;;;;;;;clorotepine (octoclothepin);;;
69;A.III.9 ;Oxyprothepin;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;4-(8-methylthio-10,11-dihydro-dibenzo[b,f] thiepin-10-yl)-1- piperazinepropanol;. ;Oxyprothepin; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Minor neurological side effects. Studied in the treatment of schizophrenia. Oxyprothepin decanoate has been evaluated in double-blind studies vs fluphenazine decanoate: no significant therapeutic differences reported.;Kabes J, Balon R, Papezova H~MAINTENANCE THERAPY WITH FLUPHENAZINE DECANOATE AND OXYPROTHEPIN DECANOATE IN SCHIZOPHRENIC-PATIENTS-A DOUBLE-BLIND CROSSOVER COMPARATIVE-STUDY~Activitas Nervosa Superior~1980~22(3)~160-2#Balon R, Kabesh I, Papezhova G~[Comparison between the effectiveness of fluphenazine decanoate and oxyprothepin decanoate in schizophrenia (double-blind crossover study)]~Zhurnal nevropatologii i psikhiatrii imeni SS Korsakova (Moscow, Russia : 1952)~1982~82(1)~116-8;Kabeš J, Balon R, Papežová G: Maintenance therapy with fluphenazine decanoate and oxyprothepin decanoate in schizophrenic patients. Double-blind cross-over comparative study. Activ Nerv Sup (Praha) 22: 160-162, 1980 - Balon R, Kabeš J, Papežová G: Comparison of efficacy of fluphenazine decanoate and hydroxyprothepine decanoate in schizophrenia. Zh Nevropatol Psikhiatr 82: 116-118, 1982 (Eng. translation).;;;;;;;oxyprothepin;;;
70;A.III.9 ;Isofloxythepin;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;4-(3-fluoro-8-isopropyl-10,11-dihydro-dibenzo[b,f]thiepin-10-yl)- 1-piperazineethanol;. ;Isofloxythepin; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;(Japan, licensed to Spofa, CZ) Inhibitor of [ H]-spiperone binding to dopamine D receptors. 3 2 Increases serum prolactin. The (-)-enantiomer has been reported to exhibit a significantly stronger neuroleptic activity than the (+)- enantiomer.;Ohno M, Yamamoto T, Ueki S~Effect of isofloxythepin, a novel neuroleptic, on hippocampal stimulation-induced wet-dog shaking in the rat~Japanese journal of pharmacology~1989~49(1)~21-6#Saeki K, Oishi R, Nishibori M, Itoh Y~Effects of isofloxythepin on central and peripheral histamine systems~Japanese journal of pharmacology~1989~50(1)~55-62;Ohno M, Yamamoto T, Ueki S: Effect of isofloxythepin, a novel neuroleptic, on hippocampal stimulationinduced wet-dog shaking in the rat. Jpn J Pharmacol 49: 21-26, 1989 - Saeki K, Oishi R, Nishibori M, et al: Effects of isofloxythepin on central and peripheral histamine systems. Jpn J Pharmacol 50: 55-62, 1989.;;;;;;;isofloxythepin (VUF B 10.662);;;
71;A.III.9 ;Clozapine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;8-chloro-11-(4-methyl-1-piperazinyl)-5Hdibenzo[ b,e][1,4]diazepine;. ;Clozapine; has been marketed or used in ;France, Portugal, Sweden, Republic of South Africa, Netherlands, Denmark, Austria, NorwaySpain, Iceland, Switzerland, Germany, United Kingdom; under the trade or premarketing names of ;Leponex, Alemoxan, Clozaril;NM: Leponex Sandoz, F, PORT, SWE - Sandoz Wander, RSA, NL, ITA: tabs. 25mg and 100mg (in NL also amps.50mg/2ml) NM: Leponex Sandoz, DK, A, FIN, NOR, ESP, ICL, NL, CH - Wander Pharma, BRD: tabs. 25mg, 50mg (in BRD) and 100mg - amps. 50mg/2ml (not in ESP, ICL, DK, NOR) NM: Alemoxan Arzneimittel Werke, BRD (deleted) NM: Clozaril Sandoz, UK: tabs. 25mg, 100mg;. ;Atypical neuroleptic. D /D antagonism >D /D - also 5-HT antagonist.May be effective in 1 4 2 4 2 refractory cases. Less likely to induce TD. Anticholinergic properties. No elevation prolactin NH N N N CH3 S CH3 levels. Early reports on WBC dyscrasia. Plasma half-life after injection 10 hours. Recent trials showed that clozapine and its N-desmethyl metabolite are potent 5-HT receptor antagonists. 1C High affinity for 5-HT /5-HT and 5-HT receptors. Potent and selective muscarinic M receptor 7 4 1 4 agonist.;"Bennett JP, Jr., Landow ER, Dietrich S, Schuh LA~Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction~Movement disorders : official journal of the Movement Disorder Society~1994~9(4)~409-14#Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Jr., Shen Y, et al.~Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors~The Journal of pharmacology and experimental therapeutics~1994~268(3)~1403-10#
Olesen OV, Thomsen K, Jensen PN, Wulff CH, Rasmussen NA, Refshammer C, et al.~Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study~Psychopharmacology~1995~117(3)~371-8#
Zorn SH, Jones SB, Ward KM, Liston DR~Clozapine is a potent and selective muscarinic M4 receptor agonist~European journal of pharmacology~1994~269(3)~R1-2#
WHO Drug Information~Clozapine and myocarditis~~1995~9(1)~34
";Bennett JP Jr, Landow ER, Dietrich S, Schuh LA: Suppression of dyskinesias in advanced Parkinson's disease: Moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 9/4: 409-414, 1994 - Roth BL, Craigo SC, Choudhary MS & al: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268/3: 1403-1410, 1994 - Olesen OV, Thomsen K, Jensen PN & al: Clozapine serum levels and side-effects during steady state treatment of schizophrenic patients: A cross-sectional study. Psychopharmacology 117/3: 371-378, 1995 - Zorn SH, Jones SB, Ward KM, Liston DR: Clozapine is a potent and selective muscarinic M 4 receptor agonist. Eur J Pharmacol Mol Pharmacol Sect 269/3: R1-R2, 1994 - Clozapine and myocarditis. WHO Drug Information 9/1: 34, 1995.;;;;;;;clozapine (W 108, LX 100-129, HF 1854);;;
72;A.III.9 ;Olanzapine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine;. ;Olanzapine; has been marketed or used in ;; under the trade or premarketing names of ;Lanzac R, Zyprex R;NM: LanzacR ZyprexR;. ;"D /D /D /5-HT antagonist. Weak activity on dopamine sites, appears to bind to M and M 1 2 4 2c receptor sites. Anticholinergic and anxiolytic properties. Phase III clinical trials. Potential ""atypical"" antipsychotic less likely to induce EPSE that classical antipsychotics. T½ around 15 hours/ T around 6.3 hours. C at 6mg around 9.7ng/ml. Seems to reduce both positive and max max negative psychotic symptoms and to have a low incidence of prolactin elevation.";"WHO Drug Information~Olanzapine~~1992~6(2)~85#Wood A, Beasley C, Tollefson G, Tran P~Efficacy of olanzapine in the positive and negative symptoms of schizophrenia~European Neuropsychopharmacology~1994~4(3)~224-5#
Borison RL~Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics~Journal of clinical psychopharmacology~1995~15(1 Suppl 1)~24S-9S#
Moore N, Bymaster F, Calligaro D, Fuller R, Rasmussen K, Stockton M, et al.~SAT-5-4 Olanzapine: An exciting atypical antipsychotic—the preclinical profile~European Neuropsychopharmacology~1995~5(3)~255-6#
Catlow JT, Barton RD, Clemens M, Gillespie TA, Goodwin M, Swanson SP~Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection~Journal of chromatography B, Biomedical applications~1995~668(1)~85-90
";Olanzapine. WHO Drug Information vol 6(2): 85, 1992 - Wood AJ, Beasley CM, Tollefson GD, Tran PV: Efficacy of olanzapine in the positive and negative symptoms of schizophrenia. Eur Neuropsychopharmacology 4/3: 224-225 (abstr S-10(5)), 1994 - Borison RL: Clinical efficacy of serotonindopamine antagonists relative to classical neuroleptics. J Clin Psychopharmacol 15/1 (suppl 1): 24S-29S, 1995 - Moore NA, Bymaster FP, Calligaro RW & al: Olanzapine: an exciting atypical antipsychotic-the preclinical profile. Eur Neuropsychopharmacology 5/3: 255-256 (abst SAT-5-4), 1995 - Catlow JT, Barton RD, Clemens M & al: Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatog B Biomed Appl 668: 85-90, 1995.;;;;;;;olanzapine (LY-170053);;;
73;A.III.9 ;HF 2046;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4] diazepine;. ;HF 2046; has been marketed or used in ;Switzerland; under the trade or premarketing names of ;105-056;NM: 105-056 Wander, CH;. ;Isomer of clozapine: 2-chloro atom substituted by 8-chlorine. Pharmacological investigations on dopamine and norepinephrine metabolism. No recent clinical data.;Burki HR, Ruch W, Asper H, Baggiolini M, Stille G~Effect of single and repeated administration of clozapine on the metabolism of dopamine and noradrenaline in the brain of the rat~European journal of pharmacology~1974~27(2)~180-90;Bürki HR, Ruch W, Asper H, et al: Effect of single and repeated administration of clozapine on the metabolism of dopamine and noradrenaline in the brain of the rat. Eur J Pharmacology 27: 180-190, 1974.;;;;;;;HF 2046;;;
74;A.III.9 ;GP 45.795;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2-chloro-11-(4-methyl-1-piperazinyl)dibenzo [b,f]thiepin- 10(11H)-one;. ;GP 45.795; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Studied in the treatment of schizophrenic psychoses. Dosage 50 to 600 mg daily. Minor extrapyramidal reactions.;Gallant DM, Bishop MP, Guerrero-Figueroa R~GP-45795: a controlled evaluation in chronic schizophrenic patients~Current therapeutic research, clinical and experimental~1972~14(4)~215-9;Gallant DM, Bishop MP, Guerrero-Figueroa R: GP-45795: A controlled evaluation in chronic schizophrenic patients. Curr Ther Res 14: 215- 219, 1972.;;;;;;;GP 45.795;;;
75;A.III.9 ;Loxapine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2-chloro-11-(4-methyl-1-piperazinyl) dibenzo[b,f][1,4] oxazepine (hydrochloride, succinate or base);. ;Loxapine; has been marketed or used in ;Netherlands, Denmark, Iceland, Belgium, United Kingdom, GreeceUnited States of America, Spain; under the trade or premarketing names of ;Loxapac, Loxitane, Desconex;NM: Loxapac Lederle, NL (deleted), DK, ICL - Lederle Cyanamid, B Novex Pharma, UK: tabs. 10mg (not in B, DK), 25, 50mg (all apparently deleted in ICL) (capsules in UK) - Lederle, F: tabs. 25mg, 50mg - soluté buv. 25mg/ml - amps. 50mg/2ml NM: Loxapac GR: tabs. 25mg NM: Loxitane Lederle, USA: caps. 5, 10, 25 and 50mg -amps. 50mg/ml - oral concentrate 25mg/ml NM: Desconex Allonga, ESP: caps.10mg, 25mg, 50mg - drops 25mg/ml - amps.50mg/ml;. ;Former designation: oxilapine. Dopamine D /D receptors antagonist with higher affinity for D than for D . Structurally related 2 3 3 2 to clozapine. Used in the treatment of schizophrenic disorders. Dosage 50 to 200 mg/day. First French reports in 1965. Plasma half-life after oral administration to healthy subjects 3 to 4 hours/ terminal half-life of a major 8-hydroxy-metabolite about 8 hours.;Midha KK, Hubbard JW, McKay G, Hawes EM, Hsia D~The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine~International journal of clinical pharmacology, therapy, and toxicology~1993~31(4)~177-83#Carlyle W, Ancill RJ, Sheldon L~Aggression in the demented patient: a double-blind study of loxapine versus haloperidol~International clinical psychopharmacology~1993~8(2)~103-8;Midha KK, Hubbard JW, Mc Kay G, & al: The role of metabolites in a bioequivalence study 1: Loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int J Clin Pharmacol Ther Toxicol 31/4: 177-183, 1993 - Carlyle W, Ancill RJ, Sheldon L: Aggression in the demented patient: A double-blind study of loxapine versus haloperidol. Int Clin Psychopharmacol 8/2: 103-108, 1993.;;;;;;;loxapine (LW 3170, SUM 3170, CL 71.563);;;
76;A.III.9 ;Metitepine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;4-(8-methylthio-10,11-dihydro-dibenzo[b,f] thiepin-10-yl)-1- methylpiperazine (maleate);. ;Metitepine; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;(Spofa, CZ) (Merrell-Dow Research Institute, F) Preliminary pharmacological studies. Investigations for quantitative structure-activity relationships. Has been compared with several related compounds.;Ricchieri G, Soncrant TT, H. H, al e~The effects of methiothepin on local glucose metabolism in the awake rat~J Neurochemistry~1986~44(Suppl)~S168#Taranger MA, Galzin AM, Langer SZ~Methiothepin enhances the potassium-evoked release of [3H]-noradrenaline in rat pineal gland~Naunyn-Schmiedeberg's archives of pharmacology~1987~336(4)~374-80;Ricchieri G, Soncrant TT, Holloway H, et al: The effects of methiothepin on local glucose metabolism in the awake rat. J Neurochemistry 44(suppl): S168, 1986 - Taranger MA, Galzin AM, Langer SZ, et al: Methiothepin enhances the potassium-evoked release of [ H]noradrenaline in rat pineal gland. Naun 3 Schmied Arch Pharmacol 336: 374-380, 1987.;;;;;;;metitepine (methiothepine);;;
77;A.III.9 ;Clomacran;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2-chloro-9-[3-(dimethylamino)propyl]acridine;. ;Clomacran; has been marketed or used in ;United States of America; under the trade or premarketing names of ;SKF 14.336;NM: SKF 14.336 SmithKline Beecham, USA;. ;Investigated for the treatment of psychotic disorders at a dosage of 150 mg to about 600 mg/day. At lower doses in geropsychiatry. Reported to be comparable to standard neuroleptics in its therapeutic efficacy. First clinical trials already in 1966.;TORRESRUIZ A, AMIN M, BAN T, PECKNOLD J~SYSTEMATIC CLINICAL STUDIES WITH CLOMACRAN. 2. STANDARD CONTROLLED CLINICAL-TRIALS IN SCHIZOPHRENIA~CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL~1979~26(1)~127-31#VERGARA L, AMIN M, BAN T~SYSTEMATIC CLINICAL-STUDIES WITH CLOMACRAN. 3. STANDARD CONTROLLED CLINICAL-TRIAL IN GEROPSYCHIATRIC ORGANIC BRAIN-SYNDROME PATIENTS~CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL~1980~27(1)~116-8;Torres-Ruiz A, Amin M, Ban TA, et al: Systematic clinical studies with clomacran: standard controlled clinical trials in schizophrenia. Curr Ther Res 26: 127-131, 1979 - Vergara L, Amin M, Ban TA, et al: Systematic clinical studies with clomacran: a standard controlled clinical trial in geropsychiatric organic brain syndrome patients. Curr Ther Res 27: 116-118, 1980.;;;;;;;clomacran;;;
78;A.III.9 ;EX 11.582 A;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2-chloro-11-[3-(dimethylamino)propylidene] morphanthridin;. ;EX 11.582 A; has been marketed or used in ;United States of America, Italy; under the trade or premarketing names of ;Ex 11.582 A, RMI 81.582;NM: Ex 11.582 A Merrell-Dow, USA NM: RMI 81.582 Richardson-Merrell, ITA;. ;Preliminary clinical investigations. Dosage 10 mg up to 200 mg/day. Minor neuroleptic activity/ anticholinergic effects. No extrapyramidal symptoms, possibly due to intrinsic parasympatholytic properties. Stereoselectivity.;Young MA, Meltzer HY~RMI-81,582, a novel antipsychotic drug~Psychopharmacology~1980~67(1)~101-6#Neale R, Gerhardt S, Liebman JM~Effects of the novel antipsychotics, RMI 81582 and clopipazan, on predictors of extrapyramidal liability in squirrel monkeys~Drug development research~1983~3(2)~171-6;Young MA, Meltzer HY: RMI-81.582, a novel antipsychotic drug. Psychopharmacology 67: 101-106, 1980 - Neale R, Gerhardt S, Liebman JM, et al: Effects of the novel antipsychotics, RMI 81582 and clopipazan, on predictors of extrapyramidal liability in squirrel monkeys. Drug Dev Res 3: 171-176, 1983.;;;;;;;EX 11.582 A;;;
79;A.III.9 ;Zotepine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2-chloro-11-(2-dimethylaminoethoxy) dibenzo[b,f]thiepin;. ;Zotepine; has been marketed or used in ;Japan, Germany, Austria; under the trade or premarketing names of ;Lodopin, Nipolept;NM: Lodopin Fujisawa, JPN (licensed to Klinge, BRD) NM: Nipolept Rhône-Poulenc Rorer, BRD, A: s-c tabs. 25mg, 50mg, 100mg;. ;other trade marks: Zopite, Setous, Majorpin Potent dopamine D and 5-HT antagonist. High affinity for 5- 2 HT receptor. Comparable to phenothiazine-type neuroleptics 7 like chlorpromazine and thioridazine. Studies suggest a less cataleptogenic activity than butyrophenone-type antipsychotics. Dosage in the treatment of schizophrenia 50 to 300 mg daily. Particularly effective in patients with negative symptoms. Bipolar therapeutic profile reported.;"Wolfersdorf M, Konig F, Straub R~Pharmacotherapy of delusional depression: experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol~Neuropsychobiology~1994~29(4)~189-93#Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Jr., Shen Y, et al.~Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors~The Journal of pharmacology and experimental therapeutics~1994~268(3)~1403-10#
Otani K, Kondo T, Kaneko S, Ishida M, Fukushima Y~Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients~International clinical psychopharmacology~1994~9(4)~287-9
";Wolfersdorf M, Konig F, Straub R: Pharmacotherapy of delusional depression: Experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol. Neuropsychobiology 29/4: 189-193, 1994 - Roth BL, Craigo SC, Choudhary MS & al: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268/3: 1403- 1410, 1994 - Otani K, Kondo T, Kaneko S & al: Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients. Int Clin Psychopharmacol 9/4: 287-289, 1994.;;;;;;;zotepine;;;
80;A.III.9 ;Clocapramine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;1-[3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f] azepin-5- yl)propyl]-4-piperidinopiperidine-4-carboxamide;. ;Clocapramine; has been marketed or used in ;Japan; under the trade or premarketing names of ;Clofekton;NM: Clofekton Yoshitomi, JPN: tabs. 10mg, 25mg;. ;Atypical neuroleptic. Efficacy in motor retardation, scanty speech and depressive symptoms reported. Dosage 30 to 100mg/day. Plasma half-life in man 46 ± 6 hours.;Yamagami S~A crossover study of clocapramine and haloperidol in chronic schizophrenia~The Journal of international medical research~1985~13(6)~301-10#Ishigooka J, Murasaki M, Wakatabe H, Miura S, Hikida K, Shibata M, et al.~Pharmacokinetic study of iminodibenzyl antipsychotic drugs, clocapramine and Y-516 in dog and man~Psychopharmacology~1989~97(3)~303-8;Yamagami S: A cross-over study of clocapramine and haloperidol in chronic schizophrenia. J Int Med Res 13: 301-310, 1985 - Ishigooka J, Murasaki M, Wakatabe H, et al: Pharmacokinetic study of iminodibenzyl antipsychotic drugs, clocapramine and Y-516, in dog and man. Psychopharmacology 97(3) : 303-308, 1989.;;;;;;;clocapramine (Y 4153);;;
81;A.III.9 ;Clospipramine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;1'-[3-(3-chloro-10,11-dihydro-5H-dibenzo[b-f] azepin-5- yl)propyl]-1,2, 3,5,6,7,8,8a-octahydroimidazo[1,2-a]pyridine-3- spiro-4'-piperidin-2-one;. ;Clospipramine; has been marketed or used in ;Japan; under the trade or premarketing names of ;Cremin;NM: Cremin Yoshitomi, JPN: f-c tabs.10mg, 25mg - granulates 10 %;. ;Active metabolite of clocapramine. Neuroleptic agent. Preliminary clinical studies in the treatment of schizophrenic psychoses. Sleepiness at a dosage of about 25 mg/ at higher dosage dysarthria and akathisia. Plasma half-life in healthy subjects about 15 ± 2 hours.;WHO Drug Information~~~1990~4(4)~202#Ishigooka J, Murasaki M, Miura S, Shibata M, Takamatsu R~Pilot study of plasma concentrations of mosapramine, a new iminodibenzyl antipsychotic agent, after multiple oral administration in schizophrenic patients~Current therapeutic research~1994~55(3)~331-42;WHO Drug Information vol 4(4): 202, 1990 - Ishigooka J, Murasaki M, Miura S & al: Pilot study of plasma concentrations of mosapramine, a new iminobenzyl antipsychotic agent, after multiple oral administration in schizophrenic patients. Curr Ther Res Clin Exp 55/3: 331-342, 1994.;;;;;;;clospipramine (Y 516 mosapramine);;;
82;A.III.9 ;CI 943;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;7,8-dihydro-8-ethyl-1,3,5-trimethyl-1H-imidazo[1,2- c]pyrazolo[3,4-e]pyrimidine;. ;CI 943; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Reduces locomotion in animal studies, without affecting amphetamine-induced stereotypy. Is not a dopamine antagonist. Exhibits antipsychotic-like profile. Clinical studies.;"DeWald HA, Beeson NW, Hershenson FM, Wise LD, Downs DA, Heffner TG, et al.~Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines~Journal of medicinal chemistry~1988~31(2)~454-61#Heffner TG, Downs DA, Meltzer LT, Wiley JN, Williams AE~CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects~The Journal of pharmacology and experimental therapeutics~1989~251(1)~105-12#
Pugsley TA, Coughenour LL, Myers SL, Shih YH, Courtland GG, Berghoff W, et al.~CI-943, a potential antipsychotic agent. II. Neurochemical effects~The Journal of pharmacology and experimental therapeutics~1989~251(1)~113-22
";DeWald HA, Beeson NW, Hershenson FM: Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines J Med Chem 31: 454-461, 1988 - Heffner TG, Downs DA, Meltzer LT, et al: CI-943, a potential antipsychotic agent. Preclinical behavioral effects. J Pharmacol Exp Ther 251: 105-112, 1989 - Pugsley TA, Coughenour LL, Myers SL, et al: CI-943, a potential anti-psychotic agent. Neurochemical effects. J Pharmacol Exp Ther 251: 113-122, 1989.;;;;;;;CI 943;;;
83;A.III.9 ;Carpipramine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;1-[3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]4- piperidinopiperidine-4-carboxamide (dihydrochloride);. ;Carpipramine; has been marketed or used in ;France, Japan, Germany; under the trade or premarketing names of ;Prazinil, Defekton, Bay b 4343;NM: Prazinil Pierre Fabre, F: tabs. 50mg NM: Defekton Yoshitomi, JPN NM: Bay b 4343 Bayer, BRD;. ;5-HT antagonist. Neuroleptic/ also antidepressive properties 2 reported. Studied in the treatment of hebephrenia and schizoaffective disorders. Weight gaining effects. Desinhibitory action in the management of motor retardation. About 16 metabolites isolated and identified. Oral dose 50 mg to 300 mg/day, occasionally doses up to 1 g daily. Preferential use in hebephrenic patients.;"Raffaitin F, Narboni V~The 5-HT antagonists: A new therapeutic class. The clinician's point of view~9th World Cong Psychiatry~1993~~#Ferreri M, Raffaitin F, Narboni V, Alby J~Neurotic inhibition and its treatment: the therapeutic effects of 5-HT antagonists (carpipramine)~Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology~1994~10(153S)~#
Vanelle JM, Olie JP, Levy-Soussan P~New antipsychotics in schizophrenia: the French experience~Acta psychiatrica Scandinavica Supplementum~1994~380(59-63)~
";Raffaitin F, Narboni V: The 5-HT antagonists: A new therapeutic class. The clinician's point of view. 9th 2 World Cong Psychiatry (Rio de Janeiro) Abs 246, 1993 - Ferreri M, Raffaitin F, Narboni V, Alby JM: Neurotic inhibition and its treatment: the therapeutic effects of 5-HT antagonists (carpipramine). 2 Neuropsychopharmacology 10 (n° 3S, part 2): 153S (abst P-58-238), 1994 - Vanelle JM, Olié JP, Levy- Soussan P: New antipsychotics in schizophrenia: The French experience. Acta Psychiatr Scand (Suppl) 89/380: 59-63, 1994.;;;;;;;carpipramine (21.679 RP);;;
84;A.III.9 ;Org 10.490;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;6,7,8,9-tetrahydro-7-methyl-5H-dibenz[b,i] [1,6]oxazecine (Z)-2-butenedioate (1:1);. ;Org 10.490; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Combined dopamine D and D receptors antagonist with 5- 1 2 HT inhibiting activity. Devoid of anticholinergic effects. No or slight liability to induce extrapyramidal effects. So far preliminary clinical studies. Further development discontinued.;Bruin RJ, Vrijmoed-de Vries MC, al e~ORG 10490: a new putative antipsychotic drug with 5-HT and DA antagonistic 2 properties~18th CINP Cong (Nice)~1992~~;Bruin RJ, Vrijmoed-de Vries MC, & al: ORG 10490: a new putative antipsychotic drug with 5-HT and DA antagonistic 2 properties. 18th CINP Cong (Nice) Abs 0-14-43, 1992.;;;;;;;Org 10.490;;;
85;A.III.9 ;Benzquinamide;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;3-diethylcarbamoyl-1,3,4,6,7,11b-hexahydro-9,10- dimethoxy-2H-benzo[a] quinolizin-2-yl acetate;. ;Benzquinamide; has been marketed or used in ;Germany, United States of America; under the trade or premarketing names of ;Promecon, Emetecon, Quantril;NM: Promecon Searle, BRD: amps. 50mg benzquinamide dry substance (as HCl salt) (deleted) NM: Emetecon Roerig, USA: vials 50mg NM: Quantril Pfizer, USA: (deleted);. ;Formerly studied in the treatment of schizophrenic psychoses. Currently used as an antiemetic.;"Hollister LE, Overall JE, Bennett JL, Kimbell I, Jr., Shelton J~Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients~Clinical pharmacology and therapeutics~1967~8(2)~249-55#
Moertel CG, Schutt AJ, Hahn RG, O'Fallon JR~Oral benzquinamide in the treatment of nausea and vomiting~Clinical pharmacology and therapeutics~1975~18(5 Pt 1)~554-7";Hollister LE, Overall JE, Bennett JL, et al: Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients. Clin Pharmacol Ther 8: 249-255, 1967 - Moertel CG, Schutt AJ, Hahn RG, et al: Oral benzquinamide in the treatment of nausea and vomiting. Clin Pharmacol Ther 18: 554-557, 1975.;;;;;;;benzquinamide (P 2647);;;
86;A.III.9 ;Tetrabenazine;is in the ;tricyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-2Hbenzo[ a]quinolizin-2-one;. ;Tetrabenazine; has been marketed or used in ;Denmark, Norway, United Kingdom, Japan; under the trade or premarketing names of ;Nitoman, Regulin;NM: Nitoman Roche, DK, NOR, UK: tabs. 25mg NM: Regulin Takeda, JPN: tabs. 2mg;. ;Catecholamine and serotonin depletor. Formerly used in the treatment of psychoses. According to recent data for the management of chorea Huntington or other motor disturbances. Plasma half-life about 6½ hours.;"Mehvar R, Jamali F, Watson MW, Skelton D~Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies~Drug metabolism and disposition: the biological fate of chemicals~1987~15(2)~250-5#Jankovic J, Orman J~Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias~Neurology~1988~38(3)~391-4#
Pletscher A~The discovery of antidepressants: a winding path~Experientia~1991~47(1)~4-8
";Mehvar R, Jamali F, Watson MWB, et al: Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug Metab Dispos 15: 250-255, 1987 - Jankovic J, Orman J: Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 38: 391-394, 1988 - Pletscher A: The discovery of antidepressants: a winding path. Experientia 47: 4-8, 1991.;;;;;;;tetrabenazine;;;
87;A.III.10 ;Citatepine;is in the ;tetracyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2,3,4,5-tetrahydro-3-methyl-1H-dibenzo [2,3:6,7]thiepino [4,5-d]azepine-7-carbonitrile;. ;Citatepine; has been marketed or used in ;Switzerland; under the trade or premarketing names of ;CGP 14.175 A;NM: CGP 14.175 A Novartis (Ciba Geigy, CH);. ;Tetracyclic psychotropic compound with antihistaminic and antiserotonergic properties. Dopamine blocking activity. According to preliminary investigations potential antipsychotic agent. Behavioral studies.;Scrip~~~1986~No 1081(March 3rd)~26#MISSING;Scrip March 3rd no 1081: 26, 1986 - Bischoff S, Vassout A, Delini-Stula A, et al: Interactions of cipazoxapine, citatepine, eresepine, and maroxepine with central dopamine (DA) receptors: effects on in vivo [ H]spiperone 3 binding, DA metabolism, and behavioral parameters. Pharmacopsychiatry 19: 306-307, 1986.;;;;;;;citatepine (citatepin, citalepine);;;
88;A.III.10 ;Maroxepine;is in the ;tetracyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2,3,4,5-tetrahydro-3-methyl-1H-dibenzo [2,3:6,7]oxepin[4,5-d]azepine;. ;Maroxepine; has been marketed or used in ;Switzerland; under the trade or premarketing names of ;CGP 13.442;NM: CGP 13.442 Novartis (Ciba Geigy, CH);. ;Preliminary pharmacological studies. Psychotropic activity anticipated. Dopamine antagonist. Closely related to citatepine, eresepine and cipazoxapine. So far no further clinical trials initiated. Development discontinued.;Waldmeier P, Bischoff S, Bittiger H, Hauser K, Vassout A, Delini-Stula A, et al.~Pharmacological profiles of four new tetracyclic dopamine antagonists, maroxepine, citatepine, eresepine, and cipazoxapine~Pharmacopsychiatry~1986~19(04)~316-7;Waldmeier PC, Bischoff S, Bittiger H, et al: Pharmacological profiles of four new dopamine antagonists, maroxepine, citatepine, eresepine, and cipazoxapine. Pharmacopsychiatry 19: 316-317, 1986.;;;;;;;maroxepine (maroxepin);;;
89;A.III.10 ;Eresepine;is in the ;tetracyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;1,2,3,4,5,10-hexahydro-3,10-dimethylazepino [4,5-d]dibenz[b,f]azepine;. ;Eresepine; has been marketed or used in ;Switzerland; under the trade or premarketing names of ;CGP 15.564 B;NM: CGP 15.564 B Novartis (Ciba Geigy, CH);. ;Exhibits, according to pharmacological studies, marked antidopaminergic effects, displaying the profile of atypical neuroleptics. Potential antipsychotic agent with, like clozapine, only limited extrapyramidal reactions.;MISSING.#Waldmeier P, Bischoff S, Bittiger H, Hauser K, Vassout A, Delini-Stula A, et al.~Pharmacological profiles of four new tetracyclic dopamine antagonists, maroxepine, citatepine, eresepine, and cipazoxapine~Pharmacopsychiatry~1986~19(04)~316-7;Bischoff S, Vassout A, Delini-Stula A, et al: Interactions of cipazoxapine, citatepine, eresepine, and maroxepine with central dopamine (DA) receptors: effects on in vivo [ H]-spiperone binding, DA 3 metabolites, and behavioral parameters. Pharmacopsychiatry 19: 306-307, 1986 - Waldmeier PC, Bischoff S, Bittiger H, et al: Pharmacological profiles of four new tetracyclic dopamine antagonists, maroxepine, citatepine, eresepine, and cipazoxapine. Pharmacopsychiatry 19: 316-317, 1986.;;;;;;;eresepine (erizepine, eresepin);;;
90;A.III.10 ;Biriperone;is in the ;tetracyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;(±)-4'-fluoro-4-(3,4,6,7,12,12a-hexahydro-pyrazino[1',2':1,6] pyrido[3,4-b]indol-2(1H)-yl) butyrophenone;. ;Biriperone; has been marketed or used in ;; under the trade or premarketing names of ;Centbutindole;NM: Centbutindole Central Drug Research Institute, India;. ;Also classified as a butyrophenone derivative. Potential neuroleptic agent/ preliminary clinical investigation in the treatment of psychoses. Extended duration of action reported. Lesser liability for extrapyramidal effects than haloperidol.;Palit G, al e~A comparison of the psychopharmacological profile of centbutindole, haloperidol, chlorpromazine and pimozide~4th Cong Eur Coll Neuropsychopharmacol~1991~~;Biriperone. Suppl to WHO Chronicle 38(2): 3, 1984 - Palit G & al: A comparison of the psychopharmacological profile of centbutindole, haloperidol, chlorpromazine and pimozide. 4th Cong Eur Coll Neuropsychopharmacol (Monte Carlo): Abs P20, 1991.;;;;;;;biriperone;;;
91;A.III.10 ;Cipazoxapine;is in the ;tetracyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;3-cyclopentylmethyl-2,3,4,5-tetrahydro-1H-dibenz[2,3:6,7] oxepin[4,5-d]azepine-7-carbonitrile;. ;Cipazoxapine; has been marketed or used in ;Switzerland; under the trade or premarketing names of ;CGP 19.486 A;NM: CGP 19.486 A Novartis (Ciba Geigy, CH);. ;Investigated for its [ H]spiperone binding activity. 3 Antidopaminergic properties. Extended duration of action. N NH Cl CH3 HN H H H C C CH3 O CH3 CH3 Moderate extra-pyramidal properties. Individually adapted oral dose range in the treatment of psychotic disorders ½ mg up to 10 mg daily.;Bischoff S~Towards the understanding of the neuroanatomical substrate of schizophrenia: The contribution of savoxepine~Novel antipsychotic medications Raven Press, New York~1992~117-34~#Leenders KL, Antonini A, Thomann R, Locher JT, Maitre L, Gerebtzoff A, et al.~Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET)~European journal of clinical pharmacology~1993~44(2)~135-40;Bishoff S: Towards the understanding of the neuro-anatomical substrate of schizophrenia. Novel Antipsychotic Drugs: 117-134, 1992. Raven Press Ltd NY - Leenders KL, Antonini HF, Thomann R, & al: Savoxepine: Striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET). Eur J Clin Pharmacol 44/2: 135-140, 1993.;;;;;;;cipazoxapine (savoxepine, savoxepin);;;
92;A.III.10 ;Org 5222;is in the ;tetracyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1Hdibenz[ 2,3:6,7]oxepino[4,5-c] pyrrolidine (maleate);. ;Org 5222; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Dopamine D -antagonist with high affinity for 5-HT receptors. 2 2 Low liability to cause cataleptic reactions. Antagonizes amphetamine-induced hyperactivity. Putative antipsychotic with anxiolytic effects. Preliminary clinical trials show an antipsychotic effect devoid of EPSE. Further development discussed due to narrow therapeutic index.;Sitsen J, Vrijmoed-de Vries M~ORG 5222: Preliminary clinical results~Novel antipsychotic drugs Raven Press, New York~1992~15-08#Vrijmoed de Vries MC~A European placebo-controlled, dose-finding study in schizophrenic patients with a potentially antipsychotic drug (ORG 5222)~European Psychiatry~1994~9(Suppl 1)~156S;Sitsen JMA, Vrijmoed -de Vries MC: ORG 5222-Preliminary clinical results. Novel Antipsychotic Drugs: 15-18, 1992. Raven Press Ltd NY - Vrijmoed de Vries MC: A European placebo-controlled, dose-finding study in schizophrenic patients with a potentially antipsychotic drug (ORG 5222). Eur Psychiatry 9 (suppl. 1): 156 S, 1994. Abstract.;;;;;;;Org 5222;;;
93;A.III.10 ;LY 170.542;is in the ;tetracyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;8,9-didehydro-6,8-dimethyl-2-(methylthio) ergoline mesylate (according to publication) systematic name: 7,9-dimethyl-5-methylthio-6a,7,8,10atetrahydro- 6H-indolo[4,3a,3-fg] quinoline mesylate;. ;LY 170.542; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Ergoline derivative. Potential antipsychotic agent. Dopamine antagonistic activity and neuroleptic-like pharmacological profile.;Wheeler WJ~Preparation of C-labelled 8,9-didehydro-6,8-dimethyl-2-methyl- thioergoline mesylate, a 14 dopamine antagonist potentially useful in the treatment of schizophrenia~Journal of Labelled Compounds and Radiopharmaceuticals~1988~25(667-74)~;Wheeler WJ: Preparation of C-labelled 8,9-didehydro-6,8-dimethyl-2-methyl- thioergoline mesylate, a 14 dopamine antagonist potentially useful in the treatment of schizophrenia. J Label Comp Radiopharm 25: 667-674, 1988.;;;;;;;LY 170.542;;;
94;A.III.10 ;SDZ 208-912;is in the ;tetracyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;;. ;SDZ 208-912; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;(Cl at C sub-stituted by methyl) 2 Novartis(Sandoz Research) Both compounds are reported to exhibit 'non-classical' neuroleptic-like effects, with high affinity for central D , and 5-HT receptors. Partial DA receptor agonist. 2 1 1A;Abbott A~5-HT3 antagonists and ligands for dopamine D1- and autoreceptors offer new leads for antipsychotic drugs~Trends in pharmacological sciences~1990~11(2)~49-51#Coward DM, Dixon AK, Urwyler S, White TG, Enz A, Karobath M, et al.~Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912~The Journal of pharmacology and experimental therapeutics~1990~252(1)~279-85;Abbott A: 5-HT antagonists and ligands for dopamine D and autoreceptors offer new leads for 3 1 antipsychotic drugs. Trends Pharmacol Sci 11 : 49-51, 1990 - Coward DM, Dixon AK, Urwyler S, et al: Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912. J Pharmacol Exp Ther 252: 279-285, 1990.;;;;;;;SDZ 208-912 (SDZ 208-911, SDZ 208-912, SDZ 208-911);;;
95;A.III.10 ;Bromerguride;is in the ;tetracyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2-bromolisuride 2K-95451;. ;Bromerguride; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Potential neuroleptic. Phase II clinical trials;;;;;;;;;bromerguride;;;
96;A.III.11 ;Butaclamol;is in the ;pentacyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;(±)-3 -tert-butyl-2,3,4,4a ,8,9,13b ,14-octahydro-1Hbenzo[ 6,7]cyclohepta[1,2,3-de] pyrido[2,1-a]isoquinolin-3-ol hydrochloride;. ;Butaclamol; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Calmodulin inhibitor. High affinity D /D /5-HT -receptors 1 2 2 antagonist and very potent neuroleptic. Clinical evaluations in the treatment of schizophrenic disorders. Enantioselectivity/ neuroleptic action related to (+)-isomer.;Casarotto MG, Craik DJ, Lloyd EJ, Partridge AC~An NMR and theoretical study of the conformation and internal flexibility of butaclamol hydrochloride~Journal of medicinal chemistry~1991~34(7)~2036-43#Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, et al.~Expression and pharmacological characterization of the human D3 dopamine receptor~The Journal of pharmacology and experimental therapeutics~1994~268(1)~417-26;Casarotto, Craik DJ, Loyd EJ, & al: An NMR and theoritical study of the conformation and internal flexibility of butaclamol hydrochloride. J Med Chem 34: 2036-2043, 1991 - Freedman SB, Patel S, Marwood R & al: Expression and pharmacological characterization of the human D dopamine receptor. 3 J Pharmacol Exp Ther 268(1): 417-426, 1994.;;;;;;;butaclamol (AY 23.028);;;
97;A.III.11 ;Dexclamol;is in the ;pentacyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;(+)-2,3,4,4a ,8,9,13b ,14-octahydro-3 -isopropyl-1Hbenzo[ 6,7]cyclohepta[1,2,3-de] pyrido[2,1-a]-isoquinolin-3- ol;. ;Dexclamol; has been marketed or used in ;United States of America; under the trade or premarketing names of ;AY 24.169, AY 22.814;NM: AY 24.169 (hydrochloride) Ayerst, USA NM: AY 22.814 (racemate);. ;Studied for neuroleptanalgesic activity/ according to pharmacological data as effective as butyrophenone-type neuroleptics like droperidol.;Moereels H, Tollenaere JP~A comparison between the conformation of dexclamol and the tricyclic and butyrophenone type dopamine antagonists~Life sciences~1978~23(5)~459-63#Liljefors T, Bogeso KP~Conformational analysis and structural comparisons of (1R,3S)-(+)- and (1S,3R)-(-)-tefludazine, (S)-(+)- and (R)-(-)-octoclothepin, and (+)-dexclamol in relation to dopamine receptor antagonism and amine-uptake inhibition~Journal of medicinal chemistry~1988~31(2)~306-12;Moereels H, Tollenaere JP: Comparison between the conformation of dexclamol and the tricyclic and butyrophenone type dopamine antagonists. Life Sci 23: 459-464, 1978 - Liljefors T, Bøgesø KP: Conformational analysis and structural comparisons of (1R,3S)-(+)- and (1S,3R)-(-)- tefludazine, (S)-(+)- and (R)-(-) octoclothepin, and (+)-dexclamol in relation to dopamine receptor antagonism and amine-uptake inhibition. J Med Chem 31: 306-312 , 1988.;;;;;;;dexclamol;;;
98;A.III.11 ;Taclamine;is in the ;pentacyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta [1,2,3-de]pyrido[2,1-a] isoquinoline;. ;Taclamine; has been marketed or used in ;United States of America; under the trade or premarketing names of ;AY 22.214, QM 7184;NM: AY 22.214 Ayerst, USA NM: QM 7184 thiophene analogue of taclamine;. ;Minor neuroleptic activity. The thiophene analogue is reported to be a very potent -adrenoceptor blocker.;Pugsley TA, Lippmann W~Effects of taclamine (AY-22,214), a new psychoactive agent, on catecholamine and serotonin metabolism~Archives internationales de pharmacodynamie et de therapie~1975~213(1)~73-87#Arribas E, Vega S, Benito C, Fernandez-Tome MP, del Rio J~Synthesis and pharmacological study of the thiophene analogue of taclamine, QM-7184, a new neuroleptic drug with potent alpha-adrenoceptor blocking activity~Arzneimittel-Forschung~1983~33(10)~1417-21;Pugsley TA, Lippmann W: Effects of taclamine (AY-22,214 ), a new psychoactive agent, on catechol and serotonin metabolism. Arch Int Pharmacodyn 213 : 73-87, 1975 - Arribas E, Vega S, Benito C, et al: Synthesis and pharmacological study of the thiophene analogue of taclamine, QM-7148, a new neuroleptic drug with potent -adrenoceptor blocking activity. Arzneim Forsch 33: 14 17-1421, 1983.;;;;;;;taclamine;;;
99;A.III.11 ;Reserpine;is in the ;pentacyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;methyl ester of 2 ,11-dimethoxy-3- -(3,4,5- trimethoxybenzoyloxy)-1 ,2 ,3 ,4,4a ,5,7,8, 13,13b ,14,14a -dodecahydro-isoquinolino [3,2-a]- -carboline-1 -carboxylic acid;. ;Reserpine; has been marketed or used in ;Belgium, Germany, France, Switzerland; under the trade or premarketing names of ;Serpasil;NM: Serpasil Ciba B, BRD, F: tabs. ¼mg (deleted) - CH (deleted): tabs. 0.1mg and 2½mg/ml - FIN, UK: tabs. 0.1mg and ¼mg;. ;Antihypertensive and neuroleptic agent;Jin-Gou X, Hui-Ping C, Xiang-Qun G, Yi-Bing Z~Determination of reserpine by in situ sensitized photochemical spectrofluorimetry~Analytica chimica acta~1995~302(2)~207-14;Xu JG, Chen HP, Gui XQ, Zhao YB: Determination of reserpine by in situ sensitized photochemical spectrofluorimetry. Anal Chim Acta 302/2-3: 207-214, 1995.;;;;;;;reserpine;;;
100;A.III.11 ;Deserpidine;is in the ;pentacyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;methyl ester of 2 -methoxy-3 -(3,4,5- trimethoxybenzoyloxy)-1 ,2 ,3 ,4,4a ,5, 7,8,13,13b , 14,14a -dodecahydro-isoquinolino [3,2-a]-( -carboline-1 -carboxylic acid;. ;Deserpidine; has been marketed or used in ;Belgium, United Kingdom, United States of America; under the trade or premarketing names of ;Harmonyl;NM: Harmonyl Abbott, B, UK: tabs. ¼mg (deleted) USA: tabs. 0.1mg, ¼mg;. ;Antihypertensive and neuroleptic agent;;;;;;;;;deserpidine ((11-demethoxy-reserpine));;;
101;A.III.11 ;Rescinnamine;is in the ;pentacyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;(trimethoxycinnamoyl-methylreserpate) methyl ester of 2 ,11-dimethoxy-3 -(3,4,5- trimethoxycinnamoyloxy)-1 ,2 ,3 ,4,4a ,5,7,8, 13,13 b ,14, 14a -dodecahydro-isoquinolino [3,2-a] - -carboline-1 -carboxylic acid;. ;Rescinnamine; has been marketed or used in ;United States of America; under the trade or premarketing names of ;Moderil;NM: Moderil Pfizer, USA: tabs. ¼mg and ½mg;. ;PROPERTIES AND REFERENCES FOR RESERPINE, DESERPIDINE AND RESCINNAMINE: Antihypertensive/ tranquilizing effects. Restricted use as neuroleptics. Reported side effects e.g. cardiovascular reactions, extrapyramidal symptoms, 'reserpine depression', epistaxis, purpura, nasal congestion, gastrointestinal complaints, pruritus, rash, and drowsiness.;Missale C, Nisoli E, Liberini P, Rizzonelli P, Memo M, Buonamici M, et al.~Repeated reserpine administration up-regulates the transduction mechanisms of D1 receptors without changing the density of [3H]SCH 23390 binding~Brain research~1989~483(1)~117-22#Lowy MT, Nash JF, Jr., Meltzer HY~Reserpine-induced DST nonsuppression in rats~Biological psychiatry~1990~27(5)~546-8;Missale C, Nisoli E, Liberini P, et al: Repeated reserpine administration upregulates the transduction mechanism of D receptors without changing the density of [ H]SCH 23390 binding. Brain Research 483: 1 3 117-122, 1989 - Lowy MT, Nash JF, Meltzer HY: Reserpine-induced DST nonsuppression in rats. Biol Psychiatry 27: 546-548, 1990. N H3C CH3 O OCH3 CH2 C O N N N OC3H7 N Cl . HCl;;;;;;;rescinnamine;;;
102;A.III.12 ;NE-100;is in the ;monocyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;N-N-dipropyl-2[4-methoxy-3-(2phenylethoxy)-phenyl]- ethylamine.HCI;. ;NE-100; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Selective sigma-receptor antagonist. Potential antipsychotic. Phase II clinical trails in 1995.;"Okuyama S, Imagawa Y, Sakagama T, al e~NE-100, a novel sigma receptor ligand. Effect on phencyclidine psychosis in experimental animals~Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology~1994~10(141S)~
#Tanaka M, Shirasaki T, Ajima A, al e~Characteristics of binding of NE-100 to sigma recognition site in guinea-pig brain membranes~Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology~1994~10(251S)~#Ishigooka J, Miuru S~Sigma receptor antagonists in the treatment of schizophrenia~Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology~1994~10(806S)~";Okuyama S, Imagawa Y, Sakagama T & al : NE-100, a novel sigma receptor ligand. Effect on phencyclidine psychosis in experimental animals. Neuropsychopharmacology 10 (n°3S, part 2) : 141S (abs P58-189)1994 - Tanaka M, Shirasaki T, Ajima A & al : Characteristics of binding of NE-100 to sigma recognition site in guinea-pig brain membranes. Neuropsychopharmacology 10 (n° 3S, part 2):251S (abst P-174-155),1994 - Ishigooka J, Miuru S : Sigma receptor antagonists in the treatment of schizophrenia. Neuropsychopharmacology 10 (n°3S, part 1): 806S (abst S-189-815),1994.;;;;;;;NE-100 (Taicho);;;
103;A.III.12 ;Mazapertine;is in the ;monocyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;1-[ -[4-(o-isopropoxyphenyl)-1-piperazinyl]-m-toluoyl] piperidine;. ;Mazapertine; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Potential antipsychotic. D /D /5-HT / - adrenergic antagonist. 2 3 1A 1A;WHO Drug Information~Mazapertine~~1994~8(4)~246# Reitz AB, Bennett DJ, Blum PS, Codd EE, Maryanoff CA, Ortegon ME, et al.~A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects~Journal of medicinal chemistry~1994~37(8)~1060-2# Buclin T, Stucki R, JAQUETMULLER F, Munafo A, Baldauf C, BRUNNERFERBER F, et al.~TOLERABILITY AND PSYCHOPHARMACOLOGICAL PROFILE OF THE NOVEL ANTIPSYCHOTIC RWJ-37796 IN HEALTHY-VOLUNTEERS~CLINICAL PHARMACOLOGY & THERAPEUTICS~1993~53(179-)~;"Mazapertine.WHO Drug Information, vol. 8 (4) : 246, 1994 - Reitz AB, Bennett DJ, Blum PS : A new arylpiperazine antipsychotic with high D /D /5- 2 3 HT /"" - adrenergic affinity and a low potential for extrapyramidal effects. J 1A 1A Med Chem 37 : 1060 - 1062, 1994 - Buclin T, Stucki R, Jaquet-Müller F & al : Tolerability and psychopharmacological profile of the novel antipsychotic RWJ-37796 in healthy volunteers. Clin Pharmacol Ther 55/2 : 179 (abstr. PII-38), 1994.";;;;;;;mazapertine (RWJ 37796);;;
104;A.III.12 ;SR 31.742A;is in the ;monocyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;1-[3-(3-chloro-4-cyclohexylphenyl)-2(Z)-propenyl] - hexahydroazepine HCl or cis-3-(hexahydroazepin-1-yl-1-(3-chloro-4-cyclohexy l phenyl)propene-1 HCl or (Z)-1-[3-(3-chloro-4-cyclohexylphenyl)-2-propenyl]-hexahydro-1H-azepine;. ;SR 31.742A; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Potent and selective central sigma receptor antagonist, potential antipsychotic and antimanic agent. In animal studies, no extrapyramidal side-effects were observed. Negative symptoms of O O CH3 N F CH3 H OH schizophrenia markedly improved. Phase II clinical trials in 1995.;Labie C, Keane PE, Soubrie P, Le Fur G~The sigma receptor ligand SR 31742A increases neurotensin in the nucleus accumbens but not in the caudate-putamen of the rat~European journal of pharmacology~1993~231(3)~465-7# Poncelet M, Santucci V, Paul R, Gueudet C, Lavastre S, Guitard J, et al.~Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A~Neuropharmacology~1993~32(6)~605-15;Labie C, Keane PE, Soubrie P, Le Fur G: The sigma receptor ligand SR 31742A increases neurotensin in the nucleus accumbens but not in the caudate-putamen of the rat.Eur J Pharmacol 231/3: 465-467, 1993 - Poncelet M, Santucci V, Paul R & al: Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A. Neuropharmacology 32/6: 605-615, 1993.;;;;;;;SR 31.742A;;;
105;A.III.12 ;MDL 100.907;is in the ;monocyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;R(+)- -(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol;. ;MDL 100.907; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;5-HT antagonist without 5-HT affinity. Potential antipychotic. Phase I clinical 2 c trials (1996).;Schmidt CJ, Kehne JH, Moser PC, Sorensen SM~Preclinical antipsychotic activity of the selective 5-HT antagonist, MDL 100,907~19th CINP Cong (Washington)~1994~~;Schmidt CJ, Kehne JH, Moser PC, Sorensen SM: Preclinical antipsychotic activity of the selective 5-HT antagonist, MDL 100,907. 19th CINP Cong (Washington): 27 2 (abst P-174-248), 1994.;;;;;;;MDL 100.907;;;
106;A.III.13 ;Pirenperone;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;3-[2-[4-(p-fluorobenzoyl)piperidino]ethyl]-2-methyl-4Hpyrido[ 1,2-a] pyrimidin-4-one;. ;Pirenperone; has been marketed or used in ;Belgium; under the trade or premarketing names of ;R 47.465;NM: R 47.465 Janssen, B;. ;"5-HT antagonistic mode of action. Devoid of neuroleptic 2 properties. Anxiolytic effects. Efficacy in conflict situations reported. Designated as a ""pure LSD-antagonist"". Studied in the treatment of anxiety states/ tentative dosage 15 mg up to 150mg/day.";Jenck F, Broekkamp CL, Van Delft AM~Effects of serotonin receptor antagonists on PAG stimulation induced aversion: different contributions of 5HT1, 5HT2 and 5HT3 receptors~Psychopharmacology~1989~97(4)~489-95# Paul D, Pinel JP~Pirenperone does not attenuate morphine analgesia in spinal rats~Psychopharmacology~1990~100(1)~98-101# Saller CF, Czupryna MJ, Salama AI~5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade~The Journal of pharmacology and experimental therapeutics~1990~253(3)~1162-70;Jenck F, Broekkamp CLE, van Delft AML: Effects of serotonin receptor antagonists on PAG stimulation induced inversion: different contributions of 5-HT , 5-HT and 5-HT receptors. Psychopharmacol 97: 489- 1 2 3 495, 1989 - Paul D, Pinel JPJ: Pirenperone does not attenuate morphine analgesia in spinal rats. Psychopharmacol 100: 98-101, 1990 - Saller CF, Czupryna J, Salama AI: 5-HT receptor blockade by ICI 2 169,369 and other 5-HT antagonists modulates the effects of D-2 dopamine receptor blockade. J Pharmacol Exp Ther 253: 1162-1170, 1990.;;;;;;;pirenperone;;;
107;A.III.13 ;Seganserin;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;3-[2-[4-(bis(p-fluorophenyl)methylene) piperidino]ethyl]-2- methyl-4H-pyrido[1,2-a] pyrimidin-4-one;. ;Seganserin; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Type 5-HT antagonistic mode of action. Studied for mood- 2 improving properties in the management of depressive neurosis. Therapeutic efficacy in the treatment of schizophrenia with negative symptomes anticipated. Development suspended.;Suppl to WHO Chronicle~Seganserin~~1986~40(5)~15;Seganserin. Suppl to WHO Chronicle vol 40(5): 15, 1986.;;;;;;;seganserin (R 56.413);;;
108;A.III.13 ;Ritanserin;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;6-[2-[4-(bis(p-fluorophenyl)methylene) piperidino]ethyl]-7- methyl-5H-thiazolo[3,2-a] pyrimidin-5-one;. ;Ritanserin; has been marketed or used in ;Belgium, United States of America; under the trade or premarketing names of ;R 55.667, Triserton R;NM: R 55.667 Janssen, B NM: Triserton USA R;. ;Highly selective 5-HT and 5-HT receptors antagonist 2 1c (predominantly 5-HT antagonist). Histamine, dopamine-D , , 2 21 and receptor sites hardly affected at therapeutic dosage. 2 Studied for the management of negative symptoms in schizophrenia. Clinical trials in the treatment of anxiety states. Particularly investigated for sleep regulation mechanisms. Development as an antidepressant and anxiolytic discontinued at phase III clinical trials level.;Kitaichi K, Yamada K, Hasegawa T, Furukawa H, Nabeshima T~Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin~Japanese journal of pharmacology~1994~66(2)~181-9 #Wiesel FA, Nordstrom AL, Farde L, Eriksson B~An open clinical and biochemical study of ritanserin in acute patients with schizophrenia~Psychopharmacology~1994~114(1)~31-8 #Naranjo CA, Poulos CX, Lanctot KL, Bremner KE, Kwok M, Umana M~Ritanserin, a central 5-HT2 antagonist, in heavy social drinkers: desire to drink, alcohol intake and related effects~Addiction (Abingdon, England)~1995~90(7)~893-905;Kitaichi K, Yamada K, Hasegawa T & al: Effects of risperidone on phencyclidine-induced behaviors: Comparison with haloperidol and ritanserin. Jpn J Pharmacol 66/2:181-189, 1994 - Wiesel FA, Nordström AL, Farde L, Eriksson B: An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 114: 31-38, 1994 - Naranjo CA, Poulos CX, Lanctot KL & al: Ritanserin, a central 5-HT antagonist, in heavy social drinkers: desire to drink, alcohol intake and related 2 effects. Addiction 90/7: 893-905, 1995.;;;;;;;ritanserin;;;
109;A.III.13 ;Setoperone;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;6-[2-[4-(p-fluorobenzoyl)piperidino]ethyl]-2,3-dihydro-7- methyl-5H-thiazolo[3,2-a] pyrimidin-5-one;. ;Setoperone; has been marketed or used in ;Belgium; under the trade or premarketing names of ;R 52.245;NM: R 52.245 Janssen, B;. ;Antipsychotic potency about equal to that of standard neuroleptics. Different pharmacological profile/ high affinity for 5-HT receptors/ no extrapyramidal symptoms. Antiautistic and 2 antidepressive properties reported. Used dosage about 15mg N N N Cl S NH O up to 120mg/day.;Blin J, Pappata S, Kiyosawa M, Crouzel C, Baron JC~[18F]setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo~European journal of pharmacology~1988~147(1)~73-82# Saller CF, Czupryna MJ, Salama AI~5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade~The Journal of pharmacology and experimental therapeutics~1990~253(3)~1162-70;Blin J, Pappata S, Kiyosawa M, et al: [ F]setoperone: a new high affinity ligand for positron emission 18 tomography study of the serotonin- receptors in baboon brain in vivo. Eur J Pharmacology 147: 73-82, 2 1988 - Saller CF, Czupryna J, Salama AI: 5-HT receptor blockade by ICI 169,369 and other 5-HT 2 2 antagonists modulates the effects of D dopamine receptor blockade. J Pharmacol Exp Ther 253: 1162- 2 1170, 1990.;;;;;;;setoperone;;;
110;A.III.13 ;Ziprasidone;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;Pfizer 5-[2-[4-(1,2-benzisothiazol-3-yl)-1 - piperazinyl]ethyl]-6-chloro-2-indolinone;. ;Ziprasidone; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;5-HT /D antagonist. Potential antipsychotic and treatment of schizoaffective disorders. In Phase 2 2 III clinical trial. Half life : 4 h. after oral administration and 2.9 h. after intravenous administration. Oral bioavailability 59%. At low doses potential anxiolytic/antidepressant;WHO Drug Information~Ziprasidone~~1994~8(4)~260# O'Connor R, Harrigan E~P-4-18 The pre-clinical profile of the new antipsychotic ziprasidone~European Neuropsychopharmacology~1995~5(3)~332;Ziprasidone. WHO Drug Information, vol 8 (4) : 260, 1994 - 0'Connor R, Harrigan E : The preclinical profile of the new antipsychotic ziprasidone. Eur Neuropsychopharmacology 5/3 : 332 (abstr. P-4-18), 1995.;;;;;;;ziprasidone (CP-88059);;;
111;A.III.13 ;Altanserin;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;3-[2-[4-(p-fluorobenzoyl)piperidino]ethyl]-2-thio-2,4(1H,3H)- quinazolinedione;. ;Altanserin; has been marketed or used in ;Belgium; under the trade or premarketing names of ;R 53.200;NM: R 53.200 Janssen, B;. ;5-HT antagonist. Studies in the management of anxiety and 2 depressive mood. Dosage about 60 mg daily.;"Litwin L, Goldstein J, Sutton E, Malick J~Effects of altanserin, a selective 5-HT 2 antagonist, on amphetamine-induced suppression of dopamine (DA) cell firing~Pharmacologist~1986~28(109)~
";Litwin LC, Goldstein JM, Sutton EB, et al: Effects of altanserin, a selective 5-HT antagonist, on amphetamine-induced suppression of 2 dopamine cell firing. Pharmacologist 28: 109, 1986.;;;;;;;altanserin;;;
112;A.III.13 ;Risperidone;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl) piperidino]ethyl-6,7,8,9- tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one;. ;Risperidone; has been marketed or used in ;Austria, Denmark, United Kingdom, Finland, Germany, Netherlands, Switzerland, ItalyRepublic of South Africa, Spain, France, Belgium, Portugal, Sweden; under the trade or premarketing names of ;Risperdal;NM: Risperdal Janssen, A, DK, UK, FIN, GR, ITA - Janssen/Organon, BRD - Janssen Nourypharma, NL - Janssen Cilga, CH, SWE, ITA: f-c tabs. 1mg, 2mg, 3mg, 4mg NM: Risperdal Janssen, RSA: tabs. 2mg, 3mg NM: Risperdal Janssen, ESP: f-c tabs.1mg, 3mg NM: Risperdal Janssen Cilag/Organon,F: f-c tabs.1mg, 2mg NM: Risperdal Janssen Cilag, B, PORT: f-c tabs.1mg, 2mg, 3mg NM: Risperdal Janssen, UK: sol.1mg/ml NM: Rispolin Organon, A: tabs. 1mg, 2mg, 3mg, 4mg NM: Belivon Organon, SWE, ITA, A: f-c tabs. 1mg, 2mg, 3mg, 4mg NM: Risperin Gador, ESP: tabs.1mg, 2mg, 3mg;. ;Full 5-HT /partial dopamine D receptors antagonist. Therapeutic claim: neuroleptic (USAN 2 2 Council). Effective in the treatment of psychotic disorders with negative and affective symptomatology. May decrease extrapyramidal effects induced by classical neuroleptics. Potential antidepressant activity which may be associated with exacerbation of manic symptoms in bipolar schizophrenics (Lancet August 20th, 1994: 554). High affinity for 5-HT receptor. 7 Promising alternative treatment of symptoms of Tourette's sybdrome.;Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Jr., Shen Y, et al.~Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors~The Journal of pharmacology and experimental therapeutics~1994~268(3)~1403-10# Borison RL, Diamond B, Pathiraja A, Meibach RC~Pharmacokinetics of risperidone in chronic schizophrenic patients~Psychopharmacol Bull~1994~30(2)~193-7# Chouinard G~Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study~Journal of clinical psychopharmacology~1995~15(1 Suppl 1)~36S-44S# DeVane CL~Brief comparison of the pharmacokinetics and pharmacodynamics of the traditional and newer antipsychotic drugs~American journal of health-system pharmacy~1995~52(suppl 1)~S15-S8 #Bruun RD, Budman CL~Risperidone as a treatment for Tourette's syndrome~The Journal of clinical psychiatry~1996~57(1)~29-31;Roth BL, Craigo SC, Choudhary MS & al: Binding of typical and atypical antipsychotic agents to 5- hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268/3: 1403-1410, 1994 - Borison RL, Diamond B, Pathiraja A, Meibach RC: Pharmacokinetics of risperidone in chronic schizophrenic patients. Psychopharmacol Bull 30/2: 193-197, 1994 - Chouinard G: Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 15 (1 suppl 1): 36S-44S, 1995 - DeVane CL: Brief comparison of the pharmacokinetics and pharmacodynamics of the traditional and newer antipsychotic drugs. Am Health-Syst Pharm 52 (suppl 1): S15-S18, 1995 - Bruun RD, Budman CL: Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry 57/1: 29-31, 1996.;;;;;;;risperidone;;;
113;A.III.13 ;Ocaperidone;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;3-[2-[4-(6-fluoro-1,2-benzisoxazol)-3-yl) piperidino]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a] pyrimidin-4-one;. ;Ocaperidone; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;D /5-HT antagonist. Antipsychotic related to 2 2 risperidone. In phase II clinical trials (1-2.5mg/day). Reduced side-effects liability. Discontinued at phase II in 1994.;WHO Drug Information~Ocaperidone~~1990~4(4)~203# Leysen JE, Janssen PM, Gommeren W, Wynants J, Pauwels PJ, Janssen PA~In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone~Molecular pharmacology~1992~41(3)~494-508# Megens AA, Niemegeers CJ, Awouters FH~Antipsychotic profile and side?effect liability of haloperidol, risperidone, and ocaperidone as predicted from their differential interaction with amphetamine in rats~Drug development research~1992~26(2)~129-45# Megens AA, Awouters FH, Meert TF, Schellekens KH, Niemegeers CJ, Janssen PA~Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598)~The Journal of pharmacology and experimental therapeutics~1992~260(1)~146-59;Ocaperidone. WHO Drug Information vol 4(4): 203, 1990 - Leysen LE, Janssen PMF, Gommeren W, & al: In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 41: 494-508, 1992 - Anton AHR, Megens AAHP, Niemegeers CJE, Awouters FHL: Antipsychotic profile and side-effects liability of haloperidol, risperidone and ocaperidone as predicted from their differential interaction with amphetamine in rats. Drug Dev Res 26: 129-145, 1992 - Megens AAHP, Awouters FHL, Meert TF, & al: Pharmacological profile of the new potent neuroleptic ocaperidone (R 79.598). J Pharmacol Exp Ther 260: 146-159, 1992.;;;;;;;ocaperidone (R 79.598);;;
114;A.III.13 ;Iloperidone;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;4'-[3-[4-(6-fluoro-1,2-benzisoxazol-3 - N S N N (CH2)4 N O O H H S R . HCl yl)piperidino) propoxy] 3'-methoxyaceto = phenone or 1[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]ethanone;. ;Iloperidone; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;5-HT /Dopamine D antagonist. Potential atypical antipsychotic. Phase II clinical trials in 1994. 2 2 P 9662 : direct sulphur isostere of iloperidone. Longer occupancy and higher affinity at 5-TH 2 receptors than D .Lower liability for EPS. 2;WHO Drug Information~Iloperidone~~1993~7(2)~85# Mutlib AE, Strupczewski JT~Picogram determination of iloperidone in human plasma by solid-phase extraction and by high-performance liquid chromatography-selected-ion monitoring electrospray mass spectrometry~Journal of chromatography B, Biomedical applications~1995~669(2)~237-46;Iloperidone.WHO Drug Information, vol. 7(2) : 85, 1993 - Mutlib AE, Strupczewski JT : Picogram determination of iloperidone in human plasma by solid-phase extraction and by high-performance liquid chromatography - selected -ion monitoring electrosray mass spectrometry. J. Chromatogr B 669 : 237-246, 1995.;;;;;;;iloperidone (HP 873, P 9662);;;
115;A.III.13 ;Perospirone;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;cis-2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-hexahydro-1Hisoindole- 1,3(2H)-dione;. ;Perospirone; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Very high binding affinities for both 5-HT and dopamine D receptors. 2 2 Strongly inhibits 5-HT receptor-mediated behavior. Neuroleptic agent, 2 however, only weak cataleptogenic activity reported. Minor central depressant effects. Potential atypical antipsychotic. Phase III clinical trials in positive and negative symptoms in schizophrenia.;WHO Drug Information~Perospirone~~1994~8(2)~102-3#Ohno Y, Ishida K, Ikeda K, Ishibashi T, Okada K, Nakamura M~Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test~Pharmacology, biochemistry, and behavior~1994~49(1)~19-23;Perospirone. WHO Drug Information vol 8(2): 102-103, 1994 - Ohno Y, Ishida K, Ikeda K & al: Evaluation of bradykinesia induction by SM-9018, a novel 5-HT and D receptor antagonist, using the mouse pole 2 2 test. Pharmacol Biochem Behav 49/1: 19-23, 1994.;;;;;;;perospirone (SM 9018);;;
116;A.III.13 ;Tefludazine;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;(E)-4-[3-(p-fluorophenyl)-6-(trifluoromethyl)-1-indanyl]-1- piperazineethanol;. ;Tefludazine; has been marketed or used in ;Denmark; under the trade or premarketing names of ;Lu 18-012;NM: Lu 18-012 Lundbeck, DK;. ;Representative of a new class of potent dopamine D /D 1 2 receptors antagonists with strong 5-HT receptor blocking 2 action. The neuroleptic activity seems to recide exclusively in the trans (E) isomer. Low tendency to cause extrapyramidal effects.;Svendsen O, Arnt J, Boeck V, Bøgesø K, Christensen A, Hyttel J, et al.~The neuropharmacological profile of tefludazine, a potential antipsychotic drug with dopamine and serotonin receptor antagonistic effects~Drug development research~1986~7(1)~35-47#Liljefors T, Bogeso KP~Conformational analysis and structural comparisons of (1R,3S)-(+)- and (1S,3R)-(-)-tefludazine, (S)-(+)- and (R)-(-)-octoclothepin, and (+)-dexclamol in relation to dopamine receptor antagonism and amine-uptake inhibition~Journal of medicinal chemistry~1988~31(2)~306-12;Svendsen O, Arnt J, Boeck V, et al: The neuropharmacological profile of tefludazine, a potential antipsychotic drug with dopamine and serotonine antagonistic effects. Drug Dev Res 7: 35-47, 1986 - Liljefors T, Bøgesø KP: Conformational analysis and structural comparisons of (1R,3S)-(+)- and (1S,3R)- N H2C COOH NH O N Cl N S O O O HN O N N N CH3 F N O2N HO O CH3 (-)-tefludazine, (S)-(+)- and (R)-(-)-octoclothepin, and (+)-dexclamol in relation to dopamine receptor antagonism and amine-uptake inhibition. J Med Chemistry 31: 306-312, 1988.;;;;;;;tefludazine;;;
117;A.III.13 ;SR-27897;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2-[[[4-(2-chlorophenyl)-2-thiazolyl]-amino]-carbonyl]- 1H-indole-acetic acid;. ;SR-27897; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Selective CCK antagonist. Potential antipsychotic. A Phase II clinical trials in 1994 for psychosis.;Scrip~~~1992~No 1776(27)~;SCRIP 1776 : 27, 1992.;;;;;;;SR-27897;;;
118;A.III.13 ;Supidimide;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2,3-dihydro-2-(2-oxo-piperidin-3-yl) benzo[d]thiazol-3-one- S,S-dioxide;. ;Supidimide; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Functional synergist of neuroleptics. Structurally related to thalidomide, but devoid of any teratogenic effects. Studied in the treatment of schizophrenia/ dosage 400mg/day. At low doses for insomnia or anxiety states.;Richter W, Giertz H~The effect of supidimide and lorazepam on sleep: a controlled clinical study in outpatients~Pharmacopsychiatr~1985~18(24-5#Youdim MB, Ashkenazi R~Serotonergic involvement in pharmacological action of the anxiolytic-sedatives thalidomide and supidimide~European journal of pharmacology~1985~119(1-2)~39-46;Richter W, Giertz H: The effect of supidimide and lorazepam on sleep: a controlled clinical study in outpatients. Pharmacopsychiatr 18: 24-25, 1985 - Youdim MB, Askenazi R: Serotonergic involvement in pharmacological action of the anxiolytic sedatives thalidomide and supidimide. Eur J Pharmacol 119: 39- 46, 1985.;;;;;;;supidimide;;;
119;A.III.13 ;AD 5423 ;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;2-(4-1-piperazinyl)-4-(4-fluorophenyl -5,6,7,8,9,10-hexahydrocyclooctan[ b] pyridine;. ;AD 5423 ; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;D /5-HT antagonist. D antagonism equipotent to haloperidol, 5- 2 2 2 HT antagonism 10 times higher. T unchanged AD 5423: 1.4- 2 max 1.7 h, T½: 4.1-48 h. Potential neuroleptic devoid of severe autonomic or sedative effects. Phase II clinical trials.;Wakatabe H, Ochiai K, Murasaki M, Miura S~Phase I clinical trial of AD 5423, a new antipsychotic drug with D and S antagonist activity~Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology~1994~10(192S)~;Wakatabe H, Ochiai K, Murasaki M, Miura S: Phase I clinical trial of AD 5423, a new antipsychotic drug with D and S antagonist activity. Neuropsychopharmacology vol 10 (n°3S, part 2): 192S (abs P-117-154), 2 2 1994.;;;;;;;AD 5423 ;;;
120;A.III.13 ;NNC 687;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;8-nitro-7-hydroxy-3-methyl-5(7-(2,3-dihydrobenzofuranyl))- 2,3,4,5-tetrahydro-1H-3-benzapine O O N HO N O OCH3 O;. ;NNC 687; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;D /D antagonist. Potential antipsychotic, anxiolytic and 1 2 antidepressant. T½ in healthy volunteers: 3-6 hrs. Discontinued at phase II clinical trials level.;Sloth-Nielsen M, Christensen JV, Ynddal L, Skrumsager BK~Phase I clinical trials of dopamine D 1 receptor antagonists~Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology~1994~10(236S)~#Karle J, Gerlach J, Clemmesen L, Hansen L, Andersen M, Andersen J, et al.~P-4-33 NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. A phase II clinical trial~European Neuropsychopharmacology~1995~5(3)~337#krumsager BK, Christensen JV, Snel S, Seiberling M~Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects~Psychopharmacology~1995~121(3)~294-9;Sloth-Nielsen M, Christensen JV, Ynddal L, Skrumsager BK: Phase I clinical trials of dopamine D 1 receptor antagonists. Neuropsychopharmacology 10 (n° 3S, part 1): 236S (abst. S-44-204), 1994 - Karle J, Gerlach J, Clemmensen L & al: NNC 010687, a selective dopamine D antagonist, in the treatment of 1 schizophrenia. A phase II clinical trial. Eur Neuropsychopharmacology 5/3: 337 (abstr P-4-33), 1995 - Skrumsager BK, Christenen JV, Snel S, Seiberling M: Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the D antagonist NNC 01-0687 in healthy subjects. Psychopharmacology 1 121: 294-299, 1995.;;;;;;;NNC 687 (NO 687, NNC01-0687 );;;
121;A.III.13 ;Panamesine;is in the ;bicyclic; category of antipsychotic.;It has a;;;;full chemical formula of ;(5S)-(-)-5-4-hydroxy-4-(1,3-benzodioxol-5- y l ) - p i p e r i d i n - 1 - y l m e t h y l - 3 - ( 4 - methoxyphenyl)-oxazolidin-2-one,HCl.;. ;Panamesine; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Antypical neuroleptic. High affinity for sigma central sites, no affinity for muscarinic, 5-HT and adrenoreceptors. In chronic preclinical studies, no post-synaptic D -receptors supersensitization 2 observed. Phase II clinical trials in 1995.;Dahmen N, Fischer V, Hödl P, Rujescu D, Reuss S, Hiemke C~P-4-4 Induction of c-fos gene expression by the sigma receptor ligand and potential neuroleptic drug EMD 57445 in rat brain~European Neuropsychopharmacology~1995~5(3)~327-8#Bartoszyk G, Bender H, Heusener A, Schnorr C~P-4-14 Pharmacology of the potential antipsychotic EMD 57445 in animals and humans~European Neuropsychopharmacology~1995~5(3)~331;Dahmen N, Fischer V, Hödl P & al : Induction of c-fos gene expression by the sigma receptor ligand and potential neuroleptic drug EMD 57445 in rat brain. Eur Neuropsychopharmacology 5/3 : 527-528 (abstr. P-4-4), 1995 - Bartoskyk GD, Bender HM, Heusener A & al : Pharmacology of the potential antipsychotic EMD 57445 in animals and humans. Eur Neuropsychopharmacology 5/3 : 331, 1995.;;;;;;;panamesine (EMD 57.445 );;;
122;A.III.14 ;Haloperidol;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4'-fluoro butyrophenone;. ;Haloperidol; has been marketed or used in ;Netherlands, Germany, Switzerland, France, Sweden, United States of America, Italy, AustriaIceland, Greece, Republic of South Africa, United Kingdom, Finland, Denmark, Portugal, Spain; under the trade or premarketing names of ;Haldol, Alased, Aloperidin, Bioperidolo, Buteridol, Cereen, Dozic, Duraperidol, Fortunan, Haloperin, Serenace, Serenase, Serenelfi, Sevium, Sigaperidol, Sylador, Zafrionil, Haloperidol;NM: Haldol Janssen, NL: tabs. 1mg, 5mg, 10mg, 20mg -caps. ½mg - drops 2mg/ml - amps. 5mg/ml NM: Haldol Janssen Cilag: tabs. ½mg, 2mg, 5mg, 20mg - amps. 5mg/ml - drops 2mg/ml and 10mg/ml NM: Haldol Janssen, BRD: tabs. 1mg, 2mg, 5mg, 10mg, 20mg - drops 2mg/ml, 10mg/ml - amps.5mg/ml NM: Haldol Janssen Cilag, CH: tabs. 1mg, 10mg - caps. ½mg - drops 2mg/ml and 10mg/ml - amps. 5mg/ml NM: Haldol Janssen Cilag, F: tabs. 1mg, 5mg, 20mg - solution buv. ½mg/ml, 2mg/ml, 20mg/ml - amps. 5mg/ml NM: Haldol Janssen, NOR: f-c tabs. ½mg, 1mg, 4mg, 10mg, 20mg - mikstur 2mg/ml and 10mg/ml - amps. 5mg/2ml NM: Haldol Janssen, UK: tabs. 5mg, 10mg - liquid 2mg/ml, 10mg/ml - amps. 5mg/ml, and amps. 10mg/2ml NM: Haldol Janssen Cilag, SWE: tabs. ½mg, 1mg, 4mg, 10mg - mixtur 2mg/ml - amps. 5mg/2ml NM: Haldol McNeil, USA: tabs. ½mg, 1mg, 2mg, 5mg, 10mg and 20mg NM: Haldol Janssen Cilag, ITA: tabs. 1mg - drops 2mg/ml, 10mg/ml - amps. 5mg/ml NM: Haldol Janssen Farm, PORT: tabs. 1mg, 2mg, 5mg, 10mg - drops 2mg/ml - amps. 2mg/ml, 5mg/ml NM: Haldol Janssen Cilag, A: tabs. 1mg, 10mg - sol. 2mg/ml - amps. 5mg/ml NM: Haldol Janssen, ICL: tabs. ½mg, 1mg, 4mg, 20mg - mixt. 2mg/ml - amps. 20mg/ml NM: Alased Elpem, GR: tabs. 2mg, 5mg, 10mg - drops 2mg/ml - amps. 5mg/ml NM: Aloperidin Janssen, GR: tabs. 1mg, 2mg, 5mg, 10mg, 20mg - amps. 5mg/ml - drops 2mg/ml and 10mg/ml NM: Bioperidolo Firma, ITA: tabs.1mg - drops 0.2 % - amps 2mg/2ml NM: Buteridol Promonta Lundbeck, BRD: tabs. 1mg, 2mg, 5mg, 10mg - drops 2mg/ml, 10mg/ml NM: Cereen Rolab, RSA: tabs. 1½mg, 5mg NM: Dozic Rosemont Pharma, UK: liquid 1mg/ml and 2mg/ml NM: Duraperidol Durachemie, BRD: solution 2mg/ml NM: Fortunan Steinhard, UK: tabs. ½mg, 1½mg, 5mg, 10mg, 20mg NM: Haloperin Orion, FIN: tabs. ½mg, 1mg, 4mg, 10mg - drops 2mg/ml -amps. 5mg/ml NM: Serenace Baker Norton Pharm, UK - Searle, RSA: tabs. 1½mg, 5mg, 10mg, 20mg - caps. ½mg - liquid 2mg/ml - amps. 5mg/ml and 20mg/2ml NM: Serenase Janssen, DK: tabs. ½mg, 2mg, 5mg, 20mg - amps. 5mg/ml - drops 2mg/ml NM: Serenase Orion, FIN: tabs. 1mg, 4mg, 10mg, 20mg - caps. ½mg - amps. 5mg/ml - mikstuura 2mg/ml NM: Serenase Lusofarmaco, ITA: tabs.1mg, 5mg, 10mg - drops 2mg/ml, 10mg/ml - amps. 2mg/2ml, 5mg/ml NM: Serenelfi Lusofarmaco, PORT: tabs. 1mg, 5mg - sol. 2mg/ml - amps.2mg/ml, 5mg/ml NM: Sevium Ni-The, GR: tabs. 2mg, 5mg, 10mg, 20mg - solution 4mg/ml NM: Sigaperidol Kytta Siegfried, BRD: tabs. 1mg, 5mg, 10mg, 20mg - drops 2mg/ml, forte drops 10mg/ml - amps. 5mg/ml NM: Sigaperidol Siegfried Pharma, CH: tabs. 1mg - drops 2mg/ml - amps. 5mg/ml NM: Sylador Dumex, DK: tabs. ½mg, 2mg, 5mg - amps. 5mg/ml NM: Zafrionil Pefanic, GR: tabs. 2mg, 5mg, 10mg, 20mg NM: Haloperidol Esteve, ESP: tabs.10mg - sol.2mg/ml - amps.5mg/ml NM: Haloperidol Roche, ESP: tabs.10mg - sol.2mg/ml;. ;Strong D /very weak D antagonist. Potent neuroleptic for the treatment of schizophrenic disorders, 2 1 severe psychotic conditions, manic states, behavioral anomalies, Huntington's chorea and Tourette's disorder. Dosage 5 to 15 mg/day, under clinical supervision up to 100 mg daily/ administration of higher doses reported. Plasma half-life after oral dosage about 17 ½ hours/ after i.v. injection approx. 15 hours. Release half-life of the decanoate ester about 3 weeks, with a steady state after 3 months. In chorea Huntington response correlating with plasma levels reported.;Aravagiri M, Marder SR, Van Putten T, Marshall BD~Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol~Journal of chromatography B, Biomedical applications~1994~656(2)~373-81# Ulrich S, Meyer FP, Neuhof S, Knorr W~Megabore capillary gas-liquid chromatographic method with nitrogen-phosphorus selective detection for the assay of haloperidol and reduced haloperidol in serum: results of therapeutic drug-monitoring during acute therapy of eight schizophrenics~Journal of chromatography B, Biomedical applications~1995~663(2)~289-96# Iwahashi K, Miyatake R, Suwaki H, Hosokawa K, Ichikawa Y~The drug-drug interaction effects of haloperidol on plasma carbamazepine levels~Clinical neuropharmacology~1995~18(3)~233-6;Aravagiri M, Marder SR, Van Putten T, Marshall BD: Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol. J Chromatogr B Biomed Appl 656/2: 373-381, 1994 - Ulrich S, Meyer FP, Neuhof S, Knorr W: Megabore capillary gas-liquid chromatographic method with nitrogen-phosphorus selective detection for the assay of haloperidol and reduced haloperidol in serum: Results of therapeutic drug-monitoring during acute therapy of eight schizophrenics. J Chromatogr B Biomed Appl 663/2: 289-296, 1995 - Iwahashi K, Miyatake R, Suwaki H & al: The drug-drug effects of haloperidol on plasma carbamazepine levels. Clin Neuropharmacol 18/3: 233-236, 1995.;Vesalium (0.3mg haloperidol + 2mg isopropamide iodide), Vésadol (0.3mg haloperidol + 3mg buzepide methyliodide);HALOPERIDOL DECANOATE IN SESAME OIL 70.52MG/ML AND 141.04MG/ML, EQUIVALENT TO 50 MG HALOPERIDOL PER ML (5 %) AND 100 MG HALOPERIDOL PER ML (10 %) RESPECTIVELY: Haldol decanoas ( amps. 50mg/ml), Haldol decanoas (amps.50mg/ml, 150mg/3ml, 100mg/ml), Haldol Decanoat (amps. 50mg/ml, 150mg/3ml), Haldol Decanoate (amps. 50mg/ml, 100mg/ml), Haldol Depot (amps. 50mg/ml, 100mg/ml), Haldol Decanoas (amps. 50mg/ml, 150mg/3ml), Haldol Decanoato (amps. 50mg/ml, 100mg/ml), Serenase Decanoat (amps. 50mg/ml, 100mg/ml), Serenase Depot (amps.50mg/ml, 150mg/3ml, 100mg/ml, 300mg/3ml), Aloperidin Decanoate (amps. 50mg/ml, 150mg/3ml), Haloperin depotinjektio (amps. 50mg/ml, 100mg/2ml, 150mg/3ml, 100mg/ml, 200mg/2ml, 150mg/ml, 300mg/3ml (range deleted));;COMB: COMBINATIONS: NM: Vesalium Janssen Cilag, A, B, CH: tabs. 0.3mg haloperidol + 2mg isopropamide iodide NM: Vésadol Janssen Cilag, F: tabs. 0.3mg haloperidol + 3mg buzepide methyliodide;DEP: DEPOT INJECTIONS HALOPERIDOL DECANOATE IN SESAME OIL 70.52MG/ML AND 141.04MG/ML, EQUIVALENT TO 50 MG HALOPERIDOL PER ML (5 %) AND 100 MG HALOPERIDOL PER ML (10 %) RESPECTIVELY: NM: Haldol decanoas Janssen Cilag, F: amps. 50mg/ml NM: Haldol decanoas Janssen Cilag B, NL, CH: amps.50mg/ml, 150mg/3ml (not in CH), 100mg/ml NM: Haldol Decanoat Janssen, BRD, A: amps. 50mg/ml, 150mg/3ml NM: Haldol Decanoate Janssen, UK: amps. 50mg/ml, 100mg/ml NM: Haldol Depot NOR, SWE, ICL: amps. 50mg/ml, 100mg/ml NM: Haldol Decanoas Janssen Cilag, ITA: amps. 50mg/ml, 150mg/3ml NM: Haldol Decanoato Janssen Farm, PORT: amps. 50mg/ml, 100mg/ml NM: Serenase Decanoat Janssen, DK: amps. 50mg/ml, 100mg/ml NM: Serenase Depot Orion Farmos, FIN: amps.50mg/ml, 150mg/3ml, 100mg/ml, 300mg/3ml NM: Aloperidin Decanoate Janssen, GR: amps. 50mg/ml, 150mg/3ml NM: Haloperin depotinjektio Orion, FIN: amps. 50mg/ml, 100mg/2ml, 150mg/3ml, 100mg/ml, 200mg/2ml, 150mg/ml, 300mg/3ml (range deleted);;haloperidol (R 1625, haloperidol decanoate, R 13.672);;;
123;A.III.14 ;Bromperidol;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4-[4-(p-bromophenyl)-4-hydroxypiperidino]-4'-fluorobutyro phenone;. ;Bromperidol; has been marketed or used in ;Netherlands, Belgium, Germany, Italy; under the trade or premarketing names of ;Impromen, Impromen Impromen, Tesoprel, Bromidol;NM: Impromen Janssen, NL: tabs. 1mg, 5mg, 10mg - amps. 5mg/ml - drops 2mg/ml (1mg 10 drops) NM: Impromen Janssen Cilag, B: tabs. 5mg, 10mg - amps. 5mg/ml (deleted) drops 2mg/ml and 10mg/ml (1mg 2 drops) NM: Impromen BRD: tabs. 5mg - drops 2mg/ml NM: Impromen Formenti, ITA: tabs. 5mg - drops 1% - amps.5mg/ml NM: Tesoprel Thiemann, BRD: tabs. 5mg - drops 2mg/ml NM: Bromidol Janssen, DK: tabs.5mg;. ;Strong D /very weak D antagonist. Incisive activity. No active metabolites. May be given once 2 1 daily/ plasma half-life after oral dose about 36 hours. Name Impromen stands for 'improves men'. Used in the treatment of schizophrenic psychoses. Slow release of the decanoate ester from the oily depot with an elimination half-life of about 28 days.;Rossi P, Chini C, Casale A, Fusi A, Madonna M, Monaci C, et al.~Action of bromperidol decanoate in the treatment of negative symptoms of schizophrenia - comparison with haloperidol decanoate [Azione del bromperidolo decanoato nel trattamento dei sintomi negativi della schizofrenia - confronto con l'aloperidolo decanoato]~Rivista di Psichiatria~1992~27(265-70)~#Yamagami S, Hirayama E, Mui K, Okuno M, Kioka T, Soma T, et al.~A single-blind comparison of bromperidol and sulpiride in hospitalized schizophrenics~Acta psychiatrica Belgica~1993~93(4)~236-44;Rossi P, Chini C, Casale A, & al: Azione del bromperidolo decanoata nel trattamento dei sintomi negativi della schizofrenia - Confronto con l'aloperidolo decanoato. Riv Psichiatr 27/6: 265-270, 1992 - Yamagami S, Hirayama E, Mui K & al: A single blind comparison of bromperidol and sulpiride in hospitalized schizophrenics. Acta Psychiatr Belg 93: 236-244, 1993.;;BROMPERIDOL DECANOATE IN SESAME OIL: Impromen decanoas (amps. 50mg/ml (68.4 mg bromperidol decanoate)), Impromen decanoas (amps. 50mg/ml, 150mg/3ml), Bromidol Depot (deleted);;;DEP: DEPOT INJECTIONS OF BROMPERIDOL DECANOATE IN SESAME OIL: NM: Impromen decanoas Janssen, NL: amps. 50mg/ml ( 68.4 mg bromperidol decanoate) NM: Impromen decanoas Janssen Cilag, B: amps. 50mg/ml and 150mg/3ml NM: Bromidol Depot Janssen, DK: amps. 50mg/ml (deleted);;bromperidol (R 11.333, azuren);;;
124;A.III.14 ;Melperone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4'-fluoro-4-(p-methylpiperidino) butyrophenone;. ;Melperone; has been marketed or used in ;Netherlands, Belgium, Sweden, Finland, Iceland, Austria; under the trade or premarketing names of ;Buronil, Eunerpan, Gemeril, Melpax, Neuril;NM: Buronil Knoll, NL: s-c tabs. 25mg (Eunerpan) (deleted) NM: Buronil Lundbeck, B: s-c tabs. 25mg - amps. 50mg/2ml - oral solution 5% NM: Buronil Lundbeck, SWE, FIN: tabs. 10mg, 25mg, 50mg, 100mg - amps. 50mg/2ml - mixtur 5mg/ml NM: Buronil Lundbeck, NOR: tabs. 5mg, 25mg, 100mg - mikstur 5mg/ml - amps. 50mg/2ml NM: Buronil Novo Nordisk, DK, ICL: tabs. 5mg, 25mg - mikstur 5mg/ml (not in ICL) - amps. 50mg/2ml NM: Buronil Lundbeck, A: s-c tabs. 25mg, 50mg, 100mg - syrup 25mg/5ml - amps. 50mg/2ml NM: Eunerpan Knoll, BRD: s-c tabs. 25mg, 100mg - amps. 50mg/2ml - oral solution 25mg/5mg NM: Gemeril Medipolar, FIN: s-c tabs. 25mg, 50mg - mixtur 5mg/ml - amps. 50mg/2ml NM: Melpax Orion, FIN: same presentations as Buronil FIN NM: Neuril Schoeller Pharma, A: s-c tabs. 25mg, 100mg - amps.50mg - syrup 25mg/5ml;. ;Stronger 5-HT antagonist than D antagonist. Much stronger D blocking effect than the other 2 2 4 neuroleptics, except clozapine. Used in the treatment of psychotic disorders at a dosage of 50 to 200 mg daily, in agitational states up to 400 mg/day. At low doses in the management of anxiety and confusional states. Weak or no extrapyramidal symptoms. Plasma half-life after single oral dose 3 hours/ in steady state about 8 hours.;Christensen I, Geismar L, Kirkegaard A, Kirkegaard G~Additional studies on side effects of melperone in long-term therapy for 1-20 years in psychiatric patients~Arzneimittel-Forschung~1986~36(5)~855-60;Christensen I, Geismar L, Kirkegaard Aa, et al: Additional studies on side effects of melperone in long-term therapy for 1 - 20 years in psychiatric patients. Arzneim Forsch 36: 855-860, 1986 - Ikeguchi S, Hashimoto S, Horie M, et al: Electrophysiological effects of melperone on isolated rabbit heart muscles. Br J Pharmacology 94: 1063-1068, 1988.;;;;;;;melperone (methylperone, flubuperone);;;
125;A.III.14 ;Droperidol;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;1-[1-[3-(p-fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2- benzimidazolinone;. ;Droperidol; has been marketed or used in ;Belgium, Netherlands, Switzerland, Austria, Finland, Denmark, Germany, GreeceNorway, Sweden, France, United Kingdom, United States of America, Italy; under the trade or premarketing names of ;Dehydrobenzperidol, Dridol, Droleptan, Inapsine, Sintodian, Thalamonal, Leptanal comp., Leptofen;NM: Dehydrobenzperidol Janssen Cilag, B - Janssen, NL: tabs. 5mg - amps. 5mg/2ml and 25mg/10ml Janssen Cilag CH, A - Janssen, BRD, DK - Medipolar, FIN: amps. 5mg/2ml, 25mg/10ml (not in DK, BRD, FIN) - GR: vials 25mg/10ml NM: Dridol Janssen Cilag, NOR, SWE: amps. 2½mg/ml (not in SWE), 10mg/2ml NM: Droleptan Janssen Cilag, F: amps.50mg/10ml - sol. buv. 2% UK: amps. 10mg/2ml - tabs. 10mg - liq. 1mg/ml NM: Inapsine Critikon, USA: amps. 2½mg/ml, vials 25mg/10ml NM: Sintodian Pharmacia, ITA: vials 25mg/10ml NM: Thalamonal Janssen, B, BRD, FIN (deleted), GR, NL: amps. 2½mg droperidol + 0.05mg benperidol per ml NM: Leptanal comp. Janssen, NOR, SWE: see Thalamonal NM: Leptofen Pharmacia, ITA: vials 25mg + 0.5mg fentanyl/10ml;. ;DA antagonist and adrenolytic. For neuroleptanalgesia and premedication. Reduces nausea 1 and vomiting after surgical procedures. Parenterally and orally also used as neuroleptic for the treatment of severe motor agitation. Terminal plasma half-life about 2¼ hours/ mean elimination half-life after i.v. administration in patients 12 7 minutes.;Lischke V, Behne M, Doelken P, Schledt U, Probst S, Vettermann J~Droperidol causes a dose-dependent prolongation of the QT interval~Anesthesia and analgesia~1994~79(5)~983-6# Kymer PJ, Brown RE, Jr., Lawhorn CD, Jones E, Pearce L~The effects of oral droperidol versus oral metoclopramide versus both oral droperidol and metoclopramide on postoperative vomiting when used as a premedicant for strabismus surgery~Journal of clinical anesthesia~1995~7(1)~35-9# Grond S, Lynch J, Diefenbach C, Altrock K, Lehmann KA~Comparison of ondansetron and droperidol in the prevention of nausea and vomiting after inpatient minor gynecologic surgery~Anesthesia and analgesia~1995~81(3)~603-7;Lischke V, Behne M, Doelken P & al: Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 79/5: 983-986, 1994 - Kymer PJ, Brown RE Jr, Lawhorn CD & al: The effects of droperidol versus metoclopramide versus both oral droperidol and metoclopramide on postoperative vomiting when used as a premedicant for strabismus surgery. J Clin Anest 7/1: 35-39, 1995 - Grond S, Lynch J, Diefenbach C & al: Comparison of ondansetron and droperidol in the prevention of nausea and vomiting after inpatient minor gynaecologic surgery. Anesth Analg 81: 603-607, 1995.;;;;;;;droperidol (R 4749);;;
126;A.III.14 ;Pipamperone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;1-[4-(p-fluorophenyl)-4-oxobutyl]piperidino-piperidine-4- carboxamide (dihydrochloride);. ;Pipamperone; has been marketed or used in ;Switzerland, Greece, Belgium, Netherlands, France, Italy; under the trade or premarketing names of ;Dipiperon, Dipipéron, Piperonil;NM: Dipiperon Janssen Cilag, CH - Janssen, GR: tabs. 40mg Janssen Cilag, B, NL: tabs. 40mg - drops 40mg/ml (4%) NM: Dipiperon Janssen, BRD: tabs. 40mg - Saft 20mg/5ml Janssen, DK: tabs. 40mg NM: Dipipéron Janssen Cilag, F: tabs.40mg- sol.buvable 4% NM: Piperonil Lusofarmaco, ITA: tabs. 80mg;. ;DA/5-HT /NE antagonist. Minor neuroleptic activity. Used in the treatment of behavioral 2 disorders, confusional states, agitation in the elderly and restlessness in mental retardation.;Seno H, Kumazawa T, Ishii A, Sato K, Suzuki O~Determination of some butyrophenones in body fluids by gas chromatography with surface ionization detection~Nihon hoigaku zasshi = The Japanese journal of legal medicine~1993~47(5)~367-71;Seno H, Kamazawa T, Ishii A & al: Determination of some butyrophenones in body fluids by gas chromatography with surface ionization detection. Nippon Hoigaku Zasschi 47(5): 367-371, 1993.;;;;;;;pipamperone (floropipamide, R 3345);;;
127;A.III.14 ;Fluanisone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4'-fluoro-4-[4-(o-methoxyphenyl)-1-piperazinyl] butyrophenone;. ;Fluanisone; has been marketed or used in ;Belgium, Switzerland, Germany, France; under the trade or premarketing names of ;Sedalande, Sédalande;NM: Sedalande Synthélabo, B - Synthelabo/Delalande, CH, BRD: drops (20 drops 5mg) - amps.20mg/ml (range deleted) NM: Sédalande Delalande, F: solution buv. (20 gtt 5mg) - sol. injectable: amps.20mg/4ml (range deleted);. ;Sedative in the management of anxiety. Dosage in the treatment of psychoses 20 to 80 mg/day. Atypical neuroleptic.;Robert G~[Comparative trials on sultopride and fluanisone]~L'Encephale~1978~4(2)~145-61#Azibi M, Draguet-Brughmans M, Bouché R~Polymorphisme des butyrophénones: azapérone et fluanisone~Pharm Acta Helvet~1981~56(190-3)~;Robert G: Essai comparatif du sultopride et de la fluanisone. L'Encéphale 4: 145-161, 1978-Azibi M, Draguet-Brughmans M, Bouché R: Polymorphisme des butyrophénones: azapérone et fluanisone. Pharm Acta Helvet 56: 190-193, 1981.;;;;;;;fluanisone (haloanisone);;;
128;A.III.14 ;Butropipazone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4'-fluoro-4-(4-phenyl-1-piperazinyl)butyrophenone;. ;Butropipazone; has been marketed or used in ;Belgium; under the trade or premarketing names of ;R 1892;NM: R 1892 (Janssen, B);. ;Potential neuroleptic agent/ structurally related to fluanisone/ behavioral differences between both drugs reported. By recrystallization from various solvents, two different forms isolated/ one of these polymorphs proved to be stable.;Azibi M, Draguetbrughmans M, Bouche R~[Polymorphism of Butyrophenones-Butropipazone]~Pharmaceutica Acta Helvetiae~1981~56(11)~325-7;Azibi M, Draguet-Brughmans M, Bouché R, et al: Polymorphisme des butyrophénones: la butropipazone. Pharm Acta Helvet 56: 325-327, 1981.;;;;;;;butropipazone;;;
129;A.III.14 ;Benperidol;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;1-[1-[3-(p-fluorobenzoyl)propyl]-4-piperidyl]-2-benzimidazolinone;. ;Benperidol; has been marketed or used in ;Belgium, Netherlands, France, United Kingdom, Italy; under the trade or premarketing names of ;Frenactil, Frénactil, Anquil, Glianimon, Psichoben;NM: Frenactil Janssen Cilag, B, NL: drops 1mg/ml NM: Frénactil Clin Midy/Sanofi Winthrop, F: gouttes 2mg/ml (deleted) NM: Anquil Janssen, UK: tabs. ¼mg NM: Glianimon Bayer, BRD: tabs. 2mg, 5mg, 10mg - Tropfen 2mg/ml - amps. 2mg/2ml - Tropon, GR: tabs. ½mg, 1½mg, 5mg - drops 2mg/ml - amps. 2mg/2ml NM: Psichoben Ravizza, ITA: tabs. 2mg - sol. 0.1% (range deleted);. ;Used in the treatment of psychotic disorders, psychomotor agitation, alcohol withdrawal syndrome and for the control of deviant sexual behavior. Dosage ½ mg to 3 mg/day.;Moerlein SM, Perlmutter JS~Specific binding of 3N-(2'-[18F]fluoroethyl)benperidol to primate cerebral dopaminergic D2 receptors demonstrated in vivo by PET~Neuroscience letters~1992~148(1-2)~97-100#Seiler W, Wetzel H, Hillert A, Schollnhammer G, Langer M, Barlage U, et al.~Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application~Psychopharmacology~1994~116(4)~457-63;Moerlein SM, Perlmutter JS: Specific binding of 3N-(2'-(18F)fluoroethyl)benperidol to primate cerebral dopaminergic D2 receptors demonstrated in vivo by PAET. Neurosci Letter 148/1-2: 97-100, 1992 - Seiler W, Wetzel H, Hillert A & al: Pharmacokinetics and bioavailibility of benperidol in schizophrenic patients after intravenous and two different kinds of oral application. Psychopharmacology 116/4: 457-463, 1994.;;;;;;;benperidol (R 4584, McN-JR-4584, 8089 CB);;;
130;A.III.14 ;Carperone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;1-[3-(p-fluorobenzoyl)propyl]-4-piperidyl-isopropylcarbamate;. ;Carperone; has been marketed or used in ;United States of America; under the trade or premarketing names of ;AL 1021;NM: AL 1021 Bristol, USA;. ;Has been studied in the treatment of schizophrenic psychoses. Dose range 200 to 300 mg/day. Minor extrapyramidal reactions or other side effects. Weight gain and postural hypotension reported. No recent data.;Gendron JL, Schiele BC~A pilot study on the use of AL-1021 in the treatment of acute schizophrenics~Current therapeutic research, clinical and experimental~1971~13(3)~169-73# Gendron JL, Zimmermann RL, Schiele BC~A double-blind comparison of AL-1021 and chlorpromazine in hospitalized schizophrenics~Current therapeutic research, clinical and experimental~1973~15(6)~333-6;Gendron JL, Schiele BC: A pilot study on the use of AL-1021 in the treatment of acute schizophrenics. Curr Ther Res 13: 169-173, 1971 - Gendron JL, Zimmermann RL, Schiele BC: A double-blind comparison of AL-1021 and chlorpromazine in hospitalized schizophrenics. Curr Ther Res 15: 333-336, 1973.;;;;;;;carperone;;;
131;A.III.14 ;Moperone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4'-fluoro-4-[4-hydroxy-4-(p-tolyl)piperidino] butyrophenone;. ;Moperone; has been marketed or used in ;Switzerland, Finland, Sweden; under the trade or premarketing names of ;Luvatren;NM: Luvatren Cilag, CH: tabs. 5mg - retard tabs. 20mg (deleted) - drops 5mg/ml (deleted) - FIN, SWE: tabs. 5mg and 20mg;. ;Used in the treatment of anxiety and psychotic disorders at doses of 15 - 60 mg/day/ according to old data up to 300 mg.;Weiser G~[Experience with the butyrophenone preparation Luvatren in the therapy of schizophrenia]~Wiener medizinische Wochenschrift (1946)~1968~118(19)~444-6# Tinant B, Germain G, Declercq J-P, Van Meerssche M, Azibi M, Draguet?Brughmans M, et al.~Détermination de la Structure de la Mopérone: Fluoro?4'(Hydroxy?4 p?Tolyl?4 Pipéridino)?4 Butyrophénone~Bulletin des Sociétés Chimiques Belges~1982~91(4)~283-7;Weiser G: Erfahrungen mit dem Butyrophenonpräparat Luvatren in der Behandlung der Schizophrenie. Wien Med Wochenschr 118: 444-446, 1968 - Tinant B: Détermination de la structure de la mopérone: fluoro-4'-(hydroxy- 4-p-tolyl-4-piperidino)-4-butyrophénone. Bull Soc Chim Belg 91: 283-287, 1982.;;;;;;;moperone (methylperidol, R 1658);;;
132;A.III.14 ;Cinuperone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4'-fluoro-4-[4-(3-isoquinolyl)-1-piperazinyl] butyrophenone;. ;Cinuperone; has been marketed or used in ;Germany, France; under the trade or premarketing names of ;HR 375;NM: HR 375 Hoechst, BRD - Roussel-Uclaf, F;. ;Antipsychotic effects according to preliminary studies. In comparison to phenothiazine- and butyrophenone-type neuroleptics different action profile. Minor dopamine receptor blocking activity, lacking cataleptic phenomena. Considered to be an atypical neuroleptic with antipsychotic as well as antidepressive and muscle-relaxant properties. High affinity for sigma receptors reported. High levels of orthostatic dysregulations observed.;Su TP~Potential antipsychotic agent HR 375 is a potent ligand of the psychotomimetic sigma receptors in the brain~Pharmacologist~1986~28(89)~# Largent BL, Wikstrom H, Snowman AM, Snyder SH~Novel antipsychotic drugs share high affinity for sigma receptors~European journal of pharmacology~1988~155(3)~345-7# Taylor D, Schlemmer R~Sigma “antagonists”—potential antipsychotics~Novel antipsychotic drugs Raven, New York~1992~189-201~;"Su TP: Potential antipsychotic agent HR 375 is a potent ligand of the psychotomimetic sigma receptors in the brain. Pharmacologist 28: 89, 1986 - Largent BL, Wikström H, Snowman AM, et al: Novel antipsychotic drugs share high affinity for sigma receptors. Eur J Pharmacology 155: 345-347, 1988 - Taylor DP, Schlemmer Jr RF: Sigma ""antagonists""-potential antipsychotics? Novel Antipsychotic Drugs: 189-201, 1992. Raven Press Ltd NY.";;;;;;;cinuperone;;;
133;A.III.14 ;Spiperone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;8-[3-(p-fluorobenzoyl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;. ;Spiperone; has been marketed or used in ;Belgium; under the trade or premarketing names of ;Spiroperidol, Spiropitan;NM: spiroperidol Janssen, B NM: spiropitan;. ;Selective dopamine D antagonist. One of the most potent neuroleptics: 2 threshold according to Haase 0.4 mg by oral administration. Considered to be a ligand of choice for DA receptor studies. Comparative studies for high H-spiperone binding to lymphocytes in schizophrenia. 3;Wodarz N, Fritze J, Riederer P, Beckmann H~3H-spiroperidol binding to peripheral mononuclear cells in schizophrenic and healthy subjects~Biological psychiatry~1993~33(10)~727-33 # Soyka M, Bondy B, Peuker B, Ackenheil M~Spiperone binding capacity in lymphocytes of patients with alcohol- and drug-induced psychosis: preliminary results~Journal of studies on alcohol~1994~55(4)~503-7 #Escandon NA, Zimmermann DC, McCall RB~Characterization of the serotonin1A receptor antagonist activity of WAY-100135 and spiperone~The Journal of pharmacology and experimental therapeutics~1994~268(1)~441-7;Wodarz N, Fritze J, Riederer P, Beckmann H: 3-H-spiroperidol binding to peripheral mononuclear cells in schizophrenic and healthy subjects. Biol Psychiatr 33/10: 727-733, 1993 - Soyka M, Bondy B, Peuker B, Ackenheil M: Spiperone binding capacity in lymphocytes of patients with alcohol- and drug-induced psychosis: Preliminary results. J Stud Alcohol 55/4: 503-507, 1994 - Escandon NA, Zimmermann DC, McCall RB: Characterization of the serotonin 1A receptor antagonistic activity of WAY-100135 and spiperone. J Pharmacol Exp Ther 268/1: 441-447, 1994.;;;;;;;spiperone (R 5147);;;
134;A.III.14 ;Bromospiperone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;1-(p-bromophenyl)-8-[3-(p-fluorobenzoyl)propyl]-1,3,8-triazaspiro [4.5]decan-4-one;. ;Bromospiperone; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Potential antipsychotic agent. Tested for dopamine receptor binding activity and degree of prolactin stimulation. Studied for regional distribution and kinetics after i.v. administration in schizophrenics and healthy control subjects, monitored by PET.;Maziere B, Loc'h C, Baron JC, Sgouropoulos P, Duquesnoy N, D'Antona R, et al.~In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and [76Br]bromospiperone~European journal of pharmacology~1985~114(3)~267-72# Martinot JL, Peron-Magnan P, Huret JD, Mazoyer B, Baron JC, Boulenger JP, et al.~Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients~The American journal of psychiatry~1990~147(1)~44-50;Mazière B, Loch C, Baron JC, et al: In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and [ Br]bromospiperone. Eur J Pharmacol 114: 267-272, 1985 - Martinot 76 JL, Peron-Magnan P, Huret JD, et al: Striatal D2 dopaminergic receptors assessed with positron emission tomography and [ Br]bromospirone in untreated schizophrenic patients. Am J Psychiatry 147: 44-50, 1990. 76;;;;;;;bromospiperone;;;
135;A.III.14 ;Fluspiperone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;8-[3-(p-fluorobenzoyl)propyl]-1-(p-fluorophenyl)-1,3,8-triazaspiro[4.5] decan-4-one;. ;Fluspiperone; has been marketed or used in ;Belgium; under the trade or premarketing names of ;R 28.930 fluorospiroperidol;NM: R 28.930 Janssen, B NM: fluorospiroperidol;. ;Fluorinated derivative of spiperone. Preliminary pharmacological investigations. Putative neuroleptic compound. No clinical references available.; ; ;;;;;;;fluspiperone;;;
136;A.III.14 ;Trifluperidol;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4-[4-(m-(trifluoromethyl)phenyl]-4-hydroxy-piperidino)-4'-fluoro butyrophenone;. ;Trifluperidol; has been marketed or used in ;Belgium, France, Germany, United Kingdom; under the trade or premarketing names of ;Triperidol, Psicoperidol;NM: Triperidol Janssen Cilag, B, F - Janssen, BRD: drops 1mg/ml NM: Triperidol Lagap, UK: tabs. ½mg, 1mg NM: Psicoperidol Lusofarmaco, ITA: s-c tabs. 1mg - sol. 0.2% - amps.;. ;2mg/ml (range deleted) Potent neuroleptic agent in the treatment of psychoses. Oral dosage ½ to 3 mg daily. No sedative effects.;Mikolajek A~Polarographische Bestimmung von Butyrophenon-Derivaten in Blut~Zeitschr Anal Chemie~1974~272(39-42)~;Mikolajek A: Polarographische Bestimmung von Butyrophenon-Derivaten in Blut. Zeitschr Anal Chemie 272: 39-42, 1974.;;;;;;;trifluperidol (R 2498);;;
137;A.III.14 ;ID 4708 ;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;2'-amino-4'-fluoro-4-[4-(m-trifluoromethyl)phenyl]-4-hydroxypiperidino) butyrophenone;. ;ID 4708 ; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Amino-substituted derivative of trifluperidol. According to pharmacological studies potential neuroleptic compound.;Honma T, Sasajima K, Ono K, Kitagawa S, Inaba S, Yamamoto H~Synthesis and preliminary pharmacology of a novel butyrophenone derivative, ID-4708~Arzneimittel-Forschung~1974~24(9)~1248-56# Honma T, Fukushima H~Correlation between catalepsy and dopamine decrease in the rat striatum induced by neuroleptics~Neuropharmacology~1976~15(10)~601-7;Honma T, Sasajima T, Kitagawa S: Synthesis and preliminary pharmacology of a novel butyrophenone derivative, ID-4708. Arzneim Forsch 24: 1248- 1256, 1974 - Honma T, Fukushima H: Correlation between catalepsy and DA decrease in striatum induced by neuroleptics. Neuropharmacology 15: 601-607, 1976.;;;;;;;ID 4708 ;;;
138;A.III.14 ;Clofluperol;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4-[4-[p-chloro-m-(trifluoromethyl)phenyl]-4-hydroxy-piperidino]-4'- fluorobutyrophenone;. ;Clofluperol; has been marketed or used in ;Belgium; under the trade or premarketing names of ;seperidol;NM: seperidol Janssen, B;. ;Neuroleptic threshold between 3 and 30 mg. Duration of action approx. 48 hours. Clinical studies in the treatment of psychotic disorders. No recent data.;Aimoto T, Masuda C, Murata T~[Biopharmaceutical studies on neuroleptic butyrophenones. II. Disposition of clofuperol in the rat (author's transl)]~Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan~1979~99(6)~576-82;Aimoto T, Masuda C, Murata T: Biopharmaceutical studies on neuroleptic butyrophenones. J Pharm Soc Jap 99: 576-582, 1979.;;;;;;;clofluperol (seperol, R 9298);;;
139;A.III.14 ;Fenaperone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4-[3-(p-fluorobenzoyl)propyl]piperazine-1-cyclohexylcarboxylate HCl;. ;Fenaperone; has been marketed or used in ;France; under the trade or premarketing names of ;67.332 MD;NM: 67.332 MD Synthélabo/Delalande, F;. ;Potential neuroleptic agent. Investigations on metabolism and pharmacokinetics. Elimination half-life about 2 hours.;Hawkins DR, Moore DH, Chasseaud LF~The metabolism of the neuroleptic agent 1 (4'-fluorophenyl)-4-(cyclohexyl-1'-piperzinyl-4'-carboxylated)-butan-1-one hydrochloride in rats and man~Xenobiotica/ the fate of foreign compounds in biological systems~1977~7(5)~315-25;Hawkins DR, Moore DR, Chasseaud LF, et al: The metabolism of the neuroleptic agent 1-(4'-fluorophenyl)-4-(cyclohexyl-1'-piperazinyl-4'- carboxylate)-butan-1-one hydrochloride in rats and man. Xenobiotica 7: 315- 325, 1977.;;;;;;;fenaperone;;;
140;A.III.14 ;Cloroperone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4'-fluoro-4-[4-(p-chlorobenzoyl)piperidino] butyrophenone;. ;Cloroperone; has been marketed or used in ;United States of America, TTA; under the trade or premarketing names of ;AHR 6134, RMI 9901;NM: AHR 6134 A.H. Robins, USA NM: RMI 9901 Richardson-Merrell, TTA;. ;Neuroleptic agent with anxiolytic properties. Tentative dosage 1 up to 10 mg/day. Preliminary studies. No recent data.;Fusaro GA, Garteiz DA, Chan KY, Leeson GA~Identification of basic metabolites of 4-[4-(p-chlo- robenzoyl)piperidino]-4'-fluorobutyrophenone, an experimental neuroleptic agent~Drug metabolism and disposition: the biological fate of chemicals~1976~4(6)~562-7;Fusaro GA, Garteiz DA, Chan KY, et al: Identification of basic metabolites of 4-(4-(p-chlorobenzoyl)piperidino)-4'-flurobutyrophenone, an experimental neuroleptic agent. Drug Metab Dispos 4: 562-567, 1976.;;;;;;;cloroperone;;;
141;A.III.14 ;Timiperone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4'-fluoro-4-[4-(2-thioxo-1-benzimidazolinyl)piperidino]butyro phenone;. ;Timiperone; has been marketed or used in ;Japan; under the trade or premarketing names of ;Tolopelon;NM: Tolopelon Daiichi, JPN;. ;Potent neuroleptic agent. Clinical studies in the treatment of schizophrenic psychoses. Oral dosage 6 up to 15 mg/day.;Nakazawa T, Ohara K, Sawa Y, Edakubo T, Matsui H, Sawa J, et al.~Comparison of efficacy of timiperone, a new butyrophenone derivative, and clocapramine in schizophrenia: a multiclinic double-blind study~The Journal of international medical research~1983~11(5)~247-58;Nakazawa T, Ohara K, Sawa Y, et al: Comparison of efficacy of timiperone, a new butyrophenone derivative, and clocapramine in schizophrenia: a multiclinic double-blind study. J Int Med Res 11: 247-258, 1983.;;;;;;;timiperone (DD 3480);;;
142;A.III.14 ;Lenperone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4'-fluoro-4-[4-(p-fluorobenzoyl)piperidino]butyrophenone;. ;Lenperone; has been marketed or used in ;United States of America; under the trade or premarketing names of ;Elanone;NM: Elanone A.H. Robins, USA;. ;Optimal antipsychotic activity at a dosage of 80 to 120 mg daily. At lower doses in the treatment of anxiety states. Studied for the management of porcine stress syndrome.;Osman MA, Pinchbeck FM, Cheng LK, Wright GJ~Determination of lenperone in dog plasma by high-performance liquid chromatography~Journal of chromatography~1985~345(2)~430-5;Osman MA, Pinchbeck FM, Cheng LK, et al: Determination of lenperone in dog plasma by high-performance liquid chromatography. J Chromatogr Biomed Appl 345: 430-435, 1985.;;;;;;;lenperone (AHR 2277);;;
143;A.III.14 ;Azaperone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4'-fluoro-4-[4-(2-pyridyl)-1-piperazinyl] butyrophenone;. ;Azaperone; has been marketed or used in ;Belgium, United Kingdom; under the trade or premarketing names of ;StresnilSuicalm;NM: Stresnil Janssen, B: vials (for veterinary use) NM: Suicalm Crown-Chem, UK;. ;Quick-acting neuroleptic with sedative and distinct antiaggressive effects. Especially used for veterinary practice: reduces agitation and sensitivity to stress in animals.;Haagsma N, Bathelt ER, Engelsma JW~Thin-layer chromatographic screening method for the tranquillizers azaperone, propiopromazine and carazolol in pig tissues~Journal of chromatography~1988~436(1)~73-9;Haagsma N, Barthelt ER, Engelsma JW: Thin layer chromatographic screening method for the tranquilizers azaperone, propiopromazine and carazolol in pig tissues. J Chromatogr 436: 73-79, 1988.;;;;;;;azaperone (R 1929);;;
144;A.III.14 ;AL 449;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4'-fluoro-4-(p-hydroxypiperidino)butyrophenone;. ;AL 449; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Slight improvement reported in the treatment of chronic psychoses at doses of 500 up to 1000 mg daily. No recent data.;Gallant DM, Bishop MP, Guerrero-Figueroa R~AL-499: a preliminary evaluation of a new butyrophenone derivative in chronic schizophrenic patients~Current therapeutic research, clinical and experimental~1968~10(5)~244-6# ;Gallant DM, Bishop MP, Guerrero-Figueroa R: AL-449, a preliminary evaluation of a new butyrophenone derivative in chronic schizophrenic patients. Curr Ther Res 10: 244-247, 1968 - Sugerman AA: A pilot study of AL-449 in chronic schizophrenic patients. Curr Ther Res 10: 533-536, 1968.;;;;;;;AL 449;;;
145;A.III.14 ;Nonaperone;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4-(3-azabicyclo[3.2.2]non-3-yl)-4'-fluoro- butyrophenone;. ;Nonaperone; has been marketed or used in ;; under the trade or premarketing names of ;Taomex;NM: Taomex Ciba Geigy, India;. ;According to preliminary pharmacological studies potential neuroleptic agent. Clinical trials for the management of psychotic disorders. Anxiolytic properties reported. So far insufficient information available.;;;;;;;;;nonaperone (Go 3315 A);;;
146;A.III.14 ;W 6123;is in the ;butyrophenone; category of antipsychotic.;It has a;;;;full chemical formula of ;4'-fluoro-4-(4,4-dimethylpiperidino)butyrophenone;. ;W 6123; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Outdated preliminary studies, reporting a minor neuroleptic activity. Extrapyramidal effects only at doses over 375 mg daily. Reduction of serum cholesterol reported.;Simpson GM, Kunz E, Watts TP~A new butyrophenone in the treatment of chronic schizophrenia~Psychopharmacologia~1965~8(3)~223-6# Simpson GM, Cooper TB~The effect of three butyrophenones on serum cholesterol levels~Current therapeutic research, clinical and experimental~1966~8(5)~249-55;Simpson GM, Kunz E, Watts TPS: A new butyrophenone in the treatment of chronic schizophrenia. Psychopharmacologia 8: 223-226, 1965 - Simpson GM, Cooper TB: The effect of three butyrophenones on serum cholesterol levels. Curr Ther Res 8: 249-255, 1966.;;;;;;;W 6123;;;
147;A.III.15  ;Fluspirilene;is in the ;diphenylbutylpiperidine and piperazine; category of antipsychotic.;It has a;;;;full chemical formula of ;8-[4,4-bis(p-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5] decan-4-one;. ;Fluspirilene; has been marketed or used in ;Netherlands, Belgium, Germany, Norway, Portugal, Iceland, United Kingdom; under the trade or premarketing names of ;Imap, Imap Imap, Redeptin;NM: Imap Janssen, NL: amps. 2mg/ml - amps. 1½mg per 3/4 ml - vials 12mg/6ml NM: Imap Janssen Cilag, B: amps. 2mg/ml - vials 12mg/6ml - Janssen, BRD: amps. 1½mg/3/4 ml, ½mg/3/4ml - vials 12mg/6ml NM: Imap NOR: amps. 10mg/ml - Janssen Cilag, CH Janssen, GR: vials 12mg/6ml NM: Imap Janssen Farm, PORT: amps. 2mg/ml NM: Imap Janssen, ICL: amps. 2mg/ml, 6mg/3ml, 10mg/ml NM: Redeptin SmithKline French, UK: amps. 2mg/ml and 6mg/3ml;. ;Strong D /weak D antagonist. In microcrystalline form as aqueous suspension for the parenteral 2 1 treatment of schizophrenic psychoses. Maintenance therapy: duration of action about one to two weeks/ longer intervals between injections possible. Elimination half-life about 3 weeks. May be mixed with the long-acting injectable antiparkinsonian agent dexetimide = R 16.470.;Kenny BA, Fraser S, Kilpatrick AT, Spedding M~Selective antagonism of calcium channel activators by fluspirilene~British journal of pharmacology~1990~100(2)~211-6# Wurthmann C, Klieser E, Lehmann E~[Interaction of therapeutic effects and side effects in drug therapy of generalized anxiety disorders with low dosage fluspirilene]~Fortschritte der Neurologie-Psychiatrie~1995~63(2)~72-7# Wurthmann C, Klieser E, Lehmann E, Pester U~Test therapy in the treatment of generalized anxiety disorders with low dose fluspirilene~Progress in neuro-psychopharmacology & biological psychiatry~1995~19(6)~1049-60;Kenny BA, Fraser S, Kilpatrick AT et al: Selective antagonism of calcium channel activators by fluspirilene. Br J Pharmacology 100: 211-216, 1990 - Wurthmann C, Klieser E, Lehmann E: Interaktion von therapeutischen Wirkungen und Nebenwirkungen in der Pharmakotherapie generalisierter Angstörungen mit niedriegdosiertem Fluspirilen. Fortschr Neurol Psychiat 63: 72-77, 1995 - Wurthmann C, Klieser E, Lehmann E, Pester U: Test therapy in the treatment of generalized anxiety disorders with low dose fluspirilene. Prog Neuro-Psychopharmacol & Biol Psychiat 19: 1049-1060, 1995.;;;;;;;fluspirilene (R 6218);;;
148;A.III.15  ;Pimozide;is in the ;diphenylbutylpiperidine and piperazine; category of antipsychotic.;It has a;;;;full chemical formula of ;1-[1-[4,4-bis(p-fluorophenyl)butyl]-4-piperidyl]-2- benzimidazolinone;. ;Pimozide; has been marketed or used in ;Germany, Netherlands, Austria, Republic of South Africa, France, Switzerland, NorwayFinland, Sweden, United Kingdom, Iceland, Italy, Portugal, Greece; under the trade or premarketing names of ;Orap, Antalon, Opiran, Pirium;NM: Orap Janssen, BRD, NL, A, RSA, ESP: tabs. 1mg - forte 4mg - Janssen Cilag, B, F, CH: tabs. 1mg - forte tabs. 4mg - drops/ solution buvable 2½mg/ml (not in CH) NM: Orap Janssen, DK: tabs. 1mg, 4mg and 10mg - Janssen, NOR: tabs. 2mg and 10mg NM: Orap Orion, FIN: tabs. 1mg (deleted), 4mg - Janssen, SWE: tabs. 2mg, 10mg NM: Orap Janssen, UK: tabs. 2mg, 4mg and 10mg NM: Orap Janssen, ICL: tabs. 2mg NM: Orap Janssen Cilag, ITA - Janssen Farm Port, PORT: tabs. 4mg (forte) NM: Antalon Arzneimittel Werke Dresden, BRD: tabs. 2mg NM: Opiran Cassenne, F: tabs. 5mg (deleted) NM: Pirium Janssen, GR: tabs. 4mg;. ;D receptor antagonist with very high affinity for 5-HT receptor. Used in the treatment of 2 7 schizophrenic psychoses and paranoic states, also as maintenance therapy. Effective in negative schizophrenic symptomatology. As adjunct in the management of Huntington's chorea. Minor sedative properties. May be given once daily: 2 - 8 mg, up to 20 mg/day. Plasma half-life after multiple oral administration in patients about 55 hours.;Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Jr., Shen Y, et al.~Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors~The Journal of pharmacology and experimental therapeutics~1994~268(3)~1403-10#WHO Drug Information~Pimozide and cardiac arrhythmias~~1995~9(1)~32# Brauer LH, de Wit H~Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers~Biological psychiatry~1996~39(1)~26-32;Roth BL, Craigo SC, Chiudhary MS & al: Binding of typical and atypical antipsychotic agents to 5- hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268/3: 1403-1410, 1994 - Pimozide and cardiac arrhythmias. WHO Drug Information 9/1: 32, 1995 - Brauer LH, De Wit H: Subjective response to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biol Psychiatry 39/1: 26-32, 1996.;;;;;;;pimozide (R 6238);;;
149;A.III.15  ;Clopimozide;is in the ;diphenylbutylpiperidine and piperazine; category of antipsychotic.;It has a;;;;full chemical formula of ;5-chloro-1-[1-(4,4-bis(4-fluorophenyl) butyl)-4-piperidyl]-2- benzimidazolinone;. ;Clopimozide; has been marketed or used in ;Belgium; under the trade or premarketing names of ;R 29.764;NM: R 29.764 Janssen, B;. ;Extended duration of action. Dosage 2½ mg to 9 mg/day or 10 - 25 mg once weekly. Plasma half-life about 100 hours.;De Cuyper HJ, Van Praag HM, Mulder WR~Therapeutical significance of clopimozide in the treatment of chronic psychotic patients~Acta psychiatrica Scandinavica~1979~59(5)~561-74 #Dahl SG~Pharmacokinetic aspects of new antipsychotic drugs~Neuropharmacology~1981~20(12B)~1299-302;de Cuyper HJA, van Praag HM, Mulder WREH: Therapeutical significance of clopimozide in the treatment of chronic psychotic patients. Acta Psychiatr Scand 59: 561-574, 1979 - Dahl SG: Pharmacokinetic aspects of new antipsychotic drugs. Neuropharmacol 20: 1299-1302, 1981.;;;;;;;clopimozide;;;
150;A.III.15  ;Penfluridol;is in the ;diphenylbutylpiperidine and piperazine; category of antipsychotic.;It has a;;;;full chemical formula of ;4-(p-chloro- , , -trifluoro-m-tolyl)-1-[4,4-bis(pfluorophenyl) butyl]-4-piperidinol;. ;Penfluridol; has been marketed or used in ;Belgium, Switzerland, France, Denmark, Portugal, Finland, Greece; under the trade or premarketing names of ;Semap, Sémap, Flupidol;NM: Semap, Sémap Janssen Cilag, B, CH, F - Janssen DK, A, NL - Janssen Farm Port, PORT: tabs. 20mg NM: Semap Orion, FIN: tabs. 20mg (deleted) NM: Flupidol Janssen, GR: tabs. 20mg;. ;D /weak D antagonist. Potent neuroleptic/ has been 2 1 recommended for the long-term therapy of psychoses. Also NH O N Cl N Cl O used in newly admitted cases. Duration of action after single oral dose about one week. Dosage 20 to 60 mg once weekly. Terminal plasma half-life in steady state between 70 and 230 hours.;Lavoie PA~Penfluridol, chlorprothixene and haloperidol block fast axonal transport in an order of potency consistent with a mechanism related to inhibition of calmodulin~Neuropharmacology~1987~26(9)~1359-65# Doongaji D, Sheth A, Apte J, Desai A~Penfluridol vs fluphenazine decanoate: A double-blind clinical study in chronic and subchronic schizophrenia~Current therapeutic research~1988~~;Lavoie PA: Penfluridol, chlorprothixene, and haloperidol block fast axonal transport in an order of potency consistent with a mechanism related to inhibition of calmodulin. Neuropharmacol 26: 1359-1365, 1987 - Doongaji DR, Sheth AS, Apte JS, et al: Penfluridol vs fluphenazine decanoate: a double-blind clinical study in chronic and subchronic schizophrenia. Curr Ther Res 43: 416-422, 1988.;;;;;;;penfluridol (R 16.341);;;
151;A.III.15  ;Amperozide;is in the ;diphenylbutylpiperidine and piperazine; category of antipsychotic.;It has a;;;;full chemical formula of ;N-ethyl-4-[4,4-bis(p-fluorophenyl)butyl]-1-piperazinecarboxamide;. ;Amperozide; has been marketed or used in ;Sweden, United States of America; under the trade or premarketing names of ;FG 5606, Hogpax ;NM: FG 5606 Kabi Pharmacia, SWE NM: Hogpax USA;. ;Initially developed as a veterinary tranquilizer. Lowers hypermotility. Limbic mode of action, 5-HT antagonist. 2 Anticonflict agent. No side effects associated with blockade of striatal dopamine receptors. Potent antiaggressive and anxiolytic properties without sedation or motor impairement. Effects on both negative and positive schizophrenic symptoms observed. Suggested as potential treatment of withdrawal symptoms of alcohol addiction. Attenuates craving for cocaine. Development as a neuroleptic discontinued.;McMillen BA, Jones EA, Hill LJ, Myers RD~Amperozide, a novel 5-HT receptor antagonist attenuates 2 craving for cocaine in rats~Faseb J~1993~Abstracts Part I(A254)~abstr 1468 #Edlund P~Identification of amperozide metabolites in urine from rats, rabbits, dogs and man by Frit?FAB LC/MS using deuterated solvents to gain additional structural information~Journal of Mass Spectrometry~1995~30(10)~1380-92;Mc Millen BA, Jones EA, Hill LJ, Myers RD: Amperozide, a novel 5-HT receptor antagonist attenuates 2 craving for cocaine in rats. Faseb J Abstracts Part I: A254 (abstr 1468), 1993 - Edlund PO: Identification of amperozide metabolites in urine from rats, dogs and man by frit-fab LC/MS deuterated solvents to gain additional structural information. J Mass Spectrom 30/10: 1380-1392, 1995 - Andersson G, Christensson E, Klint T: Behavioural pharmacology of amperozide, a new antipsychotic drug with a selective limbic mode of action. Behav Pharmacol 3 (suppl 1): 71, 1992;;;;;;;amperozide;;;
152;A.III.15  ;Aripiprazol;is in the ;diphenylbutylpiperidine and piperazine; category of antipsychotic.;It has a;;;;full chemical formula of ;7-[4-[4-(2,3-dichlorophenyl)piperazin-1- yl]butoxy]-3,4-dihydrocarbostyril or 7-[4-[4-(2,3-dichorophenyl)piperazin-1-yl]butoxy]-1,2,3,4-tetrahydroquinolin-2-one.;. ;Aripiprazol; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;D antagonist, selective functional postsynaptic. D antagonist/moderate presynaptic D 2 2 2 agonist.Potential antipsychotic with weaker EPS liability than conventional antipsychotics. Phase II clinical trials (95). T½ about 46 hrs.;Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Fujiwara K, Oshiro Y, et al.~7-{4-[4-(2, 3-Dichlorophenyl)-l-piperazinyl] butyloxy}-3, 4-dihydro-2 (lH)-quinolinone(OPC-14597): a unique antipsychotic drug candidate with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity~Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology~1994~10(194s)~# Sibley D, Gonzalez A, Burgess L, Max S, Atkinson B, Zhang L~Pharmacological characterization of OPC-14597, a novel antipsychotic agent, using cloned dopamine and serotonin receptors~Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology~1994~10(3S part 2)~252S;Kikuchi T, Tottori K, Uwahodo Y & al : 7-[4-7-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy] -3,4-dihydro-2 (1H)-quinolone (OPC-14597) : A unique antipsychotic drug candidate with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D receptor antagonistic activity. Neuropsycho- 2 pharmacology 10 (n° 3S, part 2) : 194S (abst P-117-164), 1994 - Sibley DR, Gonzalez AM, Burgess LH & al : Pharmacological characterization of OPC-14597, a novel antipsychotic agent, using cloned dopamine and serotonin receptors. Neuropsychopharmacology 10 (n° 3S, part 2) : 252S (abst P-174-161), 1994.;;;;;;;aripiprazol (OPC 14597 );;;
153;A.III.16 ;Milenperone;is in the ;benzimidazolidine; category of antipsychotic.;It has a;;;;full chemical formula of ;5-chloro-1-[3-[4-(p-fluorobenzoyl)-1-piperidinyl]propyl]1,3- dihydro-2H-benzimidazol-2-one;. ;Milenperone; has been marketed or used in ;Belgium; under the trade or premarketing names of ;R 34.009;NM: R 34.009 Janssen, B;. ;Potent dopamine receptor antagonist/ weak antagonist of 1 and histamine H receptors. No anticholinergic or -adrenolytic 1 activity. Psychotropic agent with antiaggressive effects. In behavioral disorders or aggression 5 - 30 mg/day.;Gelders YG, Reyntjens AJ, Aerts TJ~Milenperone. A selective drug for the control of behavioral disorders in epileptic and alcoholic patients~Acta psychiatrica Belgica~1984~84(2)~151-9 #De Cuyper H, van Praag HM, Verstraeten D~The effect of milenperone on the aggressive behavior of psychogeriatric patients. A double-blind placebo-controlled study~Neuropsychobiology~1985~13(1-2)~1-6;Gelders YG, Reyntjens AJM, Aerts TJL: Milenperone, a selective drug for the control of behavioral disorders in epileptic and alcoholic patients. Acta Psychiatr Belg 84: 151-159, 1984 - De Cuyper H, van Praag HM, Verstraeten D: The effect of milenperone on the aggressive behavior of psycho-geriatric patients. Double-blind placebo-controlled study. Neuropsychobiology 13: 1-6, 1985.;;;;;;;milenperone;;;
154;A.III.16 ;Axamozide;is in the ;benzimidazolidine; category of antipsychotic.;It has a;;;;full chemical formula of ;(±)-1-[1-(1,4-benzodioxan-2-yl-methyl)-4-piperidyl]-5-chloro-2- benzimidazolinone Preliminary pharmacological and behavioral studies. Putative neuroleptic agent with antipsychotic properties. So far no clinical evidence available.;. ;Axamozide; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;;Suppl to WHO Chronicle~~~1985~39(3)~;Suppl to WHO Chronicle 39: 3, 1985.;;;;;;;axamozide;;;
155;A.III.16 ;Halopemide;is in the ;benzimidazolidine; category of antipsychotic.;It has a;;;;full chemical formula of ;N-[2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1- piperidinyl]ethyl]-4-fluorobenzamide;. ;Halopemide; has been marketed or used in ;Belgium; under the trade or premarketing names of ;R 34.301R 38.570, R 29.676;NM: R 34.301 Janssen, B NM: R 38.570 metabolite NM: R 29.676 metabolite;. ;Structurally related to butyrophenone-type psychotropics. Dopamine-blocking activity. Clinical studies in the treatment of emotional withdrawal and autism. Desinhibitive effects and moderate antipsychotic properties. Minor parkinsonian symptoms. Akathisia has been reported. Oral dosage about 60 mg daily/ occasionally much higher doses.;De Cuyper HJ, Van Praag HM, Mulder WR~Therapeutical significance of clopimozide in the treatment of chronic psychotic patients~Acta psychiatrica Scandinavica~1979~59(5)~561-74# Loonen AJ, Soudijn W~Halopemide, a new psychotropic agent. Cerebral distribution and receptor interactions~Pharmaceutisch weekblad Scientific edition~1985~7(1)~1-9;De Cuyper H, van Praag HM, Verstraeten D: The clinical significance of halopemide, a dopamine-blocker related to the butyrophenones. Neuropsychobiology 12: 211-216, 1984 - Loonen AJM, Soudijn W: Halopemide, a new psychotropic agent. Cerebral distribution and receptor interactions. Pharm Wkbl Sci Ed 7: 1-9, 1985.;;;;;;;halopemide;;;
156;A.III.17 ;AL 1965;is in the ;imidazolidinone; category of antipsychotic.;It has a;;;;full chemical formula of ;1-[2-(1,4-dioxa-8-azaspiro[4.5] decyl)ethyl]-3-(3,5- dichlorophenyl) imidazolidin-2-one;. ;AL 1965; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Has been investigated in the treatment of schizophrenic psychoses. Therapeutically equipotent to haloperidol, but high incidence of extrapyramidal effects reported. Long duration of action anticipated (3 to 4 days). Dosage 15 mg up to 120 mg/day. No recent references.;Sathananthan G, Mir P, Gershon S~Antipsychotic effects of AL 1965~Current therapeutic research, clinical and experimental~1976~19(5)~516-9;Sathananthan G, Mir P, Gershon S, et al: Antipsychotic effects of AL 1965. Curr Ther Res 19: 516-519, 1976.;;;;;;;AL 1965;;;
157;A.III.17 ;Sertindole;is in the ;imidazolidinone; category of antipsychotic.;It has a;;;;full chemical formula of ;1-[2-[4-[5-chloro-1-(p-fluorophenyl)indol-3-yl]piperidino] ethyl]-2-imidazolidinone;. ;Sertindole; has been marketed or used in ;Netherlands, United Kingdom, Finland; under the trade or premarketing names of ;Serdolect R, Serlect R;NM: Serdolect Lundbeck, NL, UK, FIN: tabs.4mg, R 12mg, 16mg, 20mg NM: SerlectR;. ;Long acting 5-HT / antagonist. Very mild D antagonist. 2 2 2 Psychotropic agent with neuroleptic-like pharmacological properties. Prominent selectivity for the brain limbic area. In animal models sertindol alleviates, relieves and suppresses effects on the physical and psychological symptoms on withdrawal from drugs of abuse. Practically devoid of EPSE.;WHO Drug Information~Sertindole~~1989~3(2)~100# Tzeng TB, Stamm G, Chu SY~Sensitive method for the assay of sertindole in plasma by high-performance liquid chromatography and fluorimetric detection~Journal of chromatography B, Biomedical applications~1994~661(2)~299-306# van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB~A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia~Psychopharmacology~1996~124(1-2)~168-75#Nabulsi A, Braus A, Mack R~Reduction of hospital days in sertindole-treated patients: one-year findings~149th Annual Meeting of the American Psychiatric Association~1996~~;Sertindole. WHO Drug Information vol 3(2): 100, 1989 - Tzeng TB, Stamm G, Chu SY: Sensitive method for the assay of sertindole in plasma by high-performance liquid chromatography and fluorometric detection. J Chromatogr B Biomed Applic 661/2: 299-306, 1994 - Van Kammen DP, Mc Evoy JP, Targum SD & al: A randomized controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124/1-2: 168-175, 1996 - Braus A, Nabulsi A, Mack R & al: Reduction of hospital days in sertindole treated patients - One year findings. Eur Neuropsychopharmacol 6 (suppl 4): 109-110, (abstr P-3-025), 1996.;;;;;;;sertindole (Lu 23174);;;
158;A.III.17 ;Zetidoline;is in the ;imidazolidinone; category of antipsychotic.;It has a;;;;full chemical formula of ;1-(3-chlorophenyl)-3-[2-(3,3-dimethyl-1-azetidinyl)ethyl]-2- imidazolidinone;. ;Zetidoline; has been marketed or used in ;Italy; under the trade or premarketing names of ;MDL 308;NM: MDL 308 Lepetit/Dow Chemical, ITA;. ;Dopamine D receptor antagonist. Potential neuroleptic agent. 2 No inhibition of DA-induced stimulation of striatal adenylcyclase. Sedative properties. Less prone to induce extrapyramidal symptoms. Oral dosage about 10 mg to 30 mg/day. Mean plasma half-life 2 hrs.;Assandri A, Galliani G, Zerilli L, Tuan G, Tarzia G, Barone D~Zetidoline metabolism by rat liver microsomes. Formation of metabolites with potential neuroleptic activity~Biochemical pharmacology~1986~35(9)~1459-67# Collin S, Evrard G, Vercauteren DP, Durant F, Carrupt PA, van de Waterbeemd H, et al.~Stereoelectronic study of zetidoline, a dopamine D2 receptor antagonist~Journal of medicinal chemistry~1989~32(1)~38-42# Landi M, Dubini E, Zerilli LF~Quantitative determination of zetidoline, a new antipsychotic agent, in human blood plasma and saliva using capillary gas chromatograph-mass spectrometry~Bollettino chimico farmaceutico~1992~131(8)~304-8;Assandri A, Galliani G, Zerilli L, et al: Zetidoline metabolism by rat liver microsomes. Formation of metabolites with potential neuroleptic activity. Biochem Pharmacol 35: 1459-1467, 1986 - Collin S, Evrard G, Vercauteren DP, et al: Stereoelectronic study of zetidoline, a dopamine D2 receptor antagonist. J Med Chem 32: 38-42, 1989 - Landi M, Dubini E, Zerilli LF: Quantitative determination of zetidoline, a new antipsychotic agent, in human blood plasma and saliva using capillary gas chromatograph-mass spectrometry. Boll Chim Farm 131/8: 304-308, 1992.;;;;;;;zetidoline (MDL 308);;;
159;A.III.18 ;Oxypertine;is in the ;indole, naphtone and indan derivative; category of antipsychotic.;It has a;;;;full chemical formula of ;5,6-dimethoxy-2-methyl-3-[2-(4-phenyl-1- piperazinyl)ethyl]indole (hydrochloride);. ;Oxypertine; has been marketed or used in ;Finland, Belgium, Germany, United Kingdom; under the trade or premarketing names of ;Opertil, Equipertine, Forit, Integrin, Oxypertine, WIN 18.501;NM: Opertil Lääkefarmos, FIN: tabs. 40mg NM: Equipertine Winthrop, B: tabs. 40mg (deleted) NM: Forit Sanofi Winthrop, BRD: tabs. 40mg NM: Integrin Sanofi Winthrop, UK: caps. 10mg, tabs. 40mg NM: Oxypertine Sanofi Winthrop, UK: caps. 10mg, tabs. 40mg NM: WIN 18.501 Winthrop-Sterling, USA;. ;As neuroleptic used in the treatment of schizophrenic disorders at a dosage of 80 - 120 mg daily, up to 300 mg/day. As tranquilizer in anxiety neuroses 30 - 60 mg/day. Also for the treatment of chorea, TD or other motor disorders.;Moroji T, Okuyama T, Hagino Y, Sekiguchi R~Neurochemical and behavioral studies on the mode of action of oxypertine~Arzneimittel-Forschung~1986~36(5)~804-8# Soni SD, Freeman HL, Bamrah JS, Sampath G~Oxypertine in tardive dyskinesia: a long-term controlled study~Acta psychiatrica Scandinavica~1986~74(5)~446-50;Moroji Y, Okuyama T, Hagino Y, et al: Neurochemical and behavioral studies on the mode of action of oxypertine. Arzneim Forsch 36: 804-808, 1986 - Soni SD, Freeman HL, Bamrah JS, et al: Oxypertine in tardive dyskinesia: a long-term controlled study. Acta Psychiatr Scand 74: 446-450, 1986.;;;;;;;oxypertine;;;
160;A.III.18 ;EMD 30.533;is in the ;indole, naphtone and indan derivative; category of antipsychotic.;It has a;;;;full chemical formula of ;2-(4-hydroxy-4-phenylpiperidinomethyl)-6,7-dimethoxy- 1,2,3,4-tetrahydronaphthalen-1-one;. ;EMD 30.533; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Potential neuroleptic agent. Studied in the treatment of schizophrenia at a dosage of 4 up to 36 mg daily.;Schmauss M, Lange E, Nedopil N, Rüther E, Weiss-Brummer J~Effect of the Neuroleptic EMD 30-533 on Schizophrenic Symptoms: An Open Study~Pharmacopsychiatry~1985~18(01)~58-60;Schmau M, Lange E, Nedopil N, et al: Effect of the neuroleptic EMD 30.533 on schizophrenic symptoms: an open study. Pharmacopsychiatry 18: 58-60, 1985.;;;;;;;EMD 30.533;;;
161;A.III.18 ;Molindone;is in the ;indole, naphtone and indan derivative; category of antipsychotic.;It has a;;;;full chemical formula of ;3-ethyl-6,7-dihydro-2-methyl-5- (morpholinomethyl)indol- 4(5H)-one;. ;Molindone; has been marketed or used in ;United States of America, Finland; under the trade or premarketing names of ;Lidone, Moban;NM: Lidone Abbott, USA: caps. 5mg, 10mg, 25mg NM: Moban Endo, USA: tabs. 5mg, 10mg, 25mg - concentrate for oral use 20mg/ml NM: Moban Orion, FIN: tabs. 25mg, 50mg - mixture 20mg/ml;. ;Neuroleptic agent with atypical neuropharmacological profile. Studied in the treatment of schizophrenia. Dosage 40 mg up to 225 mg/day. May be administered once daily. Reduction of body weight reported. Terminal plasma half-life after oral administration about 6½ hours.;Prosser ES, Pruthi R, Csernansky JG~Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride~Psychopharmacology~1989~99(1)~109-16# Geibig CB, Marks LW~Treatment of clozapine- and molindone-induced agranulocytosis with granulocyte colony-stimulating factor~The Annals of pharmacotherapy~1993~27(10)~1190-4;Prosser ES, Pruthi R, Csernansky JG: Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride. Psychopharmacol 99: 109-116, 1989 - Geibig CB, Marks LW: Treatment of clozapine- and molindole-induced agranulocytosis with granulocyte colony-stimulating factor. Ann Pharmacother 27(10): 1190-1194, 1993.;;;;;;;molindone (EN 1733 A);;;
162;A.III.18 ;AL 1612;is in the ;indole, naphtone and indan derivative; category of antipsychotic.;It has a;;;;full chemical formula of ;3-ethyl-6,7-dihydro-2-methyl-5-[(1,4-dioxa-8-azaspiro[4.5] decyl)methyl] indol-4 (5H)-one;. ;AL 1612; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Studied in the treatment of schizophrenic psychoses. Extrapyramldal symptoms reported. Dosage 200 to 400 mg/day. At lower doses used in the management of anxiety and behavioral disturbances.;Elizur A, Gershon S~Evaluation of the antipsychotic activity of an indole analogue, AL-1612~Current therapeutic research, clinical and experimental~1971~13(9)~584-90# Sugerman AA~A pilot study of AL-1612 in chronic schizophrenics~Current therapeutic research, clinical and experimental~1971~13(12)~743-6;Elizer A, Gershon S: Evaluation of the antipsychotic activity of an indole analogue, AL-1612. Curr Ther Res 13: 584-590, 1971 - Sugerman AA: A pilot study of AL-1612 in chronic schizophrenics. Curr Ther Res 13: 743-746, 1971 - Chen CH, Hernandez HR, Riaz AG, et al: The use of AL-1612 on anxious neurotic outpatients: a preliminary study. Curr Ther Res 14: 303-306, 1972.;;;;;;;AL 1612;;;
163;A.III.18 ;Milipertine;is in the ;indole, naphtone and indan derivative; category of antipsychotic.;It has a;;;;full chemical formula of ;5,6-dimethoxy-3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]ethyl] -2-methylindole (hemitartrate);. ;Milipertine; has been marketed or used in ;United States of America; under the trade or premarketing names of ;WIN 18.935;NM: WIN 18.935 Winthrop, USA;. ;Major neuroleptic agent. Studied in the treatment of refractory schizophrenia. Dosage 200 to 400 mg daily. Weight loss and rather high incidence of extrapyramidal symptoms reported.;Mielke DH, Gallant DM, Bishop MP~Milipertine: an early evaluation in severely ill schizophrenics~Current therapeutic research, clinical and experimental~1973~15(6)~324-6;Mielke DH: Milipertine: an early evaluation in severely ill schizophrenics. Curr Ther Res 15: 324-326, 1973.;;;;;;;milipertine;;;
164;A.III.19 ;Sulpiride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;N-[-1-ethyl-2-pyrrolidinyl)methyl]-5-sulfamoyl-o-anisamide;. ;Sulpiride; has been marketed or used in ;Belgium, Germany, France, Switzerland, Netherlands, Denmark, AustriaGreece, Italy, Spain, United Kingdom, Republic of South Africa, Finland; under the trade or premarketing names of ;Dogmatil, Dogmatyl, Aiglonyl, Alimoral, Desmenat, Arminol, Calmoflorine, Championil, Darleton, Dixibon, Dobren, Dolmatil, Dresent, Eclorion, Esalfon, Eglonyl, Enimon, Equilid, Fardalan, Fidelan, Guastil, Lebopride, Mariastel, Meresa, Mirbanil, Neogama, Neoride, Noneston, Norestran, Normum, Nufarol, Omaha, Stamonevrol, Omiryl, Ozoderpin, Quiridil, Paratil, Restful, Silavidon, Sulpril, Sulpitil, Suprium, Synédil, Synédil Fort, Tepavil, Valirem, Zemorcon, Zymocomb, Ansium, Tepazepam;NM: Dogmatil Synthélabo, B, BRD - Synthélabo Delagrange, F, CH - Delagrange, ESP - Lorex Synthelabo, NL: amps. 100mg/2ml - caps. 50mg, tabs. 200mg (forte), syrup 5mg/ml (not in NL) - Synthelabo, DK: tabs. 200mg, 400mg - Bender, A: caps. 50mg - tabs. 200mg NM: Dogmatyl Delagrange, GR: same presentations as NL NM: Aiglonyl Gerda, F: caps. 50mg - sol. buv. 5mg/ml NM: Alimoral Medichrom, GR - Desmenat, Kleva, GR: caps. 50mg NM: Arminol Krewel Meuselbach, BRD: caps. 50mg- tabs. 200mg NM: Calmoflorine Coup, GR: tabs. 50mg, 200mg - syrup 25mg/5ml NM: Championil Synthelabo, ITA: caps. 50mg - tabs. 200mg - amps.100mg/2ml NM: Darleton Anfarm, GR: tabs. 50mg, 200mg - syrup 25mg/5ml NM: Dixibon Sandoz Pharma, ESP: caps. 50mg NM: Dobren Ravizza, ITA: tabs. 100mg, 200mg NM: Dolmatil Delandale, UK: tabs. 200mg NM: Dresent Pefanic, GR: tabs. 50mg, 100mg NM: Eclorion Norma, GR - Esalfon, Vilco, GR: tabs. 50mg, 100mg, 200mg NM: Eglonyl Noristan Ltd, RSA: caps. 50mg - tabs. 200mg - elixir 25mg/ml - amps. 100mg/ml NM: Enimon Biomedica, GR: tabs. 50mg, 200mg NM: Equilid Lepetit, ITA: tabs. 200mg NM: Fardalan Faran, GR: tabs. 50mg, 200mg NM: Fidelan Uni-Pharma, GR: caps. 50mg, 100mg - syrup 5mg/ml - amps. 100mg/2ml NM: Guastil Uriach, ESP: tabs. 50mg - syrup 25mg/5ml NM: Lebopride Spyfarma, ESP: caps.50mg - tabs. 200mg - solut.25mg/5ml NM: Mariastel Pharmathen, GR, BRD, A: tabs. 50mg, 200mg NM: Meresa Dolorgiet, BRD - Schöeller Pharma, A: caps. 50mg (also 100mg in A) - tabs. 200mg - amps. 100mg/3ml NM: Mirbanil Boehringer Ingelheim, ESP: caps. 50mg (deleted) NM: Neogama Hormosan, BRD: caps. 50mg- tabs. 200mg NM: Neoride Hobson, ESP: caps. 50mg (deleted) NM: Noneston Help, GR - Nylipack, Farmanic, GR: tabs. 50mg, 200mg NM: Norestran Relyo, GR: tabs. 50mg, 200mg - syrup 25mg/5ml NM: Normum Serpero, ITA: tabs. 200mg NM: Nufarol Rafarm, GR: tabs. 50mg, 200mg - syrup 25mg/5ml NM: Omaha Velka, GR - Stamonevrol, Biostam, GR: tabs. 50mg NM: Omiryl Erfar, GR: caps. 50mg, 100mg, 200mg NM: Ozoderpin Demo, GR: caps. 50mg - tabs. 200mg (deleted) NM: Quiridil Zoja, ITA: tabs. 200mg NM: Paratil Medica, FIN: tabs. 50mg, 200mg - mixt. 5mg/ml, amps. 100mg/2ml (range deleted) NM: Restful Bros, GR - Silavidon, Leontik, GR: tabs. 50mg, 200mg NM: Sulpril Astra, DK, tabs. 200mg NM: Sulpitil Pharmacia, UK: tabs. 200mg NM: Suprium Orion Farmos, FIN: caps. 50mg, tabs. 100mg, 200mg - mikstuura 10mg/ml NM: Synédil Yamanouchi, F: gélules 50mg- soluté buvable 50mg/10ml NM: Synédil Fort Yamanouchi, F: amps. 100mg/2ml - tabs. 200mg NM: Tepavil Prodes, ESP: tabs. 50mg, 200mg (forte) - sol.5mg/ml - amps.100mg/2ml (range deleted) NM: Valirem Genepharm, GR: tabs. 50mg, 200mg - syrup 25mg/5ml NM: Zemorcon Farmalen, GR: tabs. 50mg, 100mg, 200mg NM: Zymocomb Chrispa, GR: tabs. 50mg, 100mg, 200mg NM: Ansium LeSvi Vita-Elan, ESP: caps. 50mg sulpiride + 5mg diazepam NM: Tepazepam Prodes, ESP: 50mg sulpiride + 5mg pyridoxine;. ;Dopamine D receptor antagonist, also D and D antagonist. Atypical neuroleptic. 2 3 4 Stereoselectivity of the isomers to dopamine D and D antagonism. Used in the treatment of 1 2 N C2H5 NH H3CO S NH2 O O S O psychoses, Tourette's disorder, nausea and vomiting, vertigo, anxiety states and other conditions. Dosage 200 to 600 mg daily/ according to French data up to 3200 mg. Plasma halflife about 8 hours.;Caley CF, Weber SS~Sulpiride: an antipsychotic with selective dopaminergic antagonist properties~The Annals of pharmacotherapy~1995~29(2)~152-60# de Koning P, de Vries MH~A comparison of the neuro-endocrinological and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers~British journal of clinical pharmacology~1995~39(1)~7-14;Caley CF, Weber SS: Sulpiride: An antipsychotic with selective dopaminergic antagonist properties. Ann Pharmacother 29/2: 152-160, 1995 - de Koning P, De Vries MH: A comparison of the neuro-endocrinal and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers. Br J Clin Pharmac 39: 7-14, 1995 - Mauri MC, Bravin S, Bitetto A & al: A risk-benefit assassment of sulpiride in the treatment of schizophrenia. Drug Saf 14/5: 288-298, 1996.;;;;;;;sulpiride;;;
165;A.III.19 ;Levosulpiride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;(S)-(-)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-sulfamoylo- anisamide (L-sulpiride);. ;Levosulpiride; has been marketed or used in ;Italy; under the trade or premarketing names of ;Levobren, Levopraid;NM: Levobren Knoll, ITA: tabs.25mg - drops 2½ % - amps. 25mg/2ml NM: Levopraid Ravizza, ITA: tabs. 25mg, 50mg, 100mg - drops 5 % - amps. 25mg/2ml, 50mg/ml;. ;Atypical antipsychotic and antiemetic agent. Considered as influencing both negative and positive schizophrenic symptoms.;WHO Drug Information~Levosulpiride~~1990~4(2)~86# Mauri MC, Leva P, Coppola MT, Altamura CA~L-sulpiride in young and elderly negative schizophrenics: clinical and pharmacokinetic variables~Progress in neuro-psychopharmacology & biological psychiatry~1994~18(2)~355-6 # De Ronchi D, Ruggeri M, Balelli G, Volterra V~P-4-26 Levosulpiride vs pimozide in negative symptoms of schizophrenia~European Neuropsychopharmacology~1995~5(3)~335# Corli O, Cozzolino A, Battaiotto L~Effectiveness of levosulpiride versus metoclopramide for nausea and vomiting in advanced cancer patients: a double-blind, randomized, crossover study~Journal of pain and symptom management~1995~10(7)~521-6;Levosulpiride. WHO Drug Information Vol 4(2): 86, 1990 - Mauri MC, Leva P, Coppola MT, Altamura CA: L-sulpiride in young and elderly negative schizophrenics: clinical and pharmacokinetics variables. Prog Neuropsychopharmacol Biol Psychiatr 18: 355-366, 1994 - De Ronchi D, Ruggeri M, Balelli G, Voltera V: Levosulpiride vs pimozide in negative symptoms of schizophrenia. NeuropsychoPharmacology 5/3: 325 (Abstr P-4-26), 1995 - Corli O, Cozzolino A, Battaiotto L: Effectiveness of levosulpiride vs metoclopramide for nausea and vomiting in advanced cancer patients. A double-blind randomized, cross-over study. J Pain Sympt Manag 10/7: 521-526, 1995.;;;;;;;levosulpiride (RV 12309);;;
166;A.III.19 ;Prosulpride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;N-[(1-propyl-2-pyrrolidinyl)methyl]-2-methoxy-5-sulfamoyl benzamide;. ;Prosulpride; has been marketed or used in ;Greece, France; under the trade or premarketing names of ;I 1665;NM: GRI 1665 Synthélabo Delagrange, F;. ;Homologue of sulpiride. Dopamine receptor antagonist. Neuroleptic with psychoactivating properties. Studied for the treatment of psychotic disorders.;Mercier J, Scotto di Tella AM~[Demonstration of experimental disinhibitory activity in a series of neuroleptic orthoanisamides]~Comptes rendus des seances de la Societe de biologie et de ses filiales~1980~174(3)~335-43# Dufour H, Samuelian JC~Place du G.R.I. 1665, nouvelle orthoanisamide dans la pharmacologie des psychoses~Ann Méd Psychol~1980~138(491-492)~;Mercier J, di Sotto Tella AM: Mise en évidence d'une activité desinhibitrice expérimentale dans une série d'orthoanisamides. Compt Rend Soc Biolog 174: 335-343, 1980 - Dufour H, Samuelian JC: Place du G.R.I. 1665, nouvelle orthoanisamide dans la pharmacologie des psychoses. Ann Méd Psychol 138: 491- 492, 1980 -Kirkorian J: Approche psychopharmacologique des benzamides substituées. Sem Hôp 61: 2009-2014, 1985. N H2C C H CH2 CH 2 NH C O S N H CH3 O O H3C O NH2 N N H3C CH 2 NH C O H3CO Cl NH2;;;;;;;prosulpride;;;
167;A.III.19 ;Alpiropride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;(±)-N-[(1-allyl-2-pyrrolidinyl)methyl]-4-amino-5- (methylsulfamoyl)-o-anisamide;. ;Alpiropride; has been marketed or used in ;France; under the trade or premarketing names of ;RIV 2093;NM: RIV 2093 Synthélabo Delagrange, F;. ;Structurally related to GRI 1665 and tropapride. Preliminary pharmacological studies. So far no clinical references available.;Bressolle F, Bres J, Snoussi M, Sabatier R~Direct quantitative thin-layer chromatographic determination of a new benzamide in biological fluids: Statistical comparison with high-performance liquid chromatography~Journal of Chromatography B: Biomedical Sciences and Applications~1986~375(119-28)~;Bressole F, Bres J, Snoussi M, et al: Direct quantitative thin-layer chromatographic determination of a new benzamide in biological fluids. Statistical comparison with high-performance liquid chromatography. J Chromatogr Biomed Appl 424: 195-200, 1986.;;;;;;;alpiropride;;;
168;A.III.19 ;Lintopride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;4-amino-5-chloro-N-(1-ethyl-2-imidazolin-2-yl)methyl -o-anisamide;. ;Lintopride; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;5-HT receptor antagonist. Phase II clinical trials in 3 1995. Antiemetic.;WHO Drug Information~Lintopride~~1991~5(2)~86;Lintopride WHO Drug Information vol 5(2) : 86, 1991.;;;;;;;lintopride;;;
169;A.III.19 ;Clebopride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;N-(1-benzyl-4-piperidyl)-4-amino-5-chloro-2-methoxy benzamide;. ;Clebopride; has been marketed or used in ;Spain, Italy; under the trade or premarketing names of ;Cleboril, Clanzoflat, Flatoril, Motilex;NM: Cleboril Almirall, ESP: tabs.250?g, 500?g - sol.100?g/ml - 0.0625mg/ml (pedriatico) NM: Clanzoflat Wyeth Orfi, ESP: tabs. 0.5mg + 200mg dimeticone - emuls.0.25mg + 100mg dimeticone/2½ml NM: Flatoril Tecnobio, ITA: caps.0.5mg + 100mg dimeticone - emuls.0.25mg + 100mg dimeticone NM: Motilex Guidetti, ITA: tabs ½mg - syrup 0.01 % - amps.1mg/2ml;. ;D receptor antagonist. Licensed by Almirall to Kali-Chemie for other countries. Neuroleptic and 2 tranquilizing effects. Antiemetic. Used in the treatment of gastrointestinal disorders. Plasma halflife about 24 hours. Clebopride appears to be most suitable for transdermal use.;"Guan JH, Livni E, R. ED~[C]Clebopride: a novel D -antagonist as a potential D -receptor tracer for 11 2 2 PET~J Label Comp Radiopharm~1989~26(215-6)~#
Sempere AP, Duarte J, Palomares JM, Coria F, Claveria LE~Parkinsonism and tardive dyskinesia after chronic use of clebopride~Movement disorders : official journal of the Movement Disorder Society~1994~9(1)~114-5# Calpena AC, Blanes C, Moreno J, Obach R, Domenech J~A comparative in vitro study of transdermal absorption of antiemetics~Journal of pharmaceutical sciences~1994~83(1)~29-33 
";Guan JH, Livni E, Elmaleh DR: [ C]Clebopride: a novel D -antagonist as a potential D -receptor tracer for 11 2 2 PET. J Label Comp Radiopharm 26: 215-216, 1989 - Sempere AP, Duarte J, Palomares JM & al: Parkinsonism and tardive dyskinesia after chronic use of clebopride. Mov Disord 9(1): 114-115, 1994 - Calpena AC, Blanes C, Moreno J & al: A comparative in vitro study of transdermal absorption of antiemetics. J Pharm Sci 83(1): 29-33, 1994. anilide derivative;;;;;;;clebopride (LAS 9273);;;
170;A.III.19 ;BRL 20.596;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;N-(4-amino-5-chloro-2-methoxyphenyl)-1-benzyl-4-piperidine carboxamide;. ;BRL 20.596; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Isomer of clebopride (reversed -CONH- bond and strictly speaking no benzamide. Potent and selective DA antagonist. No gastrointestinal activity. Neuroleptic properties and clinical efficacy in psychoses reported.;King FD, Hadley MS, McClelland CM~Substituted benzamides with conformationally restricted side chains. 2. Indolizidine derivatives as central dopamine receptor antagonists~Journal of medicinal chemistry~1988~31(9)~1708-12;King FD, Hadley MS, McClelland CM: Substituted benzamides with conformationally restricted side chains. Indolizidine derivatives as central dopamine receptor antagonists. J Med Chem 31: 1708-1712, 1988.;;;;;;;BRL 20.596;;;
171;A.III.19 ;BRL 34.778;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;exo-4-amino-5-chloro-2-methoxy-N-[9-(p-fluorophenyl methyl)-9-azabicyclo[3.3.l]non-3-yl]benzamide;. ;BRL 34.778; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Putative neuroleptic agent. Selective and very potent dopamine D receptor antagonist. Behavioral activity reported. 2 So far no clinical data.;Brown F, Campbell W, Clark MS, Graves DS, Hadley MS, Hatcher J, et al.~The selective dopamine antagonist properties of BRL 34778: a novel substituted benzamide~Psychopharmacology~1988~94(3)~350-8;Brown F, Campbell W, Clark MSG, et al: The selective dopamine antagonist properties of BRL 34.778: a novel substituted benzamide. Psychopharmacol 94: 350-358, 1988.;;;;;;;BRL 34.778;;;
172;A.III.19 ;Nemonapride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;(cis)-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2- methoxy-4-(methylamino) benzamide;. ;Nemonapride; has been marketed or used in ;Japan, France; under the trade or premarketing names of ;YM-09151-2 EmirageSepanR;NM: YM-09151-2 Emirage, JPN - Negma, F NM: SepanR;. ;Potent and selective dopamine D antagonist. Compared with 2 butyrophenone-type neuroleptics less extrapyramidal effects. The cis-isomer is the active neuroleptic component/ the transform is presumably less potent. Optimal dose around 9mg/day. Phase II clinical trials in negative symptoms of schizophrenia completed. Phase III trials foreseen in 1994.;Koshija K, Morita T, Usuda S~Behavioral suppressive and desinhibiting effects on nemonapride: possible biological basis of its antipsychotic efficacies~18th CINP Cong (Nice)~1992~~# Kubota T~Neuroleptic malignant syndrome induced by nemonapride~Acta neurologica~1993~15(2)~142-4# Yamaguchi N, Kamirnura M, Morokawa Y, Fujimaki H, Watanabe H, Nagatsu Y, et al.~P-13-13-Ratio of neuroleptic to anticholinergic level and extrapyramidal symptoms induced by nemonapride~European Neuropsychopharmacology~1996~6(132-3)~;Koshija K, Morita T, Usuda S: Behavioral suppressive and desinhibiting effects on nemonapride: possible biological basis of its antipsychotic efficacies. 18th CINP Cong (Nice) Abs P-88-428, 1992 - Kubota T: Neuroleptic malignant syndrome induced by nemonapride. Acta Neurol 48/2: 142-144, 1993 - Yamaguchi N, Kamimura M, Morokawa Y & al: Ratio of neuroleptic to anticholinergic level and extrapyramidal symptoms induced by nemonapride. Eur Neuropsychopharmacol 6 (suppl 3): 132-133, (abstr P-13-13), 1996.;;;;;;;nemonapride (emonapride);;;
173;A.III.19 ;Tropapride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;(cis)-2,3-dimethoxy-N-[8-(phenylmethyl)-8-azabicyclo[3.2.1] oct-3-yl]benzamide or: N-(8-benzyl-1 H,5 H-nortropan-3 -yl)-o-veratramide;. ;Tropapride; has been marketed or used in ;France; under the trade or premarketing names of ;MD 790.501;NM: MD 790.501 Synthélabo Delalande, F;. ;Nortropan moiety. Highly potent neuroleptic agent with minor sedative and dyskinetic properties. Antagonist of postsynaptic dopamine receptors. Anticholinergic effects weak or absent. No clinical data available.;Jalfre M, Bucher B, Dorme N, Mocquet G, Porsolt RD~Neuropharmacological profile of MD 790501, a new benzamide derivative~Archives internationales de pharmacodynamie et de therapie~1983~264(2)~232-56;Jalfre M, Bucher B, Dorme M, et al: Neuropharmacological profile of MD 790501, a new benzamide derivative. Arch Int Pharmacodyn Thér 264: 232-256, 1983 -Benedetti MS, Dow J, Dostert S, et al: Localization of a new benzamide derivative, tropapride, and of l-sulpiride, in the pituitary gland of the rat. J Pharmacology 15: 433-438, 1984.;;;;;;;tropapride;;;
174;A.III.19 ;Metoclopramide;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;4-amino-5-chloro-N-[2-(diethylamino)ethyl-2-methoxybenzamide;. ;Metoclopramide; has been marketed or used in ;Belgium, Switzerland, France, Denmark, Finland, United Kingdom, Norway, Spain, GreeceGermany, Italy, Austria; under the trade or premarketing names of ;Primperan, Anausin/Anausan, Dibertil, Lumania, Dura MCP, Maxolon, Duraclamid, Movistal, Cerucal, Meclopane, Citroplus, MCP-ratiopharm, Clopan, Metopram, Emperal, Mepramid, Enterogalinol, Metoclamid, Gaspalon, Metogastron, Gastromax, Metramid, Gastronerton, Metox, Gastrobid, Nausigon, Gastrosil, Gastro-Tablinen, Parmid, Gastrotem, Paspertin, Gastro-Timelets, Pharmyork, Perton, Plasil, Gastrotranquil Retard, Primpéroxane Delagrange, Geneprami-D, Primoxan, Hyrin 10, Prokinyl, Randum, Reliberan, LuvViscal;NM: Primperan Synthélabo, B, CH, F, DK, GR - Lorex, NL - Lundbeck, FIN - Berk, UK - Nycomed, NOR - Tika, SWE - Delagrange, ESP NM: Anausin/Anausan Asta Medica,F - Dagra,NL NM: Dibertil Christiaens, B NM: Lumania Kleva, GR NM: Dura MCP Durachemie, BRD NM: Maxolon Beecham, UK NM: Duraclamid Durachemie, BRD (deleted) NM: Movistal SMB, B NM: Cerucal Arzneimittel Dresden, BRD NM: Meclopane Lagap, CH (deleted) NM: Citroplus Irbi, ITA NM: MCP-ratiopharm Ratiopharm, BRD NM: Clopan Firma, ITA NM: Metopram Leiras, FIN NM: Emperal Orion Farmos, FIN (deleted) - Ercopharm, DK NM: Mepramid DAK, DK (deleted) NM: Enterogalinol Athenpharma, GR NM: Metoclamid Hexal, BRD NM: Gaspalon Chemica, GR NM: Metogastron Hexal Pharma, A NM: Gastromax Farmitalia Carlo Erba, UK NM: Metramid Nicholas, UK (deleted) NM: Gastronerton Dolorgiet, BRD, Schoeller Pharma, A NM: Metox Steinhard, UK (deleted) NM: Movistal SMB, B NM: Gastrobid Continus NAPP Lab., UK NM: Nausigon Mundi Pharma, A NM: Gastrosil Heumann, BRD, CH - Salus Braumapharma, A NM: Gastro-Tablinen Sanorania, BRD NM: Parmid Lagap, UK NM: Gastrotem Temmler Pharma, BRD NM: Paspertin Kali-Chemie, BRD, CH, A NM: Gastro-Timelets Temmler Pharma, BRD,DK NM: Pharmyork Bros, GR NM: Perton Kali Pharma, A NM: Gastro-Timelets Salus Braumapharma, A - Asta Medica, CH NM: Plasil Lepetit, ITA NM: Gastrotranquil Retard Azupharma, BRD NM: Primpéroxane Delagrange (Synthélabo), F: combination product NM: Geneprami-D Genepharm, GR NM: Primoxan Synthélabo, F: combination product NM: Hyrin 10 Merckle, BRD NM: Prokinyl Techni-Pharma, F NM: Randum Roussel-Pharma, ITA NM: Reliberan Proel, GR NM: Luv Faran, GR NM: Viscal Zoja, ITA;. ;Available in tabs. or caps. of 10mg, syrup or drops 1mg/ml, suppositories, and other presentations. Neuroleptic-like pharmacological profile/ dopamine D receptor blocker, increasing 2 prolactin levels, sometimes extrapyramidal symptomatology. Minor or no antipsychotic effects. May possibly interfere with skills in every-day life. Used in the treatment of nausea, vomiting and gastrointestinal disorders. Plasma half-life about 5 to 8 hours.;Guinetdinov RR, Bogdanov MB, Kudrin VS, Rayevsky KS~Remoxipride and raclopride differ from metoclopramide by their effects on striatal dopamine release and biosynthesis in rats~Neuropharmacology~1994~33(2)~215-9# Kymer PJ, Brown RE, Jr., Lawhorn CD, Jones E, Pearce L~The effects of oral droperidol versus oral metoclopramide versus both oral droperidol and metoclopramide on postoperative vomiting when used as a premedicant for strabismus surgery~Journal of clinical anesthesia~1995~7(1)~35-9 # Gilbert CJ, Ohly KV, Rosner G, Peters WP~Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation~Cancer~1995~76(11)~2330-7;Guinetdinov RR, Bogdanov MB, Kudrin VS, Rayevsky KS: Remoxipride and raclopride differ from metoclopramide by their effects on striatal dopamine release and biosynthesis in rats. Neuropharmacology 33(2): 215, 1994 - Kymer PJ, Brown RE Jr, Lawhorn CD & al: The effects of oral droperidol vs oral metoclopramide vs both oral droperidol and metoclopramide on postoperative vomiting when used as premedicant for strabismus surgery. J Clin Anesth 7/1: 35-39, 1995 - Gilbert CG, Ohly KV, Rosmer G, Peters WP: Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramidebase antiemetic regimen in patients undergoing autologous bone marrow transplantation. Cancer 76/11: 2330-2337, 1995.;;;;;;;metoclopramide;;;
175;A.III.19 ;Raclopride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;(-)-(S)-3,5-dichloro-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6- hydroxy-o-anisamide;. ;Raclopride; has been marketed or used in ;Sweden; under the trade or premarketing names of ;A 40.664;NM: A 40.664 Astra, SWE;. ;Specific dopamine D receptor antagonist. Potential 2 antipsychotic. Tentative dosage in clinical evaluation about 8 mg/day. Plasma half-life 8 to 14 hours. The (R)enantiomer (FLB 472) is reported to be inactive. Clinical research discontinued early 1992.;Seeman P, Van Tol HH~Dopamine D4-like receptor elevation in schizophrenia: cloned D2 and D4 receptors cannot be discriminated by raclopride competition against [3H]nemonapride~Journal of neurochemistry~1995~64(3)~1413-5# Csernansky JG, Newcomer JW, Jackson K, Lombrozo L, Faull KF, Zipursky R, et al.~Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics~Psychopharmacology~1994~116(3)~291-6;Seeman P, Van Tol HHM: Dopamine D -like receptor elevation in schizophrenia: Cloned D and D 4 2 4 receptors cannot be discriminated by raclopride competition against (3H)-nemonapride. J Neurochem 64/3: 1413-1415, 1995 - Csernansky JG, Newcomer JW, Jackson K & al: Effects of raclopride treatment on plasma and CSF HVA: Relationship with clinical improvement in male schizophrenics. Psychopharmacology 116/3: 291-296, 1994.;;;;;;;raclopride (FLA 870);;;
176;A.III.19 ;Cipropride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;N-[-1-(cyclopropylmethyl)-2-pyrrolidinyl) methyl]-5- sulfamoyl-o-anisamide;. ;Cipropride; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Dopamine receptor antagonist. Minor neuroleptic effects. Has been studied in the treatment of nausea and vomiting. Elimination half-life about 6 hours.;Coquelin J, Narbonne G, Serrou B, CUPISSOL D, FAVIER F~DOUBLE-BLIND-STUDY OF CIPROPRIDE VERSUS PLACEBO IN CANCER CHEMOTHERAPY-INDUCED VOMITING~CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL~1983~33(5)~816-27;Coquelin JP, Narbonne G, Serrou B: Double-blind study of cipropride versus placebo in cancer chemotherapy-induced vomiting. Curr Ther Res 38: 816-827, 1983.;;;;;;;cipropride (SL 74.036);;;
177;A.III.19 ;LUR 2366;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;N-[(1-cyclopropylmethyl)pyrrolidin-2-yl] methyl-4-amino-5- ethylsulfonyl-o-anisamide;. ;LUR 2366; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Aminated derivative of cipropride. Potential neuroleptic agent. Reported to exhibit a higher affinity for dopamine D 4 than for D receptor sites. No further clinical studies. 2;Martres MP, Sokoloff P, Delandre M, Schwartz JC, Protais P, Costentin J~Selection of dopamine antagonists discriminating various behavioral responses and radioligand binding sites~Naunyn-Schmiedeberg's archives of pharmacology~1984~325(2)~102-15# KIRKORIAN J~Approche psychopharmacologique des benzamides substitués~La Semaine des hôpitaux de Paris~1985~61(27)~2009-14;Martres MP, Sokoloff P, Delandre M, et al: Selection of dopamine antagonists discriminating various behavioral responses and radioligand binding sites. Naun Schmiedebergs Arch Pharmacology 325: 102-115, 1984 - Kirkorian J: Approche psychopharmacologique des benzamides substituées. Sem Hôp 61: 2009-2014, 1985.;;;;;;;LUR 2366;;;
178;A.III.19 ;Amisulpride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-ethyl-sulfonyl-oanisamide;. ;Amisulpride; has been marketed or used in ;France, Portugal, Italy, Austria; under the trade or premarketing names of ;Solian, Socian, Deniban, Sulamid;NM: Solian Synthélabo, F: tabs.50mg, 200mg - amps. 200mg/4ml NM: Socian Delagrange, PORT: tabs. 50mg - oral amps. 50mg NM: Deniban Synthelabo, ITA - Bender, A: tabs. 50mg (in A also 100mg) NM: Sulamid Baldacci, ITA: tabs. 50mg;. ;Dopamine D receptor antagonist. Studied in the treatment of deficitary and productive 2 schizophrenic psychoses. Dosage 300 mg to 1200 mg daily. Minor extrapyramidal symptoms. At lower doses stimulatory effects. Quick onset of action. Elimination half-life about 12 to 19 hours. Clinical trials in dysthymia.;Allouche G, Joober R, Vanelle JM, Brochier T, Olie JP~[Sequence in prescribing neuroleptics: a therapeutic alternative in refractory schizophrenia?]~L'Encephale~1994~20(6)~777-80# Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F~Improvement of some schizophrenic deficit symptoms with low doses of amisulpride~The American journal of psychiatry~1995~152(1)~130-4# Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F~Treatment of negative symptoms in schizophrenia with amisulpride~The British journal of psychiatry : the journal of mental science~1995~166(1)~68-72;Allouche G, Joober R, Vanelle JM & al: Séquence de prescription de neuroleptiques: Une alternative thérapeutique dans les schizophrénies résistantes. L'Encéphale XX: 777-780, 1994 - Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F: Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152/1: 130-133, 1995 - Boyer P, Lecrubier Y, Puech AJ & al: Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166: 68-72, 1995.;;;;;;;amisulpride (amino sultopride, AST Dan 2163);;;
179;A.III.19 ;Sultopride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-ethyl sulfonyl-oanisamide;. ;Sultopride; has been marketed or used in ;Belgium, France, Portugal, Greece; under the trade or premarketing names of ;Barnetil, Barnetyl, Barnotil;NM: Barnetil Delagrange Synthélabo, B, F: tabs.400mg - amps. 200mg/2ml - drops 244mg/1ml (1gt 10mg) NM: Barnetil Delagrange, PORT: tabs. 400mg - sol. 244mg/ml NM: Barnetyl GR: tabs. 400mg -amps. 220mg/2ml NM: Barnotil Synthelabo, ITA: tabs. 400mg - amps. 200mg/2ml;. ;Deaminated derivative of amisulpride. Neuroleptic agent for the treatment of behavioral disorders, psychomotor disturbances and psychoses with delusional manifestations. Oral dosage 200 mg to 1200 mg daily. Elimination half-life about 3 hours. A potential arhytmogenic effect, in some experimental conditions, has been observed. It is therefor recommended not to inject more than one ampoule at once and to divide the prescribed number of ampoules over the whole day.;SCOTTO J~L'utilisation actuelle du sultopride en psychiatrie~La Semaine des hôpitaux de Paris~1984~60(27)~1966-7#Bucci L~Treatment of an aggressive, compulsive adolescent with sultopride~The American journal of psychiatry~1985~142(7)~882-3#Montaz L, Varache N, Harry P, Aymes C, Turcant A, Delille F, et al.~[Torsades de pointes during sultopride poisoning]~Journal de toxicologie clinique et experimentale~1992~12(8)~481-6;Scotto JC: L'utilisation actuelle du sultopride en psychiatrie. Sem Hôp 60: 1966-1967, 1984 - Bucci L: Treatment of an aggressive, compulsive adolescent with sultopride (letter to editor): Am J Psychiatry 142: 882-883, 1985 - Montaz L, Varache N, Harry P, & al: Torsades de pointe lors d'une intoxication par sultopride. J Toxicol Clin Exp 12/8: 481-486, 1992.;;;;;;;sultopride (LIN 1418);;;
180;A.III.19 ;Eticlopride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;(-)-(S)-5-chloro-3-ethyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]- 6-methoxysalicylamide;. ;Eticlopride; has been marketed or used in ;Germany; under the trade or premarketing names of ;FLB 131;NM: FLB 131 Byk Gulden, BRD;. ;Like some other methoxysalicylamides selective and potent inhibitor of dopamine D receptors. Neuroleptic 2 properties. Potential antipsychotic agent.;Merali Z, Piggins H~Effects of dopamine D1 and D2 receptor agonists and antagonists on bombesin-induced behaviors~European journal of pharmacology~1990~191(3)~281-93#Hogberg T~The development of dopamine D2-receptor selective antagonists~Drug design and discovery~1993~9(3-4)~333-50;Merali Z, Piggins H: Effects of dopamine D and D receptor agonists and antagonists on bombesin-induced 1 2 behaviors. Eur J Pharmacol 191: 281-293, 1990 - Hogberg T: The development of dopamine D 2 receptor selective antagonists. Drug Res Discov 9(3-4): 333-350, 1993.;;;;;;;eticlopride (A 38.503);;;
181;A.III.19 ;Remoxipride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;(-)-(S)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6- dimethoxybenzamide;. ;Remoxipride; has been marketed or used in ;Denmark, Austria, Finland, Netherlands, Sweden, IcelandFrance, Belgium, Italy; under the trade or premarketing names of ;Roxiam;NM: Roxiam Astra, DK, A, FIN, NL, SWE: SR caps. 50mg (only in SWE), 75mg (not in NL), SR caps 150mg (300mg only in NL and SWE) - mixt. 25mg/ml - amps. 200mg/ml. NM: Roxiam Astra, UK: caps. 150mg, 300mg NM: Roxiam Astra, ICL: caps. 150mg - amps. 200mg/ml - mixt. 25mg/ml NM: Roxiam Astra, F: not launched NM: Roxiam Astra Pharmaceutica, B - Astra Chemicals: caps. 150mg, 300mg NM: Roxiam Zambeletti, ITA: caps.75mg, 150mg NM: Remidon Bracco, ITA: caps.75mg, 150mg;. ;Preferential D receptor antagonist. Studied in the treatment of schizophrenia. Some cases of 2 aplastic anemia reported. Dosage 60 to 300 mg/day. Plasma half-life in steady state about 7½ hours. The product has been world-wide withdrawn but remains available for named-patient and for compassionate use.;Astra's Roxiam hits toxicity troubles~Marketletter~~1993~November 8(18)~# Keks N, McGrath J, Lambert T, Catts S, Vaddadi K, Burrows G, et al.~The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia~Acta psychiatrica Scandinavica~1994~90(5)~358-65# Lambert T, Keks N, McGrath J, Catts S, Hustig H, Vaddadi K, et al.~Remoxipride versus thioridazine in the treatment of first episodes of schizophrenia in drug?naive patients: A case for specific, low potency D2 antagonists~Human Psychopharmacology: Clinical and Experimental~1995~10(6)~455-60;Astra's Roxiam hits toxicity troubles. Marketletter, November 8, 1993: 18 - Ramsayer T, Gallhofer B: Remoxipride versus haloperidol in healthy volunteers: Psychometric performance and subjective tolerance profile. Int Clin Psychopharmacol 10/1: 31-37, 1995 - Keks N, McGrath J, Lambert T & al: The Australian multicenter double-blind comparative study of remoxipride and thioridazine in schizophrenia. Acta Psychiatr Scand 90/5: 358-365, 1994 - Lambert T, Keks N, McGrath J & al: Remoxipride versus thioridazine in the treatment of first episode of schizophrenia in drug-naive patients: a case for specific, low potency D antagonists. Hum Psychopharmacol 10/6:455-460, 1995. 2;;;;;;;remoxipride (A 33.547 FLA 731);;;
182;A.III.19 ;Veralipride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;5-sulfamoyl-2, 3-dimethoxy-N-[(1-(2-propenyl)-2- pyrrolidinyl)methyl]benzamide;. ;Veralipride; has been marketed or used in ;Belgium, France, Spain, Italy; under the trade or premarketing names of ;Agréal, Agradil, Veralipril;NM: Agréal Synthélabo, B, F - Delagrange, ESP: caps. 100mg NM: Agradil La Farmaco Chimica, ITA: tabs.100mg NM: Veralipril Midy, ITA: tabs. 100mg;. ;Antidopaminergic and antigonadotrophic effects. Also neuroleptic-like properties. Pharmacokinetic studies. Mean elimination half-life about 4 hours.;Iruela LM, Caballero L, Ibanez-Rojo V, Palanca I~Panic-like symptoms after veralipride withdrawal~The Journal of clinical psychiatry~1993~54(12)~488-9# Masmoudi K, Decocq G, Chetaille E, Rosa A, Mizon JP, Andrejak M~[Extrapyramidal disorders induced by veralipride (Agreal). Apropos of 5 cases]~Therapie~1995~50(5)~451-4;Iruela LM, Caballero L, Hamez-Rojo V, Palanca I: Panic-like symptoms after veralipride withdrawal. J Clin Psychiatry 54(12): 488-489, 1993 - Masmoudi K, Decocq G, Chetaille E: Extrapyramidal side effects of veralipride: Five cases. Therapie 50/5: 451-454, 1995.;;;;;;;veralipride;;;
183;A.III.19 ;Zacopride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;4-amino-5-chloro-N-3-quinuclidinyl-o-anisamide (as (E)-2- butenedioate = fumarate);. ;Zacopride; has been marketed or used in ;United States of America; under the trade or premarketing names of ;AHR 11.190;NM: AHR 11.190 A.H. Robins, USA;. ;Antiemetic agent. Highly selective 5-HT binding sites 3 antagonist (about 10-fold more potent than ondansetron). Nonspecific neuroleptic activity and potential anxiolytic effects anticipated. Clinical trials in anxiety and schizophrenia. Development apparently N H2 N C CH2 NH C OCH3 Cl NH2 H3C CH3 O discontinued at phase II clinical trials.;McNeish CS, Svingos AL, Hitzemann R, Strecker RE~The 5-HT3 antagonist zacopride attenuates cocaine-induced increases in extracellular dopamine in rat nucleus accumbens~Pharmacology, biochemistry, and behavior~1993~45(4)~759-63# Ansseau M, Pitchot W, Gonzalez Moreno A~Anxiolytic activity of single doses of the 5-HT3 antagonist zacopride~European Neuropsychopharmacology~1994~4(3)~355;McNeish CS, Svingos AL, Hitzemann R, Strecker RE: The 5-HT antagonist zacopride attenuates 3 cocaine-induced increases in extracellular dopamine in rat nucleus accumbens. Pharmacol Biochem Behav 45(4): 759-763, 1993 - Ansseau M, Pitchot W, Gonzalez Moreno A: Anxiolytic activity of single doses of the 5-HT antagonist zacopride. Eur Neuropsychopharmacol 4/3: 355 (abst P2-24), 1994 - Moreno 3 AG, Pitchot W, Ansseau M: Placebo-controlled study of the anxiolytic activity of a single dose of zacopride among in patients with generalized anxiety disorder. Eur Psychiatry 9 (suppl 1): 87S, 1994.;;;;;;;zacopride;;;
184;A.III.19 ;Prideperone;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;N-[2-(4-(p-fluorobenzoyl)piperidino)ethyl]-2-methoxy benzamide-5-carbonitrile;. ;Prideperone; has been marketed or used in ;Switzerland; under the trade or premarketing names of ;CGP 19.736 A;NM: CGP 19.736 A Novartis (Ciba-Geigy, CH);. ;Preliminary pharmacological investigations. According to animal studies potential neuroleptic compound. So far insufficient data.;Suppl to WHO Chronicle~Prideperone~~1985~39(4)~15;Prideperone. Suppl WHO Chronicle vol 39(4): 15, 1985.;;;;;;;prideperone;;;
185;A.III.19 ;Dazopride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;4-amino-5-chloro-N-(1,2-diethyl-4-pyrazolidinyl)-oanisamide Potential neuroleptic. Antiemetic properties. Studied in the management of gastrointestinal disturbances.;. ;Dazopride; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;;Costall B, Domeney AM, Gunning SJ, Kelly ME, Naylor RJ, Nohria V, et al.~The action of dazopride to enhance gastric emptying and block emesis~Neuropharmacology~1987~26(7A)~669-77;Costall B, Domeney AM, Gunning SJ, et al: The action of dazopride to enhance gastric emptying and block emesis. Neuropharmacology 26(7A): 669-677, 1987.;;;;;;;dazopride;;;
186;A.III.19 ;Iodosulpride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;N-[-1-cyclopropylmethyl-2-pyrrolidinyl) methyl]-5-ethyl sulfonyl-4-iodo-2-methoxybenzamide;. ;Iodosulpride; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Highly sensitive and selective ligand for dopamine D 2 receptors. Putative neuroleptic agent.;Sales N, Martres MP, Bouthenet ML, Schwartz JC~Ontogeny of dopaminergic D-2 receptors in the rat nervous system: characterization and detailed autoradiographic mapping with [125I]iodosulpride~Neuroscience~1989~28(3)~673-700#Rognan D, Sokoloff P, Mann A, Martres MP, Schwartz JC, Costentin J, et al.~Optically active benzamides as predictive tools for mapping the dopamine D2 receptor~European journal of pharmacology~1990~189(1)~59-70;Sales N, Martres MP, Bouthenet ML: Ontogeny of dopaminergic D receptors in the rat nervous system: characterization and 2 detailed autoradiographic mapping with [ I] iodosulpride. Neurosci 28: 673-700, 1989 - Rognan D, 125 Sokoloff P, Mann P, et al: Optically active benzamides as protective tools for mapping the dopamine D 2 receptor. Eur J Pharmacol. Mol Pharmacol Sect 189: 59-70, 1990.;;;;;;;iodosulpride;;;
187;A.III.19 ;Tiapride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;N-[2-(diethylamino)ethyl]-5-methylsulfonyl-o-anisamide HCl;. ;Tiapride; has been marketed or used in ;France, Switzerland, Belgium, Greece, Germany, Austria, ItalyPortugal, Spain; under the trade or premarketing names of ;Tiapridal, Tiapridex, Delpral, Equilium, Italprid, Luxoben, Normagit, Sereprile, Tiapride, Tiaprizal;NM: Tiapridal Synthélabo , F, CH, B - Delagrange GR, PORT- Lorex Synthélabo NL:tabs. 100mg - amps. 100mg/2ml NM: Tiapridex Synthelabo, BRD: tabs. 100mg - amps. 100mg/2ml NM: Delpral Byk, A: tabs. 100mg - amps. 100mg/2ml NM: Equilium Fumouze, F: tabs. 100mg - amps. 100mg/2ml NM: Italprid Teofarma, ITA: tabs. 100mg - amps.100mg/2ml NM: Luxoben Asta Medica, ITA: tabs. 100mg NM: Normagit Fidelis, PORT: sol. NM: Sereprile Synthelabo, ITA: tabs. 100mg - amps. 100mg/2ml NM: Tiapride Panpharma, F - Delagrange, ESP: same as Tiapridal NM: Tiaprizal Delagrange, ESP: tabs. 100mg - amps.100mg/2ml - sol.12mg/ml (=24drops);. ;Dopamine D antagonist. Promoted as 'visceral neuromodulator'. Reports on the treatment of 2 alcoholism, chorea, pain conditions, parkinsonism, nausea, mood disturbances and tardive dyskinesia. Studied in the management of cognitive dysfunction in the elderly. Significant analgesic effects. Elimination half-life 3 to 4 hours.;Bukatina E, Grigoriyeva I, Smirnov O~Tiapride with senile psychoses. The effect on negative symptoms of schizophrenia~European Neuropsychopharmacology~1994~4(3)~389# Peters DH, Faulds D~Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome~Drugs~1994~47(6)~1010-32# Shaw GK, Waller S, Majumdar SK, Alberts JL, Latham CJ, Dunn G~Tiapride in the prevention of relapse in recently detoxified alcoholics~The British journal of psychiatry : the journal of mental science~1994~165(4)~515-23;Bukatina EE, Grigoriyeva IV, Smirnov OR: Tiapride with senile psychosis. The effect on negative symptoms of schizophrenia. Neuropsychopharmacology 4/3: 390 (abst P-3-33), 1994 - Peters DH, Faulds D: Tiapride: A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 47/6: 1010-1032, 1994 - Shaw GK, Waller S, Majumdar Sk & al: Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 165/OCT: 515-523, 1994.;;;;;;;tiapride;;;
188;A.III.19 ;Mosapride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;4-amino-5-chloro-2-ethoxy-H-[[4-(p-fluorobenzyl)-2- morpholinyl]methyl] benzamide;. ;Mosapride; has been marketed or used in ;Japan; under the trade or premarketing names of ;AS 4370;NM: AS 4370 (Dainippon, JPN);. ;Pharmacological studies suggest potent gastrokinetic activity without dopamine D receptor antagonist effects. 5-HT agonist. 2 4 Steady state after 2 days of multiple administration.;Sakashita M, Yamaguchi T, Miyazaki H, Sekine Y, Nomiyama T, Tanaka S, et al.~Pharmacokinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects~Arzneimittel-Forschung~1993~43(8)~867-72#Sakashita M, Mizuki Y, Hashizume T, Yamaguchi T, Miyazaki H, Sekine Y~Pharmacokinetics of the gastrokinetic agent mosapride citrate after intravenous and oral administrations in rats~Arzneimittel-Forschung~1993~43(8)~859-63;Sakashita M, Yamaguchi T, Miyazaki H & al: Pharmacokinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administration in healthy subjects. Arzneim Forsch 43(8): 867-872, 1993 - Sakashita M, Mizuki Y, Hashizume T & al: Pharmacokinetics of the gastrokinetic agent masopride citrate after intravenous and oral administrations in rats. Arzneim Forsch 43(8): 859-863, 1993.;;;;;;;mosapride;;;
189;A.III.19 ;Batanopride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;(±)-4-amino-5-chloro-N-[2-(diethylamino) ethyl]-2-[(1- methylacetonyl)oxy]benzamide;. ;Batanopride; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Antiemetic agent. No psychotropic properties reported. Development apparently discontinued.;WHO Drug Information~~~1989~3(2)~88# King GL, Landauer MR~Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret~The Journal of pharmacology and experimental therapeutics~1990~253(3)~1026-33;WHO Drug Information 3(2): 88, 1989 - King GL, Landauer MR: Effects of zacopride and BMY 25801 (batanopride) on radiationinduced emesis and locomotor behavior in the ferret. J Pharmacol Exp Ther 253: 1026-1033, 1990.;;;;;;;batanopride (BMY 25.801);;;
190;A.III.19 ;LY 104.119;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;[R-(R,S)]-4-[3-[(2-hydroxy-2-phenylethyl)amino]butyl] benzamide HCl;. ;LY 104.119; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Weight-reducing agent, increasing heath production according to animal studies. Reported to be a -agonist. Stimulates AMP concentrations in adipose tissue and enhances lipolysis. Preliminary studies.;Yen TT, Fuller RW, Hemrick-Luecke SK, Dininger NB~Effects of LY104119, a thermogenic weight-reducing compound, on norepinephrine concentrations and turnover in obese and lean mice~International journal of obesity~1988~12(1)~59-67;Yen TT, Fuller RW, Hemrick-Luecke SK, et al: Effects of LY 104119, a thermogenic weight-reducing compound, on norepinephrine concentrations and turnover in obese and leane mice. Int J Obesity 12: 59-67, 1988.;;;;;;;LY 104.119;;;
191;A.III.19 ;Bromopride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide;. ;Bromopride; has been marketed or used in ;Germany, Italy, Spain; under the trade or premarketing names of ;Viaben, Cascapride, Plesium, Valopride, Opridan;NM: Viaben Schürholz, BRD: amps. 10mg/2ml - caps. 10mg - drops 12mg/ml (1gt ½ mg) (range deleted) NM: Cascapride Merck, BRD: caps. 10mg NM: Plesium Chiesi, ITA: caps. 10mg - amps. 10mg/2ml NM: Valopride Delagrange, ESP (deleted) - Synthelabo, ITA: caps. 10mg - amps. 10mg/2ml NM: Opridan Locatelli, ITA: f-c tabs.60mg - sol.60mg/10ml;. ;Used in the treatment of gastrointestinal disturbances. Insignificant neuroleptic-like properties. Terminal plasma half-life about 2.6 hours.;Nasello AG, Vanzeler ML, Felicio LF~A comparison of bromopride and domperidone effects on rat conditioned avoidance and motor activity~Pharmacology & toxicology~1991~68(1)~46-50;Nasello AG, Felicio LF: Avoidance behavior, prolactin, HVA, and DOPAC in offspring of bromoprid-treated rats. Pharmacol Biochem Behav 37: 571-575, 1990 -Nasello AG, Vanzeler MLA, Felicio LF, et al: A comparison of bromopride and domperidone effects on rat conditioned avoidance and motor activity. Pharmacol Toxicol 68: 46-50, 1991.;;;;;;;bromopride;;;
192;A.III.19 ;Cisapride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;(cis)-4-amino-5-chloro-N-[1-[3-(p-fluorophenoxy)propyl]-3- methoxy-4-piperidyl]-o-anisamide;. ;Cisapride; has been marketed or used in ;Belgium, France, Austria, Sweden, Switzerland, Netherlands, Norway, Denmark, United Kingdom, Finland, Italy, Germany, Spain; under the trade or premarketing names of ;Prepulsid, Alimix, Arcasin, Cipril, Cyprid, Fisiogastrol, Kelosal, Propulsin, Pulsitil, Trautil;NM: Prepulsid Janssen Cilag, B, F, A, SWE, CH - Janssen NL, NOR, DK, UK, FIN: tabs. 5mg (not in B, DK, UK, SWE), 10mg, 20mg (not in UK) - mixt./susp. 1mg/ml (not in UK, DK) - (in B, FIN also suppos. 30mg) - Janssen Cilag, ITA: tabs.10mg - efferv.tabs 10mg - susp. 0.1 % NM: Alimix S.K.B., BRD: tabs. 5mg, 10mg - susp.1mg/ml NM: Alimix Janssen, UK: tabs. 10mg NM: Alimix Cilag Farmaceutica, ITA: tabs.10mg - efferv.tabs. 10mg - susp.0.1 % NM: Arcasin Esteve, ESP: tabs.5mg, 10mg - susp.1mg/ml - powders 10mg NM: Cipril Fisons Italchemici, ITA: tabs.10mg - efferv.tabs. 10mg - susp.0.1 % NM: Cyprid Janssen Cilag, B: tabs.5mg - drops 1mg/ml NM: Fisiogastrol S.A.L.V.A.T, ESP: tabs.5mg, 10mg - susp.1mg/ml NM: Kelosal Kendall, ESP: tabs.5mg, 10mg - susp.1mg/ml NM: Propulsin Janssen, BRD: tabs. 5mg, 10mg - susp.1mg/ml NM: Pulsitil Janssen Cilag, A: tabs. 5mg, 10mg - susp.1mg/ml NM: Trautil C.E.P.A, ESP: tabs.5mg, 10mg - susp.1mg/ml;. ;ACR stimulator. No antidopaminergic action. Stimulates gastrointestinal motility. Studied in the treatment of functional constipation. Trials in the management of cystic fibrosis. Terminal plasma half-life about 10 hours.;Stacher G, Bergmann H, Gaupmann G, Schneider C, Kugi A, Hobart J, et al.~Fat preload delays gastric emptying: reversal by cisapride~British journal of clinical pharmacology~1990~30(6)~839-45# Fumagalli I, Hammer B~Cisapride versus metoclopramide in the treatment of functional dyspepsia. A double-blind comparative trial~Scandinavian journal of gastroenterology~1994~29(1)~33-7#Diaz Neira W, Sanchez Bernados V, Mena MA, Garcia de Yebenes J~Effects of cisapride on plasma L-dopa levels and clinical response to Parkinson's disease~Arch Neurobiol (Madrid)~1994~57(1)~26;Stacher G, Bergmann H, Gaupmann G, et al: Fat preload delays gastric emptying: reversal by cisapride. Br J Clin Pharmacol 30: 839-845, 1990 - Fumagalli I, Hammer B: Cisapride versus metoclopramide in the treatment of functional dyspepsia. A double-blind comparative trial. Scand J Gastroenterol 29(1): 33-37, 1994 - Diaz Neira W, Sanchez Bernados V, Mena M A, Garcia de Yebenes J: Effects of cisapride on plasma L-dopa levels and clinical response to Parkinson's disease. Arch Neurobiol (Madrid) 57(1): 26, 1994.;;;;;;;cisapride;;;
193;A.III.19 ;Renzapride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;(±)-(endo)-4-amino-5-chloro-2-methoxy-N-(1-azabicyclo [3.3.1]non-4-yl)benzamide (hydrochloride);. ;Renzapride; has been marketed or used in ;United Kingdom; under the trade or premarketing names of ;BRL 24.924;NM: BRL 24.924 SmithKline Beecham, UK;. ;Low affinity for dopamine receptors and only minor CNS effects. 5-HT receptor antagonist and 5-HT receptor agonist. 3 4 Potent gastrokinetic action reported. Antiemetic properties.;Karasawa T, Yoshida N, Furukawa K, Omoya H, Ito T~Comparison of gastrokinetic effects of AS-4370, cisapride and BRL24924~European journal of pharmacology~1990~183(6)~2181# Sanger GJ~New antiemetic drugs~Canadian journal of physiology and pharmacology~1990~68(2)~314-24#Steward L, Barnes N~The 5-HT  4 receptor agonists renzapride and (S)-zacopride stimulate dopamine release from rat striatal slices~British journal of pharmacology~1994~111(155P-P)~;Karasawa T, Yoshida N, Furukawa K, et al: Comparison of gastrokinetic effects of AS-4370, cisapride and BRL 24924. Abstr XI Int Congr Pharm. Eur J Pharmacol 183: 2181, 1990 - Sanger GJ: New antiemetic drugs. Can J Physiol Pharmacol 68: 314-324, 1990 - Steward LJ, Barnes NH: The 5-HT receptor 4 agonists renzapride and (S)-zacopride stimulate dopamine release from rat striatal slices. Br J Pharmacol 111 (suppl): 155P, 1994. Abstr.;;;;;;;renzapride;;;
194;A.III.19 ;Alizapride;is in the ;benzamides (o-anisamide); category of antipsychotic.;It has a;;;;full chemical formula of ;N-[(1-allyl-2-pyrrolidinyl)methyl]-6-methoxy-1H-benzotriazole- 5-carboxamide;. ;Alizapride; has been marketed or used in ;Belgium, Spain, Netherlands, Greece, Italy, France, Switzerland, Germany; under the trade or premarketing names of ;Litican, Lyostene, Limican, Nausilen, PliticanLitican Vergentan;NM: Litican Synthélabo, B, ESP (deleted) - Lorex, NL: tabs. 50mg - amps. 50mg/2ml - drops 12mg/ml NM: Lyostene Niadas, GR: tabs. 50mg - drops - amps. 50mg/2ml - suppos. 20mg, 50mg NM: Limican Synthelabo, ITA: tabs. 50mg - amps. 50mg/2ml NM: Nausilen Baldacci, ITA: tabs. 55.8mg - drops 1.34 % - amps. 55.8mg/2ml - suppos.55.8mg NM: Plitican Synthélabo, F, CH: same presentations as Litican NM: Vergentan Synthelabo, BRD: tabs. 50mg - amps. 50mg/2ml;. ;Used in the treatment of nausea and vomiting. Dosage 50 to 100 mg tdd. May induce minor neuroleptic-like effects. At high dosage sedation, orthostatic hypotension and hyperprolactinemie reported. Elimination half-life approx. 3 hours.;BEAUFFIGEAU A, RAUD Y~Nouvelles indications de l'alizapride (Plitican) dans le domaine cardiovasculaire~La Semaine des hôpitaux de Paris~1985~61(44)~3111-3#Joss RA, Galeazzi RL, Bischoff AK, Pirovino M, Ryssel HJ, Brunner KW~The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomizle-blind trial~Clinical pharmacology and therapeutics~1986~39(6)~619-24 ;Beauffigeau A, Raud Y: Nouvelles indications de l'alizapride (Plitican) dans le domaine cardiovasculaire. Sem Hop 61: 3111-3113, 1985 - Joss RA, Galeazzi RL, Bischoff AK, et al: The antiemetic activity of highdose alizapride and highdose meticlopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. Clin Pharmacol Ther 39: 619-624, 1986.;;;;;;;alizapride;;;
195;A.III.2 0a ;Timelotem;is in the ;benzodiazepine; category of antipsychotic.;It has a;;;;full chemical formula of ;(±)-10-fluoro-1,2,3,4,4a,5-hexahydro-3-methyl-7-(2- thienyl)pyrazino[1,2-a][1,4]benzodiazepine;. ;Timelotem; has been marketed or used in ;Germany; under the trade or premarketing names of ;KC 7507;NM: KC 7507 Kali-Chemie/Solvay, BRD;. ;Tricyclic benzodiazepine, almost devoid of typical tranquilizer properties. Lack of binding to benzodiazepine receptors/ absence of muscle relaxing and anticonvulsant effects. Pharmacological profile of an antipsychotic compound with neuroleptic-like side effects.;Ruhland M, Tulp M, Muesch H, Fuchs A~Timelotem-an Antipsychotic Benzodiazepine Derivative~Pharmacopsychiatry~1986~19(04)~218-9#;Ruhland M, Tulp M, Muesch HR, et al: Timelotem - an antipsychotic benzodiazepine. Pharmacopsychiatry 19: 218-219, 1986 - Ruhland M, Fuchs AM: Lack of antagonism by Ro 15-1788 on timelotem (KC 7507) - a benzodiazepine with antipsychotic and anxiolytic properties. Pharmacopsychiatry 19: 216-217, 1986. N O2N HO O CH3;;;;;;;timelotem;;;
196;A.III.2 0a ;Pentiapine;is in the ;benzodiazepine; category of antipsychotic.;It has a;;;;full chemical formula of ;5-(4-methylpiperazinyl)imidazo[2,1-b][1,3,5] benzthiadiazepine;. ;Pentiapine; has been marketed or used in ;Switzerland; under the trade or premarketing names of ;CGS 10.746;NM: CGS 10.746 Ciba-Geigy, CH;. ;Benzothiadiazepine derivative with neuroleptic-like pharmacological profile. Atypical antipsychotic properties. Decreases DA release. Effective anti-conflict agent.;Altar CA, Boyar WC, Wasley A, Gerhardt SC, Liebman JM, Wood PL~Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists~Naunyn-Schmiedeberg's archives of pharmacology~1988~338(2)~162-8#Schechter MD, Boja JW~CGS 10746B is able to attenuate the effects of amphetamine: further evidence for dopaminergic mediation~Pharmacology, biochemistry, and behavior~1988~30(4)~1089-92;Altar CA, Boyar WC, Wasley A, et al: Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists. Naun Schmied Arch Pharmacol 338: 162-168, 1988 - Schechter MD, Boja JW: CGS 10746 B is able to attenuate the effects of amphetamine: further evidence for dopaminergic mediation. Pharmacol Biochem Behav 30: 1089-1092, 1988.;;;;;;;pentiapine;;;
197;A.III.2 0a ;KC 5944;is in the ;benzodiazepine; category of antipsychotic.;It has a;;;;full chemical formula of ;1,2,3,4,4a,5-hexahydro-3-methyl-7(2-thienyl) pyrazino[1,2-a] [1,4]benzodiazepine;. ;KC 5944; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Tricyclic benzodiazepine-type psychotropic. Does not bind to BDZ receptors. Pharmacological profile similar to that of neuroleptics. Antiaggressive properties at high doses.;Ruhland M, Liepmann H, Muesch HR~1.2-Anellated 1.4-benzodiazepine derivatives--a new class of antipsychotics~Pharmacopsychiatry~1985~18(1)~174-7;Ruhland M, Liepmann H, Muesch HR, et al: 1,2 Anellated 1,4- benzodiazepine derivatives - a new class of antipsychotics. Pharmacopsychiatry 18: 174-177, 1985.;;;;;;;KC 5944;;;
198;A.III.2 0a ;NNC 687;is in the ;benzodiazepine; category of antipsychotic.;It has a;;;;full chemical formula of ;8-nitro-7-hydroxy-3-methyl-5(7-(2,3-dihydrobenzofuranyl))- 2,3,4,5-tetrahydro-1H-3-benzapine;. ;NNC 687; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;D /D antagonist. Potential antipsychotic, anxiolytic and 1 2 antidepressant. T½ in healthy volunteers: 3-6 hrs. Discontinued at phase II clinical trials level.;Sloth-Nielsen M, Christensen JV, Ynddal L, Skrumsager BK~Phase I clinical trials of dopamine D 1 receptor antagonists~Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology~1994~10(236)S~# Skrumsager BK, Christensen JV, Snel S, Seiberling M~Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects~Psychopharmacology~1995~121(3)~294-9;Sloth-Nielsen M, Christensen JV, Ynddal L, Skrumsager BK: Phase I clinical trials of dopamine D 1 receptor antagonists. Neuropsychopharmacology 10 (n° 3S, part 1): 236S (abst. S-44-204), 1994 - Karle J, Gerlach J, Clemmensen L & al: NNC 010687, a selective dopamine D antagonist, in the treatment of 1 schizophrenia. A phase II clinical trial. Eur Neuropsychopharmacology 5/3: 337 (abstr P-4-33), 1995 - Skrumsager BK, Christenen JV, Snel S, Seiberling M: Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the D antagonist NNC 01-0687 in healthy subjects. Psychopharmacology 1 121: 294-299, 1995. N Cl HO CH3;;;;;;;NNC 687 (NO 687, NNC01-0687 );;;
199;A.III.2 0.b ;NNC-22-0010;is in the ;benzazepine; category of antipsychotic.;It has a;;;;full chemical formula of ;(R)-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3- benzazepin-7-ol;. ;NNC-22-0010; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Dopamine D receptor antagonist. Potential antipsychotic agent, 1 not fitting into established categories of psychotropics. Nearly same affinity for D and D receptors. Highly selective and very 1 3 potent dopamine D receptor antagonist. Comparative studies 1 against D antagonists in schizophrenia. Development apparently 2 discontinued.;"Meshul CK, Janowsky A, Casey DE, Stallbaumer RK, Taylor B~Coadministration of haloperidol and SCH-23390 prevents the increase in ""perforated"" synapses due to either drug alone~Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology~1992~7(4)~285-93#Ozaki T, Yokotani N, Katsumoto E, Onishi H, Yamagami S~The difference among effects of haloperidol,(?)-sulpiride and SCH23390 on the expression of< i> c-fos</i> and< i> c-jun</i> mRNA inductions~European Neuropsychopharmacology~1994~4(3)~365#Salmi P, Svensson T, Ahlenius S~P-4-19 d-Amphetamine-induced abnormal behavior in the rat antagonized by SCH 23390 or raclopride~European Neuropsychopharmacology~1995~5(3)~332-3";Meshul CK, Lanowsky A, Casey DE, & al: Coadministration of haloperidol and SCH-23390 prevents the increase in 'perforated' synapses due to either drug alone. Neuropsychopharmacology 7/4: 285-293, 1992 - Ozaki T, Yokotani N, Katsumoto E & al: The difference amongst effects of haloperidol, (-)sulpiride and SCH 23390 on the expression of c-fos and c-jun m RNA induction. Eur Neuropsychopharmacol 4/3: 365 (Abstr P-3-2), 1994 - Salmi P, Svensson TH, Ahlenius S: d-Amphetamine-induced abnormal behavior in rat antagonized by SCH 23390 or raclopride. Eur Neuropsychopharmacol 5/3: 332-333 (abstr P-4-19), 1995.;;;;;;;NNC-22-0010 (SCH 23.390);;;
200;A.III.2 0.b ;SCH 39.166;is in the ;benzazepine; category of antipsychotic.;It has a;;;;full chemical formula of ;6aS-trans-11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5Hbenzo[ d]napht[2,1-b]azepin-12-ol;. ;SCH 39.166; has been marketed or used in ;; under the trade or premarketing names of ;;;. ;Selective and potent dopamine D receptor antagonist. Potential 1 antipsychotic. Few side-effects anticipated. Longer acting in animal experiences than previously available D antagonists. Phase II 1 clinical trials. Further development apparently discontinued.;Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A~Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity~The Journal of pharmacology and experimental therapeutics~1988~247(3)~1093-102#de Beaurepaire R, Labelle A, Naber D, Jones BD, Barnes TR~An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states~Psychopharmacology~1995~121(3)~323-7;Chipkin RE, Iorio LC, Coffin VL, & al: Pharmacological profile of SCH 39.166: A dopamine D selective 1 benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247: 1093-1102, 1988 - Karlsson P, Smith L, Farde L, & al: Lack of apparent antipsychotic effect of the dopamine D receptor 1 antagonist SCH 39166 in schizophrenia. Neuropsychopharmacology vol 10 (n°35, part 2): 325 (abs O-85- 124), 1994 - de Beaurepair R, Labelle A, Nader D & al: An open trial of the D antagonist SCH 39166 1 in six cases of acute psychotic states. Psychopharmacology 121: 323-327, 1995.;;;;;;;SCH 39.166;;;
;A.III.2 0.b ;Receptor-binding profiles of recent antipsychotic;;benzazepine;;;;;;;;;Receptor-binding profiles of recent antipsychotic;;;;;;;;; ;;;;;;;Receptor-binding profiles of recent antipsychotic;;;
;;sulpiride/ amisulpride;;;;;;;;;;;sulpiride/ amisulpride;;;;;;;;;;;;;;;;sulpiride/ amisulpride;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;risperidone;;;;;;;;;;;risperidone;;;;;;;;;;;;;;;;risperidone (sertindole, ziprasid (o (n (e () () () () () () () () () ()))));;;e
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;clozapine;;;;;;;;;;;clozapine;;;;;;;;RF: Ref.: Gerlach J, Peacock L: New antipsychotics: The present status. Int Clin Psychopharmacol 10 (suppl 3): 39-48, 1995.;Gerlach J, Peacock L: New antipsychotics: The present status. Int Clin Psychopharmacol 10 (suppl 3): 39-48, 1995.;;;;;;;clozapine;;;
;;quetiapine;;;;;;;;;;;quetiapine;;;;;;;;;;;;;;;;quetiapine;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
ID_Con;Name;Sub Heading 1;Text 1;Sub Heading 2;Text 2;Sub Heading 3;Text 3;Sub Heading 4;Text 4;;;;;;;;;;;;;;;;;;;;;;;
1;Schizophrenia;;Schizophrenia is a severe form of mental illness characterised by positive symptoms such as delusions (fixed, false beliefs out of keeping with the person’s background) and hallucinations (perceptions without a cause)/ negative symptoms such as social withdrawal, loss of motivation and an inability to experience pleasure/ and abnormalities in cognition. These symptoms lead to significant social and occupational dysfunction and the majority of sufferers also experience a lack of insight, believing that they do not have a disorder that warrants treatment (Tandon 2009). People with schizophrenia also have a significantly reduced life expectancy compared with the general population (Tiihonen 2009), due to unnatural deaths (i.e. suicide and accidents) and physical disorders (i.e. heart disease, endocrine diseases, respiratory disease and infectious diseases) (Saha 2007). The onset of schizophrenia tends to be in adolescence or early adulthood. One meta-analysis reported the median (10% to 90% quantile) incidence of schizophrenia to be 15.2/100,000 population with a greater distribution in males compared with females/ the male/female rate ratio median (10% to 90% quantile) was 1.40 (95% CI 0.9 to 2.4) (McGrath 2004).;;The lifetime prevalence of schizophrenia is relatively high - at 7.2/1000 population - because it usually starts in early adult life and is a chronic disease (Saha 2005). In the Global Burden of Disease Study 2010, mental illness and behavioural disorders accounted for 7.4% of all DALYs (Disability Adjusted Life Years), and were attributable to more than 15 million DALYs each/ schizophrenia ranked as fifth under this category (accounting for 0.6%) after depression, anxiety, drug-use and alcohol-use disorders (Murray 2012). Medication is the mainstay of treatment for schizophrenia/ however, 5% to 15% of people continue to experience symptoms in spite of medication and may also develop undesirable adverse effects (Johnstone 1998) - improved quality of life is then particularly important for these individuals.;;;;;;;;;;;;;;;;;;;;;;;;;;;
2;Tardive dyskinesia;;Dyskinesia is a movement disorder characterised by involuntary, repetitive body movements that can be tardive (having a slow or belated onset). Tardive dyskinesia is characterized by repetitive, involuntary, purposeless movements, such as grimacing, tongue protrusion, lip smacking, puckering and pursing of the lips, and rapid eye blinking. Rapid movements of the extremities and impaired movements of the fingers may also occur. Tardive dyskinesia tends to be a chronic condition of insidious onset, the severity of which spontaneously fluctuates (APA 1992). Orofacial dyskinesia and trunk and limb dyskinesia may have different responses to treatment (APA 1992/ Jeste 1982).;;Tardive dyskinesia is often seen as a side effect of long-term or high-dose use of neuroleptic drugs. Within the first four years of using neuroleptic drugs, 18.5% of young adults and 31% of those over 55 years of age develop tardive dyskinesia (Saltz 1991). It has been estimated that with each year of neuroleptic use, 5% of the patients will show signs of tardive dyskinesia, i.e., 5% after one year, 10% after two years, 15% after three years with no clear upper limit (Jeste 1993). The incidence of tardive dyskinesia varies with the type of neuroleptic drug. However, among newer atypical antipsychotics, only clozapine has been shown to have a lower risk of tardive dyskinesia than older antipsychotics (Rauchverger 2007/ Fernandez 2003). Tardive dyskinesia may persist after withdrawal of the drug for months, years or even permanently, and it can result in considerable social and physical disability (Barnes 1993).;;;;;;;;;;;;;;;;;;;;;;;;;;;
3;Akathisia;;"Shortly after the introduction of antipsychotic drugs, akathisia was recognised as one of the most common and distressing early-onset adverse effects. This movement disorder is characterised by a subjective report of inner restlessness, mental unease, or dysphoria, which can be intense (Marder 1991, Halstead 1994). Associated with this experience are patterns of restless movement, including rocking from foot to foot and walking on the spot when standing, and shuffling and tramping the legs, rocking back and forth, or swinging one leg on the other when sitting (Braude 1983). In severe cases, people constantly pace up and down in an attempt to relieve the sense of unrest.
Estimates of the prevalence of akathisia in neuroleptic-treated people ranges between 20% and 75%, occurring more frequently in the first three months of treatment (Ayd 1961, Grebb 1995). It is usually related not only to acute administration of a neuroleptic, but also to a rapid dosage increase (Barnes 1992). Akathisia may be difficult to distinguish from psychotic agitation or anxiety, especially if the person describes a subjective experience of akathisia in terms of being controlled by an outside force (Grebb 1995). If the akathisia is mistaken for psychosis, the antipsychotic drug dose may be increased leading to a worsening of the condition.
";Technical background ;While the pathophysiology of neuroleptic-induced acute akathisia remains unknown, antagonism of mesocortical and mesolimbic dopaminergic pathways is a plausible if not completely satisfactory hypothesis. The notion that dopaminergic blockade underlies the emergence of akathisia is supported by the PET studies of Farde and co-investigators (Farde 1992). In one study these investigators examined striatal dopamine D2 receptor occupancy in patients who had responded to antipsychotic medication. In those who exhibited extrapyramidal side-effects (parkinsonism or akathisia) the D2 receptor occupancy ranged from 77-89%, while the range for those without such symptoms was 74-80%. These findings link D2 occupancy to extrapyramidal side effects.;;;;;;;;;;;;;;;;;;;;;;;;;;;
4;Parkinsonism;;"Extrapyramidal side effects (EPSE) can be divided into acute and chronic. Acute EPSE include the dystonias, parkinsonism and akathisia, and those classified as chronic are tardive dyskinesia and tardive dystonia (APA 2006).
Parkinsonism is a group of symptoms which resemble idiopathic Parkinson’s disease/ the commonly observed symptoms include tremor, bradykinesia (slow movement), rigidity (limb stiffness), mask-like face and postural instability. The less frequently observed symptoms include festinant (an involuntary tendency to take short accelerating steps when walking), hurrying gait, 3-5Hz resting tremor, micrographia (reduction in size of handwriting) and rhythmic disturbance of handwriting (Gervin 2000). These effects, cause distress by affecting physical and social functioning. They usually emerge within a few days or weeks after starting antipsychotic treatment or a dose increase.
";;"There are a number of scales for measuring EPSE generally, which include items for parkinsonism. These scales include the Extrapyramidal Symptom Rating Scale (Chouinard 1980), the Targeting Abnormal Kinetic Effects Scale (Wojcik 1980), the Extrapyramidal Symptoms Scale and the Simpson-Angus Scale (Simpson 1970). The Simpson-Angus Scale is the most widely used and was devised to measure drug-induced parkinsonism.
Although parkinsonism is frequently seen in clinical life, the incidence from well-conducted surveys is less clear and varies up to 40% (Gervin 2000) dependent on the type and dose of antipsychotic medication. Recent research has shown that there is no difference in the incidence of EPSE between people treated with atypical and typical antipsychotics (Miller 2008). Risk factors for developing parkinsonism are female gender, older age, non-smoker, dose duration and type of treatment, cognitive impairment, acquired immunodeficiency syndrome (AIDS), tardive dyskinesia and pre-existing movement disorder (Thanvi 2009).
Parkinsonism is associated with potent D2 receptor antagonists/ more than 80% dopamine D2 receptor occupancy is consistent with drug-induced parkinsonism (Hirose 2006). Newer generation antipsychotics are also associated with drug-induced parkinsonism (Peluso 2012).";;;;;;;;;;;;;;;;;;;;;;;;;;;
5;Aggression;;Acutely psychotic people may exhibit agitated and aggressive behaviour which can present a danger to themselves or others. In order to ensure a safe and therapeutic environment, de-escalation techniques should be used to calm the patient (NICE 2005/ Rocca 2006). Frequently, however, the behaviour may be too disturbed or agitated for these methods to be effective, and it might prove imperative that further action in the form of rapid tranquillisation is given (NICE 2005/ Rocca 2006). The aim of rapid tranquillisation is to achieve a state of calm which is sufficient to minimise risk of harm to the agitated person themselves, or to others around them, and allow treatment of the underlying condition (Battaglia 2005/ NICE 2005). Rapid tranquillisation may serve as primary therapy in such instances but may also be used in conjunction with other de-escalation methods (Marder 2006/ NICE 2005).;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
6;serious mental illness;;The definition of severe mental illness (SMI) with the widest consensus is from the National Institute of Mental Health (NIMH 1987). It is based on three criteria: i) diagnosis of functional psychosis/ ii) duration – which includes prolonged illness and long-term treatment and operationalised over at least two years/ and iii) disability (NIMH 1987). The prevalence of SMI in the population based on a European survey is estimated at two per thousand (Ruggeri 2000). ;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
7;Amenorrhoea;Amenorrhoea-definition, types and symptoms:;"Amenorrhoea (uh-men-o-REE-uh) is the absence of menstruation, i.e., one or more missed menstrual periods. Women who have missed at least three menstrual periods in a row have amenorrhoea as do girls who haven't begun menstruation by the age of 16. These cases are categorized as primary amenorrhea.
Secondary amenorrhoea occurs when a woman who has been having normal menstrual cycles stops getting her periods for six or more months. Women who are pregnant, breastfeeding, or in menopause are not considered to have secondary amenorrhea. These conditions are very common and are considered as physiological causes of amenorrhea. The true secondary causes of amenorrhoea include problems with the reproductive organs or with the glands that help regulate hormone levels. Amenorrhoea as a pathological state is a symptom with multiple possible aetiologies.
";Prolactin physiology and regulation;"Prolactin is secreted in a pulsatile manner by the anterior pituitary gland. There are 13 or 14 peaks per day, with an inter-pulse interval of about 95 minutes. The upper limit of unstipulated prolactine levels in men and women varies between laboratories, ranging from 350 mU/l to 550 m U/l (Veldhuis 1988). Hypothalamic dopamine is the predominant prolactin-inhibiting factor. Released into the portal hypophyseal circulation it binds to D2 receptors on lactotroph cells. Stimulation of D2 receptors has inhibitory effects on prolactin gene transcription, synthesis and release.
Serotonin (5-HT) has a stimulatory role in prolactin regulation mediated through 5-HT1A and 5-HT2 receptors. Oestrogens can modulate prolactin secretion by inhibiting hypothalamic dopamine synthesis, reducing the number of pituitary D2 receptors, enhancing prolactin gene transcription and synthesis.
The hyperprolactaemia can be clinically manifested as amenorrhea, cessation of normal cyclic ovarian function in female and hypospermatogenesis in male (Petty 1999)
";Literature on hyperprolactaemia and its secondary complication;Women with pituitary adenoma and hyperprolactinaemia had 17% decrease in cortical bone and 25% in trabecular bone (Klibanski 1980/ Cann 1984/ Koppelman 1984). In men hyperprolactinaemia resulting from prolactin-secreting pituitary tumours also cause hypogonadism and osteoporosis. Greenspan 1986 demonstrated significant loss of BMD in forearm and vertebrae in men with hyperprolactinaemia. ;Antipsychotic-induced hyperprolactinaemia;"All conventional antipsychotic drugs cause dose dependent blockade of D2 receptors on lactotroph cells removing the main inhibitory influence on prolactin level and cause hyperprolactinaemia. This is defined as a level above the upper limit of normal (>24.20 ng/ml for females and >18.77 ng/ml for males). Elevation of prolactin levels occurs within a few hours of treatment initiation and persists with long term treatment (Smith 2002). Women have significantly greater prolactin elevations than men during chronic antipsychotic treatment with equivalent doses (Wode-Helgodt 1977/ Kuruvilla 1992/ Smith 2002).
When oral antipsychotic therapy is discontinued, baseline prolactin levels may take up to three weeks to return to the normal range depending on the half-life of the drug and its metabolites as well as storage in fatty tissues (Turkington 1972). In the case of depot medication, normalization may take as long as 4-6 months (Wistedt 1981).
Psychotropic drugs have been associated with menstrual dysfunction (Wieck 2003/ Kinon 2003). Within the prevalence of antipsychotic-induced amenorrhoea , well conducted studies of women treated with conventional antipsychotics have reported prevalence rates of approximately 45% for oligomenorrhoea/amenorrhoea and 19% for galactorrhoea. An illness-related under-function of the hypothalamic-pituitary-gonadal axis in female patients with schizophrenia may also contribute to menstrual irregularities. Also, there is evidence in literature to show that baseline menstrual problems get worsened and that galactorrhoea or gynecomastia gets manifested only after exposure to antipsychotic medication (Kohen 2008). In an extensive study conducted in India, the prevalence of amenorrhoea in female on risperidone was found to be 60% (Ravan 2009/ Paul 2013).
";;;;;;;;;;;;;;;;;;;;;;;
8;Amenorrhea;Amenorrhoea-definition, types and symptoms:;"Amenorrhoea (uh-men-o-REE-uh) is the absence of menstruation, i.e., one or more missed menstrual periods. Women who have missed at least three menstrual periods in a row have amenorrhoea as do girls who haven't begun menstruation by the age of 16. These cases are categorized as primary amenorrhea.
Secondary amenorrhoea occurs when a woman who has been having normal menstrual cycles stops getting her periods for six or more months. Women who are pregnant, breastfeeding, or in menopause are not considered to have secondary amenorrhea. These conditions are very common and are considered as physiological causes of amenorrhea. The true secondary causes of amenorrhoea include problems with the reproductive organs or with the glands that help regulate hormone levels. Amenorrhoea as a pathological state is a symptom with multiple possible aetiologies.
";Prolactin physiology and regulation;"Prolactin is secreted in a pulsatile manner by the anterior pituitary gland. There are 13 or 14 peaks per day, with an inter-pulse interval of about 95 minutes. The upper limit of unstipulated prolactine levels in men and women varies between laboratories, ranging from 350 mU/l to 550 m U/l (Veldhuis 1988). Hypothalamic dopamine is the predominant prolactin-inhibiting factor. Released into the portal hypophyseal circulation it binds to D2 receptors on lactotroph cells. Stimulation of D2 receptors has inhibitory effects on prolactin gene transcription, synthesis and release.
Serotonin (5-HT) has a stimulatory role in prolactin regulation mediated through 5-HT1A and 5-HT2 receptors. Oestrogens can modulate prolactin secretion by inhibiting hypothalamic dopamine synthesis, reducing the number of pituitary D2 receptors, enhancing prolactin gene transcription and synthesis.
The hyperprolactaemia can be clinically manifested as amenorrhea, cessation of normal cyclic ovarian function in female and hypospermatogenesis in male (Petty 1999)
";Literature on hyperprolactaemia and its secondary complication;Women with pituitary adenoma and hyperprolactinaemia had 17% decrease in cortical bone and 25% in trabecular bone (Klibanski 1980/ Cann 1984/ Koppelman 1984). In men hyperprolactinaemia resulting from prolactin-secreting pituitary tumours also cause hypogonadism and osteoporosis. Greenspan 1986 demonstrated significant loss of BMD in forearm and vertebrae in men with hyperprolactinaemia. ;Antipsychotic-induced hyperprolactinaemia;"All conventional antipsychotic drugs cause dose dependent blockade of D2 receptors on lactotroph cells removing the main inhibitory influence on prolactin level and cause hyperprolactinaemia. This is defined as a level above the upper limit of normal (>24.20 ng/ml for females and >18.77 ng/ml for males). Elevation of prolactin levels occurs within a few hours of treatment initiation and persists with long term treatment (Smith 2002). Women have significantly greater prolactin elevations than men during chronic antipsychotic treatment with equivalent doses (Wode-Helgodt 1977/ Kuruvilla 1992/ Smith 2002).
When oral antipsychotic therapy is discontinued, baseline prolactin levels may take up to three weeks to return to the normal range depending on the half-life of the drug and its metabolites as well as storage in fatty tissues (Turkington 1972). In the case of depot medication, normalization may take as long as 4-6 months (Wistedt 1981).
Psychotropic drugs have been associated with menstrual dysfunction (Wieck 2003/ Kinon 2003). Within the prevalence of antipsychotic-induced amenorrhoea , well conducted studies of women treated with conventional antipsychotics have reported prevalence rates of approximately 45% for oligomenorrhoea/amenorrhoea and 19% for galactorrhoea. An illness-related under-function of the hypothalamic-pituitary-gonadal axis in female patients with schizophrenia may also contribute to menstrual irregularities. Also, there is evidence in literature to show that baseline menstrual problems get worsened and that galactorrhoea or gynecomastia gets manifested only after exposure to antipsychotic medication (Kohen 2008). In an extensive study conducted in India, the prevalence of amenorrhoea in female on risperidone was found to be 60% (Ravan 2009/ Paul 2013).
";;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
ID-REF;Category;Title;Abr;In-text citaiton;Text;RT;AU;TI;TO;SO;YR;EN;PB;CY;VL;NO;PG;ED;MD;NT;ID;;;;;;;;;;;
27;Global state scales;Clinical Global Impression Scale;CGI Scale;Guy 1976;This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven-point scoring system is used with low scores showing decreased severity and/or overall improvement.;Book;Guy U;;;ECDEU assessment manual for psychopharmacology;1976;;National Institute of Mental Health;;;;;;;;;;;;;;;;;;;
15;Global state scales;Investigator's Assessment Questionnaire;IAQ;Tandon 2005;The IAQ is a quantifiable clinical tool that can provide detailed information regarding common safety, efficacy and tolerability concerns that patients experience while taking antipsychotics. It has been shown to highly correlate with time to study discontinuation which is a common measure of effectiveness.;Journal article;Tandon R, Devellis RF, Han J, Li H, Frangou S, Dursun S, et al;Validation of the investigator's assessment questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder;;Psychiatry Research;2005;;;;136;02-Mar;211-21;;;;PUBMED 16115690;;;;;;;;;;;
16;Global state scales;Arizona Sexual Experience Scale;ASEX;McGahuey 2000;This is a brief scale for self-rating of sexual function. It has five items and is rated in five steps. Possible scores range from five to 30 with higher scores indicating more sexual dysfunction.;PUBMED 10693114;McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al;The Arizona Sexual Experience Scale (ASEX): reliability and validity;;Journal of Sex & Marital Therapy;2000;;;;26;1;25-40;;;;PUBMED 10693114;;;;;;;;;;;
26;Mental state scales;Positive and Negative Syndrome Scale;PANSS;Kay 1986;This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from one - absent to seven - extreme. It can be divided into three sub scales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates lesser severity.;Book;Kay SR, Opler LA, Fiszbein A;;;Positive and Negative Syndrome Scale (PANSS) Manual;1986;;Multi-Health Systems;North Tonawanda (NY);;;;;;;;;;;;;;;;;;
22;Mental state scales;Positive and Negative Syndrome Scale-Excited Component;PANSS-EC;Chaichan 2008;The PANSS-EC scale is derived as a sub scale of PANSS and is a simple scale used to measure the degree of agitation. The scale consists of five items (poor impulse control, tension, hostility, uncooperativeness, excitement), each being ranked from one to seven giving a potential maximum score of 35 points.;Journal Article;Chaichan W;Evaluation of the use of the positive and negative syndrome scale-excited component as a criterion for administration of p. r. n. medication;;Journal of Psychiatric Practice;2008;;;;14;2;105-13;;;;PUBMED 18360196;;;;;;;;;;;
39;Mental state scales;Brief Psychiatric Rating Scale;BPRS;Overall 1962;This consists of 18 to 24 items (depending on the version) each rated on a scale from one (absent) to seven (extreme).;Journal Article;Overall JE, Gorham DR;The brief psychiatric rating scale;;Psychological Reports;1962;;;;10;;799-812;;;;;;;;;;;;;;;
27;Adverse effects scales;Abnormal Involuntary Movement Scale;AIMS;Guy 1976;This scale has been used to assess tardive dyskinesia, a long-term, drug-induced movement disorder and short-term movement disorders such as tremor.;Book;Guy U;;;ECDEU assessment manual for psychopharmacology;1976;;National Institute of Mental Health;;;;;;;;;;;;;;;;;;;
36;Adverse effects scales;Simpson Angus Scale;SAS;Simpson 1970;This 10-item scale (with a scoring system of zero to four on each item) measures drug-induced parkinsonism, a short-term drug-induced movement disorder. A low score indicates low levels of parkinsonism.;Journal Article;Simpson EN, Angus JWF;A rating scale for extrapyramidal adverse effects;;Acta Psychiatrica Scandinavica Supplementum;1970;;;;212;;11_09;;;;;;;;;;;;;;;
44;Adverse effects scales;Barnes Akathisia Scale;BAS;Barnes 1989;The scale comprises items rating the observable, restless movements that characterise akathisia, a subjective awareness of restlessness, and any distress associated with the condition. These items are rated from zero (normal) to three (severe). In addition, there is an item for rating global severity (from zero (absent) to five (severe)). A low score indicates low levels of akathisia.;Journal Article;Barnes TR;A rating scale for drug-induced akathisia;;British Journal of Psychiatry;1989;;;;154;;672-6;;;;;;;;;;;;;;;
20;Quality of Life;Euro-QoL-5D;EQ-5D;Jelsma 2001;The EuroQoL-5D is a generic preference based measure of health-related quality of life. It has five domains which are mobility, self-care, usual activities, pain/ discomfort and anxiety/ depression, each having three short questions. The EQ-5D Utility score assesses all five items on a scale of zero to one, where zero represents worst possible health and one represents perfect health. The EQ-5D Health Dimension Scale assesses each item on three possible scores where one is the best and three the worst score.;Journal Article;Jelsma J, Mhundwa K, De Weerdt W, De Cock P, Chimera J, Chivaura V;The reliability of the Shona version of the EQ-5D;;Central African Journal of Medicine;2001;;;;47;1;08_13;;;;PUBMED 11961858;;;;;;;;;;;
21;Quality of Life;Quality of Life Scale;QLS;Heinrichs 1984;Quality of Life Scale (QLS), a 21-item scale divided into four domains including Interpersonal relations, Instrumental role, Intrapsychic foundations and common objects/activities scored on a seven-point scale with lowest score indicating severe dysfunction.;Journal Article;Heinrichs DW, Hanlon TE, Carpenter WT Jr;The quality of life scale: An instrument for rating the schizophrenic deficit syndrome;;Schizophrenia Bulletin;1984;;;;10;3;388-98;;;;PUBMED 6474101;;;;;;;;;;;
19;Quality of Life;Impact of Weight on Quality of Life;IwQOL-Lite;Kolotkin 2002;This is a survey instrument that is used to quantitatively assess an individual's perception of how their weight affects their day-to-day life. This instrument is especially valuable to obesity researchers, clinicians, psychologists, medical device and/or pharmaceutical companies seeking to validate the effectiveness of their treatments for obesity using metrics that go beyond the physical measurements of weight loss.;Journal Article;Kolotkin RL, Crosby RD;Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample;;Quality of Life Research;2002;;;;11;2;157-71;;;;PUBMED 12018739;;;;;;;;;;;
38;Quality of Life;World Health Organisation Quality of Life Scale;WHOQoL-Bref;O'Carroll 2000;The WHOQoL-Bref is a 26-item self-report comprising satisfaction with health, psychological functioning, social relationships and environmental opportunities. Each item is scored on a five-point scale from one (poor) to five (worse). ;Journal Article;O'Carroll RE, Smith K, Couston M, Cossar JA, Hayes PC;A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation;;Quality of Life Research;2000;;;;9;;121-4;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
REF-SZ;RT;AU;TI;SO;YR;EN;PB;CY;VL;NO;PG;ED;NT;ID;;;;;;;;;;;;;;;;;;
1;Journal article;Tandon R, Nasrallah HA, Keshavan MS;"Schizophrenia, ""just facts"" 4. Clinical features and conceptualisation";Schizophrenia Research;2009;;;;110;;Jan-23;;;;;;;;;;;;;;;;;;;;;
2;Journal article;Saha S, Chant D, McGrath J;A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time?;Archives of General Psychiatry;2007;;;;64;10;1123-31;;;;;;;;;;;;;;;;;;;;;
3;Journal article;Saha S, Chant D, WelhamJ, McGrath J;A systematic review of the prevalence of schizophrenia;PloS Medicine;2005;;;;2;;413-33;;;;;;;;;;;;;;;;;;;;;
4;Book;Johnstone E, Freeman C, Zealley A;;Companion to Psychiatric Studies;1998;6th;Churchill Livingstone;Edinburgh;;;;;;;;;;;;;;;;;;;;;;;;
5;Journal article;Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al;11 year follow up of mortality in patients with schizophrenia: a population based cohort study (FIN11 study);Lancet;2009;;;;374;;620-7;;;;;;;;;;;;;;;;;;;;;
6;Journal article;McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D;A systematic review of the incidence of schizophrenia;BMC Medicine;2004;;;;2;;13;;;;;;;;;;;;;;;;;;;;;
7;Journal article;Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al;Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010;Lancet;2012;;;;380;9859;2197-223;;;DOI 10.1016/S0140-6736(12)61689-4;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
REF-TD;RT;AU;TI;SO;YR;EN;PB;CY;VL;NO;PG;ED;NT;ID;;;;;;;;;;;;;;;;;;
1;Book;American Psychiatry Association;;Tardive dyskinesia: a task force report of the American Psychiatric Association;1992;;American Psychiatric Association;;;;;;;;;;;;;;;;;;;;;;;;;
2;Journal article;Rauchverger B, Isakov V, Jabarin M;Olanzapine-induced tardive dystonia successfully treated by tetrabenazine;Journal of Neuropsychiatry and Clinical Neurosciences;2007;;;;19;4;4845;;;;;;;;;;;;;;;;;;;;;
3;Book;Barnes TRE, Edwards JG;;Antipsychotic Drugs and their Side-Effects;1993;;Harcourt Brace & Company;London;;;;;;;;;;;;;;;;;;;;;;;;
4;Book;Jeste DV, Wyatt RJ;;Understanding and treating tardive dyskinesia;1982;;Guilford Press;New York;;;;;;;;;;;;;;;;;;;;;;;;
5;Journal article;Fernandez HH, Friedman JH;Classification and treatment of tardive syndromes;Neurologist;2003;;;;9;1;1627;;;;;;;;;;;;;;;;;;;;;
6;Journal article;Jeste D, Caligiuri M;Tardive dyskinesia;Schizophrenia Bulletin;1993;;;;19;;303-16;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
REF-Conditions;RT;AU;TI;SO;YR;EN;PB;CY;VL;NO;PG;ED;NT;ID;;;;;;;;;;;;;;;;;;
PARKS;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
1;Journal article;Simpson GM, Angus JWS;A rating scale for extrapyramidal side-effects;Acta Psychiatrica Scandanavica Supplementum;Mar-70;;;;45;Supplementum 212;11_9;;;;;;;;;;;;;;;;;;;;;
2;Book;American Psychiatric Association;;American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006;2006;;Amer Psychiatric Pub Incorporated;;;;;;;;;;;;;;;;;;;;;;;;;
3;Journal article;Chouinard G, Ross-Chouinard A, Annable L, Jones BD;Extrapyramidal Rating Scale;Canadian Journal of Neurological Sciences;1980;;;;7;3;233-39;;;;;;;;;;;;;;;;;;;;;
4;Journal article;Gervin M, Barnes TRE;Assessment of drug-related movement disorders in schizophrenia;Advances in Psychiatric Treatment;2000 September 1, 2000;;;;6;5;332-41;;;;;;;;;;;;;;;;;;;;;
5;Journal article;Thanvi B, Treadwell S;Drug induced parkinsonism: a common cause of parkinsonism in older people;Postgraduate Medical Journal;2009 June 1, 2009;;;;85;1004;322-6;;;;;;;;;;;;;;;;;;;;;
6;Journal article;Hirose G;Drug induced parkinsonism;Journal of Neurology;2006;;;;253;3;22_4;;;;;;;;;;;;;;;;;;;;;
7;Journal article;Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al;Extrapyramidal side-effects of antipsychotics in a randomised trial;British Journal of Psychiatry;2008 October 1, 2008;;;;193;4;279-88;;;;;;;;;;;;;;;;;;;;;
8;Journal article;Peluso MJ, Lewis SW, Barnes TRE, Jones PB;Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs;British Journal of Psychiatry;2012;;;;200;5;387-92;;;;;;;;;;;;;;;;;;;;;
9;Journal article;Wojcik JD, Gelenberg AJ, LaBrie RA, Mieske M;Prevalence of tardive dyskinesia in an outpatient population;Comprehensive Psychiatry;1980;;;;21;5;370-80;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
AGGRESSION;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
1;Other;The National Institute for Clinical Excellence;Violence: the short-term management of disturbed/violent behaviour in psychiatric in-patient settings and emergency departments;NICE Clinical Guideline 25;Feb-05;;;;30;4;586-98;;;;;;;;;;;;;;;;;;;;;
2;Journal article;Rocca P, Villari V, Bogetto F;Managing the aggressive and violent patient in the psychiatric emergency;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2006;;;;67;Suppl 10;13-21;;;;;;;;;;;;;;;;;;;;;
3;Journal article;Marder SR;A review of agitation in mental illness: treatment guidelines and current therapies;Journal of Clinical Psychiatry;2006;;;;65;9;1207-22;;;;;;;;;;;;;;;;;;;;;
4;Journal article;Battaglia J;Pharmacological management of acute agitation;Drugs;2005;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
SERIOUS MENTAL ILLNESS;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
1;Other;National Institute of Mental Health;Towards a model for comprehensive community-based mental health system;Washington, DC: NIMH;1987;;;;;;;;;;;;;;;;;;;;;;;;;;;
2;Journal article;Ruggeri M, Leese M, Thornicroft G, Bisoffi G, Tansella M;Definition and prevalence of severe and persistent mental illness;British Journal of Psychiatry;2000;;;;177;;149-55;;;PUBMED 11026955;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
AKATHISIA;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
1;Journal article;Marder SR, Midha KK, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, et al;Plasma levels of fluphenazine in patients receiving fluphenazine decanoate;British Journal of Clinical Psychiatry;1991;;;;158;;658-65;;;;;;;;;;;;;;;;;;;;;
2;Section of book;Barnes TRE;Neuromuscular effects of neuroleptics: akathisia;Adverse effects of psychotropic drugs;1992;;Guilford Publications;New York;15 Supple 1 Pt - A;;201-17;Lieberman J, Kane JM;;;;;;;;;;;;;;;;;;;;
3;Journal article;Farde L, Norstrom AL, Halldin C;PET studies of dopamine receptors in relation to antipsychotic drug treatment;Clinical Journal of Neuropharmacology;1992;;;;175;;468A-469A;;;;;;;;;;;;;;;;;;;;;
4;Journal article;Ayd FJ;A survey of drug-induced extrapyramidal reactions;JAMA;1961;;;;;;1054-60;;;;;;;;;;;;;;;;;;;;;
5;Section of book;Grebb JA;Medication induced movement disorders;Comprehensive textbook of psychiatry;1995;;Williams & Wilkins;New York;164;2;177-83;Kaplan HI, Sadock BJ;;;;;;;;;;;;;;;;;;;;
6;Journal article;Halstead SM, Barnes TR, Speller JC;Akathisia: prevalence and associated dysphoria in an inpatient population with chronic schizophrenia;British Journal of Psychiatry;1994;;;;143;;139-50;;;;;;;;;;;;;;;;;;;;;
7;Journal article;Braude WM, Barnes TRE, Gore S;Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions;British Journal of Psychiatry;1983;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
AMEN;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
1;Journal article;Wode-Helgodt, B., Eneroth, P., Fryo, B., ;Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients;Acta Psychiatrica Scandinavica;1977;;;;56;;280-293;;;;;;;;;;;;;;;;;;;;;
2;Journal article;Cann CE, Martin MC, Genant HK, Jaffe RB;Decreased spinal mineral content in amenorrheic women;JAMA;1984;;;;251;;626-629;;;;;;;;;;;;;;;;;;;;;
3;Journal article;VELDHUIS, J. D. & JOHNSON, M. L.;Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone. J;Clin Endocrinol Metab;1988;;;;67;;116-23;;reference is incorrectly presented - see handbook;;;;;;;;;;;;;;;;;;;
4;Journal article;Wistedt B, Wiles D, Kolakowska T.;Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics.;Lancet;1981 May;;;;23-Jan;;(8230):1163;;;PUBMED PMID: 6112518;;;;;;;;;;;;;;;;;;
5;Journal article;Wieck A, Haddad PM;Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review;British Journal of Psychiatry;2003;;;;182;;199-204;;;PUBMED 12611781;;;;;;;;;;;;;;;;;;
6;Journal article;Koppelman MC, Kurtz DW, Morrish KA, Bou E, Susser JK, Shapiro JR et al.;Vertebral body bone mineral content in hyperprolactinemic women.;J Clin Endocrinol Metab;1984;;;;59;;1050-1053;;;;;;;;;;;;;;;;;;;;;
7;Journal article;GREENSPAN, S. L., NEER, R. M., RIDGWAY, E. C. & KLIBANSKI, A.;Osteoporosis in men with hyperprolactinemic hypogonadism;Ann Intern Med;1986;;;;104;;777-82;;this reference is incorrectly presented - see other refs and handbook for correct presentation of refs for a cochrane review;;;;;;;;;;;;;;;;;;;
8;Journal article;Kuruvilla A, Peedicayil J, Srikrishna G;A study of serum prolactin levels in schizophrenia: comparison of males and females;Clinical and Experimental Pharmacology and Physiology;1992;;;;19;;603-6;;;;;;;;;;;;;;;;;;;;;
9;Journal article;Smith S, Wheeler MJ, Murray R et al;The effects of antipsychotic-induced hyperprolactinemia on the hypothalamic pituitary gonadal axis;Journal of Clinical Psychopharmacology;2002;;;;22;;109  -114;;;;;;;;;;;;;;;;;;;;;
10;Journal article;Kinon BJ, Gilmore JA, Liu H, Halbreich UM;Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone;Psychoneuroendocrinology;2003;;;;28 Suppl 2;;55-68;;;PUBMED 12650681;;;;;;;;;;;;;;;;;;
11;Journal article;Thomas Paul, Jayaprakash Russell Ravan, Naveen Thomas, Nihal Thomas, Prasanna Samuel & Deepa Braganza;Risperidone associated changes in prolactin and bone mineral density: a study from South India;Endocrine Abstracts;2013;;;;31;;17;;;;;;;;;;;;;;;;;;;;;
12;Journal article;KLIBANSKI, A., NEER, R. M., BEITINS, I. Z., RIDGWAY, E. C., ZERVAS, N. T. & MCARTHUR, J. W.;Decreased bone density in hyperprolactinemic women;N Engl J Med;1980;;;;303;;1511-4;;this reference is incorrectly presented - see other refs and handbook for correct presentation of refs for a cochrane review;;;;;;;;;;;;;;;;;;;
13;Unpublished data;Ravan Jayaprakash;Prevalence of osteoporosis and proxy clinical indicators of osteoporosis in patients on long term  Risperidone;MD Thesis submitted at CMC Vellore, Dr MGR Medical University, Tamil Nadu;2009;;;;;;;;;;;;;;;;;;;;;;;;;;;
14;Journal article;KOHEN, D. and WILDGUST, H. J.;The evolution of hyperprolactinaemia as an entity in psychiatric patients;J Psychopharmacol;2008;;;;22;;6_11;;his reference is not linked in text;;;;;;;;;;;;;;;;;;;
15;Journal article;Petty RG;Prolactin and antipsychotic medications: mechanism of action.;Schizophr Research;1999;;;;35;Suppl;S67-73;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
